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SUMMARY 
 
The oncogenic transcription factors E2F and Myc bind to specific DNA 
sequences at distinct times during the G1 phase of the mammalian cell cycle, 
and regulate transcription of a plethora of target genes. E2F and Myc 
associate with TRRAP, a subunit of distinct macromolecular complexes that 
contain the histone acetyltransferases (HATs) Gcn5/PCAF or Tip60. During 
the course of my thesis I investigated several aspects of TRRAP-associated 
HAT-complexes. Firstly, I used chromatin immunoprecipitation (CHIP) to show 
that E2F recruits a TRRAP/Tip60 complex to its target genes. This was 
accompanied by localized changes in histone acetylation, centered to the E2F 
binding sites. Prevention of E2F-binding correlated with a failure to acetylate 
H4 on target promoters, and inability to enter the cell cycle upon mitogenic 
stimulation. Furthermore, the coactivator complex targeted most, if not all, 
promoters investigated in this study, establishing Tip60 recruitment and H4 
acetylation as a common feature of E2F-dependent coactivation. Secondly, I 
demonstrated that Myc recruits HAT activity and associates with Tip60 and 
Gcn5/PCAF. Consistent with this, Tip60 was also recruited to Myc targets. 
Thirdly, at least two components of a Gcn5/PCAF-containing TRRAP complex 
were found associated with G1-specific cell cycle regulator Cyclin E. 
Moreover, the HAT activity of PCAF was susceptible to cell cycle arrest. 
Altogether, these results provide evidence that TRRAP-associated HAT-
complexes play an important regulatory role during the mammalian cell cycle.  
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ZUSAMMENFASSUNG 
 
Die onkogenischen Transkriptionsfaktoren E2F und Myc binden spezifische 
DNS-Sequenzen zu unterschiedlichen Zeitpunkten waehrend des Zellzyklus, 
und regulieren Transkription von vielen unterschiedlichen Genen. Sowohl E2F 
als auch Myc assoziieren mit TRRAP, einer Komponente von mindestens 
zwei verschiedenen macromolekularen Protein-Komplexen, welche die 
Histon-Acetyl-Transferasen (HAT) Gcn5/PCAF oder Tip60 enthalten. 
Waehrend meiner Dissertation studierte ich verschiedene Aspekte dieser 
TRRAP-assoziierten HAT-Komplexe. Zuerst verwendete ich Chromatin-
Immunopraezipitation, um zu zeigen, dass ein TRRAP/Tip60 Komplex zu 
E2F-regulierten Genen rekrutiert wird. Dies war begleitet von lokalisierten 
Veraenderungen der Histon-Acetylierung, welche zu E2F Bindungssequenzen 
zentriert waren. Eine E2F-Mutante, welche das spezifische Binden von E2F 
zu Ziel-Genen blockierte, verhinderte Rekrutierung des TRRAP/Tip60-
Komplexes, der Histon H4-Acetylierung, und des Wiedereintretens in einen 
neuen Zellzyklus nach Stimulierung mit Serum. Ausserdem beobachtete ich 
Histon H4-Acetylierung und Kofaktor-Rekrutierung bei allen untersuchten E2F 
Ziel-Genen, was diese Vorgaenge als klasisch fuer E2F Funktion etabliert. 
Des weiteren konnte ich zeigen, dass Myc HAT-Aktivitaet rekrutiert, und die 
beiden TRRAP assoziierten HAT-Enzyme Gcn5/PCAF und Tip60 binden 
kann. Schliesslich fand ich, dass mindestens zwei Komponenten eines 
Gcn5/PCAF Komplexes von dem Zellzyklus-Regulator Cyclin E gebunden 
werden, und dass die HAT-Aktivitaet von PCAF durch einer Blockierung des 
Zellzyklus beeintraechtigt wird. Zusammengenommen lassen diese Resultate 
vermuten, dass TRRAP und seine assoziierten HAT-Komplexe eine wichtige 
Rolle in der Regulierung des Zellzyklus von Saeugetier-Zellen spielen.  
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INTRODUCTION 
 
1. Cancer Cells 
The development of tumors in metazoans proceeds via the process of 
transformation. Accumulation of somatic mutations during the life-span of an 
individual organism, as well as inherited mutations, both contribute to 
transformation (Vogelstein and Kinzler 1993). Different tissues give rise to 
distinct tumors, but all cancer cells exhibit several common features: They 
avoid programmed cell death (apoptosis), grow and divide inappropriately, 
and (re-) acquire the capability to migrate and invade other tissues (Hanahan 
and Weinberg 2000). The genes affected by transforming mutations can be 
divided into two categories: Oncogenes, and tumor suppressors (Weinberg 
1994). Oncogenes arise through mutations affecting their cellular 
counterparts, the proto-oncogenes. They act in a dominant manner, to induce 
cell division, or migration, for example. In contrast, loss of function of both 
alleles of tumor suppressor genes is required to contribute to transformation, 
as products of tumor suppressor genes signal to inhibit cellular growth and 
division, or detachment and migration. Transformation of cells is associated 
with changes of gene regulation (Leonhardt and Cardoso 2000; Baylin et al. 
2001; Wade 2001), which results in altered signaling pathways, for instance 
deregulation of the cell division cycle (Sherr 1996). Thus, in order to 
understand the molecular mechanisms of transformation, we must know how 
these processes are controlled in both normal and transformed cells.  
 
2. Chromatin and Transcriptional Regulation 
2.1. Chromatin Structure 
All eukaryotes package genomic DNA into chromosomes. These are 
comprised of chromatin, a highly ordered DNA-protein structure that allows for 
compact storage of the DNA in the limited space of the nucleus (Horn and 
Peterson 2002). The fundamental unit of chromatin is the nucleosome 
(Kornberg and Lorch 1999b), which consists of 146bp of genomic DNA tightly 
wrapped around a histone octamer (two copies of each core histone H2A, 
H2B, H3, and H4; Luger et al. 1997). Core histones are evolutionarily highly 
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conserved, positively charged proteins, which share two signature structural 
features (Hayes and Hansen 2001; Hansen 2002): A core "histone-fold" 
domain sufficient for histone-histone and histone-DNA interactions, an N-
terminal tail, and a C-terminal tail. These tails protrude from the core, and 
contain sites for a plethora of covalent modifications (Figure 1; Goll and 
Bestor 2002).  
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Figure 1: Histone Tail Modifications. 
Schematic depicting covalent modifications of individual amino acid residues (S = Serine; K = 
Lysine; R = Arginine) in histone tails. Note that H3K9 can be either acetylated or methylated, 
but the two modifications are mutually exclusive. For further explanations, see text. Ac, 
Acetylation; Ub, Ubiquitination; R-Me, Arginine-Methylation; PO4, Phosphorylation; and K-Me, 
Lysine-Methylation. Modified from Goll and Bestor, 2002.  
 
In order to gain access to the DNA, the cellular transcription machinery 
must be able to modulate the structure of chromatin. Transcriptional activation 
correlates with relaxation of an inherently repressive chromatin structure, 
whereas repression is associated with condensation of chromatin. Two kinds 
of enzymatic activities that modulate chromatin structure have been identified: 
(a) chromatin-modifying-enzymes that covalently modify chromatin 
components (Workman and Kingston 1998), and (b) chromatin-remodeling-
enzymes that non-covalently change the structure and/or the position of 
nucleosomes (Strahl and Allis 2000). Both classes of proteins occur in vivo as 
large multi-subunit protein complexes (Kornberg and Lorch 1999a). 
Chromatin-modifying-enzymes include histone acetyltransferases (HATs) and 
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deacetylases (HDACs), DNA methyltransferases (DNMTs), histone 
methyltransferases (HMTs), histone kinases, and histone ubiquitin-
transferases. Recently, many of these activities have been associated with 
transcriptional regulation. In particular, HATs and HDACs have emerged as 
important co-regulators involved in a variety of transcriptional responses 
(Sterner and Berger 2000; Roth et al. 2001).  
 
2.2. Histone Acetylation is Relevant for Transcriptional Regulation 
It is now well established that regulation of histone acetylation is important 
for regulation of gene transcription (reviewed in Sterner and Berger 2000; 
Roth et al. 2001). In most cases, histone acetylation is linked to gene 
transactivation, while deacetylation is associated with transcriptional 
repression. A critical step in proving that acetylation can act to regulate 
transcription was the biochemical characterization of p55, the Tetrahymena 
thermophila orthologue of the known yeast transcriptional adaptor Gcn5p, as 
a HAT (Brownell et al. 1996). In metazoans, a regulatory role for histone 
acetylation in gene regulation was suggested by the characteristics of dosage 
compensation. For example, male fruit flies (Drosophila melanogaster) induce 
hyperacetylation of H4 lysine 16 (H4K16) throughout their single X-
chromosome, which correlates with a two-fold increase in transcription 
(Lucchesi 1998; Pannuti and Lucchesi 2000). Similarly, in mammals, the 
transcriptionally inactive state of one of the two female X-chromosomes 
correlates with chromosome-wide hypoacetylation of both H3 and H4.  
Precisely how acetylation regulates transcription is a matter of debate, but 
two, possibly overlapping models have emerged in the literature. The first 
model suggests that gene wide acetylation of histones, which reduces their 
net positive charges, weakens their interaction with the negatively charged 
DNA, thus creating a relaxed, more “open” chromatin structure. Deacetylation, 
in contrast, would cause stabilization of histone-DNA interactions, and induce 
a "closed" chromatin state. Consistent with this model, hypoacetylation of H3 
throughout the coding regions of active genes correlates with transcriptional 
inhibition in yeast (Kristjuhan et al. 2002). In the alternative model, 
modification of histone tails creates a dynamic platform upon which the 
transcriptional machinery is assembled. Thus, different modifications may act 
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sequentially or in combination to create a “histone code”, which translates into 
initiation of promoter specific downstream events (Strahl and Allis 2000; 
Jenuwein and Allis 2001). This model is supported by a wealth of evidence; 
for example, methylated H3K9 specifically recruits HP1, which then induces 
heterochromatin formation, ultimately inducing gene silencing (Hall et al. 
2002; Nielsen et al. 2002; Peters et al. 2002). The identification of domains 
that specifically interact with certain modified histones, such as the acetyl-
histone binding bromodomain, also supports this hypothesis (Horn and 
Peterson 2001; Zeng and Zhou 2002). Ultimately, histone acetylation may 
regulate gene transcription via both kinds of mechanisms.  
 
2.3. HATs and HDACs 
HATs are enzymes that transfer acetyl-moieties onto the lysines of N-
terminal histone tails (Sterner and Berger 2000; Roth et al. 2001). Both HATs 
and HDACs generally lack intrinsic DNA-binding activity. Instead, they are 
recruited to DNA by sequence specific transcription factors (TFs) to stimulate 
either transcriptional activation or repression. Therefore, HATs and HDACs 
play important roles in many transcriptional activation and repression 
pathways.  
Mammalian HDACs can be subdivided into three classes (Fischle et al. 
2001; Marks et al. 2001, Kuo et al. 1998). Class I HDACs (HDAC1-3, HDAC8) 
are similar to the yeast transcriptional repressor Rpd3p, and are subunits of at 
least two distinct corepressor complexes, the Sin3 complex and the NuRD 
complex. Class II HDACs (HDAC4-7, HDAC9-11) are related to yeast Hda1p, 
act as transcriptional repressors independent of Sin3 complexes, and have 
been implicated in various roles in cell differentiation and development. Class 
III HDACs (SIRT1-7) are related to yeast Sir2p, are biochemically and 
structurally distinct from Classes I and II, and appear to be involved in gene 
silencing and heterochromatin formation at centromeres and telomeres 
(Gasser and Cockell 2001).  
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HAT 
Organisms 
containing 
the HAT 
Known transcription-
related functions 
Specificity of 
recombinant 
enzyme in vitro
Known HAT-complexes, 
nucleosomal histone 
specificities in vitro 
GNAT family 
Hat1 Yeast to humans 
None (histone-
deposition-related HAT) H4 
Yeast HAT-B, HAT-A3 (no 
nucleosome acetylation) 
Gcn5 Yeast to humans Coactivator (adaptor) H3/H4 
Yeast ADA, SAGA (H3/H2B); 
human GCN5 complex, 
STAGA, TFTC (H3) 
PCAF Humans, mice Coactivator H3/H4 
Human PCAF complex 
(H3/weak H4) 
Elp3 Yeast Transcript elongation ND Elongator, polymerase II holoenzyme (H3/weak H4) 
Hpa2 Yeast Unknown H3/H4  
MYST family 
Sas2 Yeast Silencing H4K16  
Sas3 Yeast Silencing/ Transcription H3/H4/H2A NuA3 (H3) 
Esa1 Yeast Cell cycle progression H4/H3/H2A NuA4 (H4/H2A) 
MOF Drosophila Dosage compensation H4/H3/H2A MSL complex (H4) 
Tip60 Humans HIV Tat interaction H4/H3/H2A Tip60 complex 
MOZ Humans 
Leukemogenesis, upon 
chromosomal 
translocation 
ND  
MORF Humans Unknown (strong homology to MOZ) H4/H3/H2A  
HBO1 Humans ORC interaction H3/H4 HBO1 complex 
p300/CBP 
p300/CBP Metazoans Global coactivator H2A/H2B/H3/H4  
Nuclear Receptor Coactivators 
SRC-1 Humans, mice H3/H4  
ACTR Humans, mice H3/H4  
TIF2 Humans, mice 
Nuclear receptor 
coactivators 
(transcriptional 
response to hormone 
signals) ND  
General Transcriptional Factors 
TAFII250 Various  TBP-associated factor H3/H4 TFIID 
TFIIIC   TFIIIC (H2A/H3/H4) 
TFIIIC220 Humans ND  
TFIIIC110 Humans ND  
TFIIIC90 Humans 
RNA polymerase III 
transcription initiation 
H3  
Table 1: Known and Putative HATs. 
Known and putative HATs, their occurrence in distinct species, biological functions, substrate 
specificity towards histones (preferred substrate in bold), and associated complexes are 
listed. HATs are divided in five families. ND, not determined.  
 
Like HDACs, HATs can be subdivided in several classes based on their 
sequence homologies, but all HATs share a highly conserved motif containing 
an acetyl-CoA binding site (Roth et al. 2001). Historically, HATs have been 
subdivided into type A (nuclear), and type B (cytoplasmic) HATs. The latter 
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are irrelevant for transcriptional regulation, and perform housekeeping roles in 
cells, functioning to acetylate newly synthesized histones (Brownell and Allis 
1996). More precisely, HATs can be classified into several subfamilies based 
on their sequence homologies (Table 1): The GNAT family, the MYST family, 
TAFII250, TFIIIC, steroid receptor coactivators (SRC-1, ACTR, and Tif-2), and 
p300/CBP (for review, see Sterner and Berger 2000; Roth et al. 2001). Most 
HATs and HDACs are components of large multi-subunit protein complexes 
(Table 2). Interestingly, several HAT/HDAC-complexes have been described 
to interact with each other, and with other chromatin modifying complexes, 
and synergistic activation of transcription has been proposed (see chapter 
2.7. pp.28).  
 
2.3.1. HATs I: The GNAT Family  
The GNAT (Gcn5-related N-Acetyltransferases) family of enzymes 
includes several non-histone acetyltransferases, including prokaryotic 
representatives (Neuwald and Landsman 1997). They have been grouped 
together on the basis of their sequence similarity in several homology regions 
and acetylation-related motifs. The family members that have been 
associated with transcription are yeast Gcn5p, mammalian PCAF and Gcn5 
(yeast Gcn5p homologues), and Elp3p, a subunit of the yeast Elongator 
complex (Wittschieben et al. 2000; Kristjuhan et al. 2002).  
Gcn5 is the most studied HAT to date. A variety of in vitro studies indicate 
that it acetylates preferably H3 and H2B (Kuo et al. 1996, Xu et al. 1998, 
Yang et al. 1996, Schiltz et al 1999, Grant 1999). Recent in vivo chromatin 
immunoprecipitation analysis (CHIP, see chapter 4.3; pp. 49) confirmed that 
the substrate specificity of yeast Gcn5p is directed towards H3 (K9, K14, K18, 
K23, and K27), and H2B (K11, and K16) (Suka et al. 2001). In addition to the 
HAT domain, Gcn5 proteins contain an adjacent Ada2 interaction domain, a 
C-terminal bromodomain that has been implicated in histone binding, and 
(only in higher eukaryotes) an N-terminal domain that appears to be critical for 
substrate recognition and protein-protein interactions. In yeast, Gcn5p acts as 
a transcriptional adaptor for several sets of target genes, including as gal1, 
gal4, and his3 (Kuo et al. 1998; Wang et al. 1998). While Gcn5p itself is 
dispensable for growth, a composite mutation of Gcn5p and Sas3p 
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(apparently the other main H3 HAT in yeast, see chapter 2.3.2; pp. 20) 
causes terminal arrest of yeast cells in G2/M due to lack of H3-specific HAT 
activity (Howe et al. 2001). Humans and mice possess Gcn5 and PCAF, two 
highly similar homologues of yeast Gcn5p. However, they play distinct roles in 
mouse development (Table 2): While Gcn5-/--mice die during embryogenesis, 
PCAF-/--mice are viable and fertile (Xu et al. 1998; Yamauchi et al. 2000). 
Whether this results from biochemical differences between the two 
homologues, or due to differences in their developmental expression pattern, 
is unclear.  
Gcn5 interacts with a variety of other transcription-associated proteins. In 
yeast, there are at least two distinct HAT-complexes containing Gcn5p as 
catalytic subunit, the SAGA and Ada complexes (Grant et al. 1997; Grant et 
al. 1998a; Grant et al. 1998c). No Ada-like complex has been described in 
higher metazoans, and no clear function has yet been attributed to the Ada 
complex. In contrast, the SAGA complex is critical for certain types of 
transcription both in vitro and in vivo. SAGA contains the Ada and Gcn 
proteins, that mediate activator interaction and nucleosome acetylation, the 
Spt proteins, that mediate TBP interaction, several TBP associated factors 
(TAFs), and the large protein Tra1p (Grant et al. 1998a; Saleh et al. 1998; 
Sterner et al. 1999). Mutation of different subunits affects transcription of 
distinct sets of target genes. In mammalian cells, three similar but distinct 
orthologues of the SAGA complex have been identified, the Gcn5 containing 
STAGA and TFTC complexes, and the PCAF containing PCAF complex 
(Table 3; Martinez et al. 1998; Ogryzko et al. 1998; Brand et al. 1999). They 
all exhibit subunit compositions remarkably similar to the SAGA complex. 
Both STAGA and TFTC have been linked to transcriptional activation (Hardy 
et al. 2002; Yanagisawa et al. 2002). However, the presence of spliceosome-
associated proteins, as well as Damaged-DNA-Binding-Proteins, in both of 
these complexes suggests that they are also involved in chromatin 
modification in response to DNA-damage and/or mRNA processing (Brand et 
al. 2001; Martinez et al. 2001). 
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HAT Genotype Phenotype 
+/+ Normal 
+/- Normal 
PCAF 
 
 
-/- Normal 
+/+ Normal 
+/- Normal 
GCN5 
 
 
 
 
-/- 
Embryonic lethal (10.5 dpc) with loss of 
paraxial mesoderm and chordamesoderm 
due to increased apoptosis 
+/- & +/- Normal PCAF & GCN5 
 -/- & -/- Embryonic lethal prior to 6.5 dpc 
+/+ Normal 
+/- Decreased viability in utero 
p300 
 
 
 
 
-/- Embryonic lethal (9-11 dpc), with decreased proliferation, heart defects, open neural tube
+/+ Normal CBP 
 
 
 
+/- 
Defective skeletal formation and 
hematopoietic differentiation; increased 
malignancies 
 -/-  
Embryonic lethal with characteristics similar 
to p300-/--mice 
p300 & CBP 
 
+/- & +/- 
 
Embryonic lethal, similar to p300 or CBP-/--
mice 
Table 2: Comparison of Phenotypes of HAT-Deficient Mice. 
 
2.3.2. HATs II: The MYST Family  
MYST family HATs (named after the family's founding members MOZ, 
Ybf2p/Sas3p, Sas2p, Tip60; Borrow et al. 1996) share among them unique 
sequence features, most prominently the MYST-homology-domain, which 
includes an acetyl-CoA binding motif (Table 1). Most MYST family HATs also 
have a Zinc finger domain, the only exception being Esa1p (Sterner and 
Berger 2000; Roth et al. 2001).  
MYST family HATs have been associated with a variety of functions. 
Yeast Sas2p is required to acetylate H4K16, establishing heterochromatin 
boundaries (Suka et al. 2002). Yeast Sas3p (and the associated NuA3 
complex; Table 3) plays a role in silencing, transcriptional and/or replicational 
elongation, and genome wide acetylation (John et al. 2000; Howe et al. 2001; 
Reifsnyder et al. 1996, Takechi and Nakayama 1999). The gene encoding 
human MOZ is translocated to genes of other HATs (CBP or Tif2) in leukemia, 
and aberrant chromatin acetylation due to mistargeting of specific HAT 
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activities might ultimately lead to leukemogenesis (Borrow et al. 1996; Liang et 
al. 1998; Kitabayashi et al. 2001). MORF, a close homologue of MOZ, 
appears to function in both transcriptional repression and activation 
(Champagne et al. 1999; Panagopoulos et al. 2001; Pelletier et al. 2002). 
However, the physiological roles of MOZ and MORF remain unknown. 
Another human MYST HAT, HBO1, has been identified as a protein 
associated with the DNA replication initiation proteins MCM2 and Orc1, 
suggesting a role in DNA replication (Iizuka and Stillman 1999; Sharma et al. 
2000; Burke et al. 2001). The best-characterized MYST proteins, however, 
are yeast Esa1p (Smith et al. 1998; Clarke et al. 1999), and its human 
homologue, Tip60 (Kamine et al. 1996).  
Various in vitro studies indicate that Esa1 and Tip60 preferentially 
acetylate lysines in H4 and H2B (Yamamoto and Horikoshi 1997; Kimura and 
Horikoshi 1998). Consistent with this, Esa1p has recently been shown to 
target all lysines in the N-terminal tail of H4, except K16, plus H2A (K7), and 
H2B (K11 and K16) in vivo (Suka et al. 2001). Esa1p is essential for growth 
and viability in yeast. Interestingly, deletion of Esa1p causes terminal arrest in 
G2/M phase, similar to the composite sas3/gcn5 mutation, suggesting that 
functional H3 and H4 HAT activities are essential for cell division in yeast. 
Esa1p is the catalytic subunit of a HAT-complex termed NuA4 (Table 3; Allard 
et al. 1999), which is involved in transcriptional regulation. Esa1p is targeted 
to a small subset of ribosomal protein (RP) promoters, depending on 
recruitment by the sequence specific transcription factors Rap1p or Abf1p 
(Galarneau et al. 2000; Eisen et al. 2001). Recruitment correlates with 
coordinate regulation of RP-genes in response to growth stimuli. In addition, 
the NuA4 complex is recruited to DNA double strand breaks in vivo, and 
appears to participate in non-homologous end-joining repair, and in a novel 
pathway of replication-coupled repair (Bird et al. 2002). Both pathways require 
Esa1p, suggesting that this HAT is also involved in chromatin-remodeling 
processes unrelated to transcriptional activation.  
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HAT-complex 
(species) 
SAGA 
(yeast) 
PCAF/STAGA/
TFTC (human)
ADA (yeast) Tip60 
(human) 
NuA4 
(yeast) 
      
HAT Gcn5p Gcn5/PCAF Gcn5p Tip60 Esa1p 
 Ada1p     
 Ada2p hAda2 Ada2p   
 Ada3p hAda3 Ada3p   
 Ada5p/Spt20p     
 Spt3p hSpt3    
 Spt7p     
 Spt8p     
Tra1-like Tra1p TRRAP  TRRAP Tra1p 
H4-like TAFII60 PAF65α    
WD40 repeat 
containing TAFII90 PAF65ß 
   
H2B-like TAFII61/68 TAF 15/20    
 TAFII23/25 TAF30    
H3-like TAFII17/20 TAF31    
 Sin4p     
   Ahc1p   
Actin    γ-actin Act1p 
ARP    BAF53 Act3p/Arp4p 
    EPC Epl1p 
RuvB-like    Tip48/49 absent 
    p400  
      
      
Chromodomain    MRG-X/ MRG15? Eaf3p 
    Ing1? Yng2p 
Table 3: Subunit Composition of Selected HAT-Complexes. 
HAT-complex subunits of five HAT-complexes are listed in columns. Homologues appear in 
the same row. ARP, actin-related-protein.  
 
The closest human homologue of Esa1p is Tip60. It was originally 
identified as a protein interacting with HIV Tat protein, suggesting a function in 
transcriptional regulation after infection with HIV. Indeed, Tip60 has been 
associated with transcriptional coactivation (Dechend et al. 1999; Cao and 
Sudhof 2001; Baek et al. 2002). NF-κB, Bcl-3, Jab1, and nuclear hormone 
receptors can all bind Tip60. Recently, a ternary complex consisting of Tip60, 
the Fe65 transcriptional adaptor, and the cytoplasmic tail of amyloid-β 
precursor protein (APP) has been identified. This complex is recruited to the 
kai1 gene, and HAT activity of Tip60 was required for histone acetylation 
(Baek et al. 2002). However, another report suggests roles of Tip60 in repair 
of damaged DNA, and in apoptosis (Ikura et al. 2000). Consistent with this, 
Tip60 is normally degraded by the ubiquitin-proteasome pathway, but is 
stabilized following UV-irradiation (Legube et al. 2002).  
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Tip60 is the HAT of a multi-subunit protein complex in mammalian cells, 
the Tip60 complex (Table 3; Ikura et al. 2000). This complex also contains two 
ATP-dependent DNA helicases, Tip48 and Tip49 (Ikura et al. 2000; Fuchs et 
al. 2001). They are probably involved in transcriptional activation and 
repression in mammalian cells, and their Drosophila orthologues appear to 
play similar roles (Bauer et al. 2000). Other subunits of the Tip60 complex 
include γ-actin, the actin-related-protein (ARP) BAF53 (both of which are also 
components of other chromatin-remodeling-complexes; for review see Rando 
et al. 2000; Olave et al. 2002), and EPC, a human homologue of the 
Drosophila Enhancer-of-Polycomb protein, further suggesting a role in 
transcriptional regulation (Stankunas et al. 1998; Galarneau et al. 2000). 
Another subunit of the Tip60 complex is p400, a putative helicase (Fuchs et 
al. 2001). Interestingly, p400 was also purified as a component of the p400 
complex, which is identical to the Tip60 complex, except that it does not 
contain Tip60 (but apparently does have HAT activity). Finally, the Tip60 
complex contains TRRAP, a transcriptional regulatory protein also found in 
the human STAGA/TFTC and PCAF complexes (McMahon et al. 1998; 
Vassilev et al. 1998; Ikura et al. 2000). TRRAP is essential for mouse 
embryonic development (Herceg et al. 2001), and its homologue Tra1p is 
required for viability in yeast (Grant et al. 1998b). Tra1p is a component of the 
yeast HAT-complexes SAGA and NuA4 (Table 3). It is noteworthy, that 
TRRAP homologues are present in at least two distinct classes of HAT-
complexes in both yeast and humans, and the fact that PCAF/STAGA/TFTC 
complexes are apparently analogous to SAGA suggests that the Tip60 
complex may be analogous to NuA4. This possibility is supported by the fact 
that both catalytic subunits (Esa1p and Tip60) are MYST proteins. However, 
the human Tip60 complex differs from yeast NuA4 at least in containing the 
additional subunits Tip48, Tip49 and p400. Finally, the NuA4 complex 
contains the two additional subunits, Yng2p and Eaf3p, and while orthologues 
of both proteins have been identified in humans, it remains to be determined 
whether they are associated with the Tip60 complex (Loewith et al. 2000; 
Choy et al. 2001; Eisen et al. 2001; Nourani et al. 2001; Choy and Kron 
2002).  
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2.3.3. HATs III: p300/CBP 
The p300/CBP HATs are very large proteins present only in higher 
eukaryotes (for review see Goodman and Smolik 2000; Sterner and Berger 
2000; Chan and La Thangue 2001; Roth et al. 2001). They play essential 
roles in balancing cell proliferation and differentiation. Both p300 and CBP are 
required for embryonic development in mice (Yao et al. 1998; Oike et al. 
1999b; Kung et al. 2000). Their importance is further emphasized by gene-
dosage-associated phenotypes in both humans and in mice (Table 2; Petrij et 
al. 1995; Giles et al. 1998; Oike et al. 1999a; Murata et al. 2001). Importantly, 
mutations in CBP or p300 have been found in tumors (Sobulo et al. 1997), 
and CBP has tumor suppressor activity in mice. In cultured cells, these two 
highly homologous proteins are, with few exceptions, functionally 
interchangeable, and thus are referred to as p300/CBP. They function as 
coactivators for a variety of transcription factors involved in proliferation or 
differentiation, such as nuclear hormone receptors, and differentiation specific 
transcription factors, e.g. GATA-1 (Boyes et al. 1998), EKLF (Zhang and 
Bieker 1998), and MyoD (Puri et al. 1997a; Puri et al. 1997b). Via MyoD, they 
are critical for muscle cell terminal differentiation ex vivo and in vivo (Puri et al. 
1997a; Puri et al. 1997b). Furthermore, p300/CBP are essential for 
transformation by viral oncoproteins such as E1A (Arany et al. 1994; Eckner 
et al. 1994), and papilloma-virus E7 (Patel et al. 1999; Zimmermann et al. 
1999). Consistent with this, there is evidence that they are required for the 
G1/S transition in cycling cells (Ait-Si-Ali et al. 1998; Ait-Si-Ali et al. 2000; 
Chan et al. 2001).  
 
2.3.4. Acetylation of Non-Histone Substrates 
Besides histones, many HATs can also acetylate other proteins. 
Substrates include non-histone chromatin proteins, such as the members of 
the high mobility group proteins (HMG; Wong et al. 1991). Moreover, many 
sequence-specific transcription factors, for example p53 (Gu and Roeder 
1997, Liu et al. 1999), EKLF (Zhang and Bieker 1998), E2F1 (Martinez-Balbas 
et al. 2000; Marzio et al. 2000), HNF-4 (Soutoglou et al. 2000; Soutoglou et al. 
2001), and dTCF (Waltzer and Bienz 1998), several cofactors, such as ACTR 
(Chen et al. 1999b), and general transcription factors (Imhof et al. 1997) can 
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be acetylated by one or more HATs (reviewed in Sterner and Berger 2000; 
Roth et al. 2001). Acetylation can alter their DNA-binding activities (E2F1, 
GATA-1, and p53), stabilize protein levels (E2F1), regulate nuclear 
localization (HNF-4), or affect protein-protein interactions (TCF and ACTR). 
Moreover, PCAF undergoes autoacetylation (Liu et al. 2000), which may 
facilitate intramolecular interactions and regulate HAT activity. Finally, 
proteins such as tubulin (reviewed in Polevoda and Sherman 2002; Palazzo 
et al. 2003) and two members of the importin-α protein family involved in 
nuclear import can also be acetylated (Bannister et al. 2000). Thus, while 
acetylation is apparently an important step in regulation of a plethora of 
transcriptional regulation pathways, it also regulates other cellular processes.  
 
2.4. DNA and Histone Methylation 
Many chromatin-modifying-activities other than HATs/HDACs have been 
identified. DNA methylation has been associated with epigenetic silencing and 
maintenance of genome integrity (Geiman and Robertson 2002, Robert, 
2003). Aberrant DNA methylation contributes to carcinogenesis, as it results 
in alteration of gene expression (Rhee et al. 2002, Di Croce et al. 2002). For 
example, in colorectal cancer, the loci of mlh1, mgmt, and cdkn2a are 
hypermethylated, leading to downregulation of the corresponding gene 
products (Rocco and Sidransky 2001; Kondo et al. 2003). The enzymes 
catalyzing DNA methylation are the DNA methyltransferases (DNMTs). At 
least DNMT1, the predominant DNA methyltransferase in human cells, has 
been found to associate with transcriptional corepressors, notably with the 
tumor suppressor Rb (see chapter 3.1. pp. 29; Robertson et al. 2000).  
Besides DNA, histone tails are also substrates for methylation, which can 
occur at both arginine and lysine residues (for review, see Zhang and 
Reinberg 2001). For example, methylation of H3K9 by lysine-specific histone 
methyltransferases (HMTs), such as SUV39H1, is a critical step in 
transcriptional silencing (Peters et al. 2001; Peters et al. 2002; Schotta et al. 
2002). Methylated H3K9 recruits the HP1 protein, which induces 
heterochromatin formation (Lachner et al. 2001). Interestingly, SUV39H1 and 
HP1 can interact with HDACs, suggesting that histone deacetylation and 
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histone methylation cooperate to induce transcriptional silencing at 
chromosomal loci (Vaute et al. 2002). However, histone lysine methylation 
does not always coincide with repression or silencing. In yeast, active genes 
strictly correlate with trimethylated H3K4, whereas inactive genes exhibit both 
di- and trimethylated H3K4 (Santos-Rosa et al. 2002). Therefore, lysine 
methylation may be important for transactivation as well as repression, at 
least in yeast.  
The enzymes catalyzing transfer of methyl-moieties to arginines are the 
protein arginine methyltransferases (PRMTs). Apparently, they are involved in 
both transactivation and repression (for reviews see McBride and Silver 2001; 
Stallcup 2001; Davie and Dent 2002; Kouzarides 2002). For example, PRMT1 
and CARM1 can act as coactivators of hormone receptors following hormone 
treatment of human cells (Chen et al. 1999a; Koh et al. 2001; Ma et al. 2001; 
Xu et al. 2001b). In contrast, PRMT5 seems to be required for repression of 
the human ccne1 gene (encoding Cyclin E), as it was recently purified as a 
subunit of a transcriptional repressor complex specific for the ccne1 promoter 
(Fabbrizio et al. 2002). In summary, while DNA methylation is specific for 
gene silencing, histone methylation may result in gene repression or 
activation, depending on the cellular and promoter context.  
 
2.5. Histone Phosphorylation 
Histones are also substrates for kinase dependent phosphorylation 
(Berger 2002; Geiman and Robertson 2002). In human cells, phosphorylation 
of H3S10 occurs after treatment of cells with epidermal growth factor (EGF; 
Chadee et al. 1999; Sassone-Corsi et al. 1999). Moreover, recent CHIP data 
showed that EGF-activated genes indeed are both acetylated and 
phosphorylated at H3 (Cheung et al. 2000). Interestingly, kinetic analyses 
suggest that phosphorylation precedes acetylation. In fact, it may be an 
important determinant in HAT recruitment, as several HATs display 
preference for phosphorylated H3. The kinase responsible for histone 
phosphorylation appears to be Rsk2, which has been implicated in growth 
control (Sassone-Corsi et al. 1999; Merienne et al. 2001). In yeast, a H3S10 
kinase complex has been purified that contains Snf1p as catalytic subunit (Lo 
et al. 2001). Snf1p and Gcn5p function in an obligate sequence to enhance 
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ino1 transcription by modifying histone H3S10 and K14, respectively (Lo et al. 
2000). Thus, phosphorylation and acetylation are targeted to the same 
histone in a highly coordinated manner.  
 
2.6. Chromatin-Remodeling-Complexes 
All the enzymes described above covalently modify either DNA or DNA 
associated proteins. In contrast, ATP-dependent chromatin-remodeling-
enzymes utilize the energy from ATP hydrolysis to induce conformational 
changes in chromatin (for reviews, see Guyon et al. 1999; Phelan et al. 1999; 
Becker and Horz 2002, Kingston and Narlikar 1999; Fry and Peterson 2002; 
Peterson 2002). By exposing or occluding specific DNA sequences, they 
determine whether DNA is accessible or not in the context of chromatin. Like 
HATs, many of the enzymatic subunits of chromatin-remodeling-complexes 
contain a variety of domains that are associated with transcriptional functions, 
for example bromodomains (in yeast Swi2p), chromodomains, and PhD 
fingers (both in human Mi-2). Based on sequence similarities in their catalytic 
ATPase domain, chromatin-remodeling-enzymes can be subdivided in three 
families: The Swi2/Snf2 family, the ISWI family, and the Mi-2 family (reviewed 
in Narlikar et al. 2002). Except for Mi-2, which has only been described in 
human cells, orthologues of the other two families have been identified in 
yeast, Drosophila, and humans, suggesting that some of these enzymes play 
highly conserved roles in chromatin-remodeling. While all three families are 
capable of inducing conformational changes in chromatin that alter DNA 
accessibility, there are critical differences in molecular mechanisms. For 
instance, histone tail removal negates remodeling by NURF, a complex 
containing Drosophila ISWI, but does not affect remodeling by Brg1, a human 
Swi2/Snf2 family protein (Langst et al. 1999; Langst and Becker 2001, Clapier 
et al. 2001). Thus, the precise mechanism of chromatin-remodeling employed 
by each family remains to be elucidated.  
Like HATs, chromatin-remodeling-enzymes occur in cells as subunits of 
large multi-subunit complexes (Narlikar et al. 2002). In yeast, there are two 
complexes containing Swi2/Snf2-like subunits, the Swi/Snf complex, and the 
RSC complex. The former is conserved in humans as the so-called BAF 
complex (Wang et al. 1996a; Wang et al. 1996b; Zhao et al. 1998b). It 
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contains either of two catalytic subunits, Brg1 or hBrm, a variety of Brg/hBrm-
associated-factors (BAFs), and γ-actin. The fact that γ-actin and BAF53 are 
common subunits of the BAF and Tip60 complexes suggests a general role 
for these proteins in chromatin-remodeling (Rando et al. 2000; Olave et al. 
2002). The BAF complex interacts with, and is involved in, transcriptional 
activation and repression by several transcription factors, including NFI/CTF 
(Liu et al. 2001), the glucocorticoid receptor (GR; Fryer and Archer 1998), and 
Rb (Trouche et al. 1997; Strobeck et al. 2000). The latter interaction is 
noteworthy, since Brg1 and/or hBrm are necessary cofactors for Rb-
dependent repression, and inhibition of proliferation. Cells lacking Brg1 or 
hBrm exhibit a transformed phenotype, and reintroduction of Brg1 induces cell 
cycle arrest and flat cell morphology, suggesting induction of senescence. 
Furthermore, Brg1 itself (Wong et al. 2000) and two other subunits of the BAF 
complex, BAF47/Ini1/Snf5 (Versteege et al. 1998; Klochendler-Yeivin et al. 
2000; Roberts et al. 2002; Versteege et al. 2002) and BRCA1 (Bochar et al. 
2000; Morrow and Gradishar 2002; Venkitaraman 2002), are tumor 
suppressors. In summary, the BAF complex appears to play an important role 
in transcriptional regulation and proliferation control in mammalian cells.  
 
2.7. Combinatorial Function of Chromatin-Modifying and/or Remodeling-
Complexes in Transcription 
Studies in yeast have shown that chromatin-remodeling-complexes and 
HAT-complexes are functionally connected. For example, while neither SAGA 
subunit deletions, nor mutations of the Swi/Snf-complex-components are 
lethal, composite mutations of subunits of both complexes cause loss of 
viability (Roberts and Winston 1997). Consistent with this hypothesis, ordered 
recruitment of both kinds of complexes to the HO promoter by the 
transcription factor Swi5p has been demonstrated in yeast, revealing that 
Swi/Snf-complex-dependent chromatin-remodeling is a prerequisite for SAGA 
recruitment (Cosma et al. 1999; Cosma 2002). In contrast, on the pho8 
promoter SAGA recruitment appears to precede Swi/Snf-complex binding 
(Gregory et al. 1999). Thus, different promoters may exhibit distinct 
requirements for ordered action of various complexes. Additionally, 
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recruitment of SAGA to many genes involved in mitotic exit has been shown 
to require the Swi/Snf-complex, maybe due to the highly condensed 
metaphase chromosome structure (Krebs et al. 2000). In mammalian cells, 
E2F/Rb-dependent gene repression involves HDACs as well as the 
Brg1/hBrm, the homologues of the Swi2/Snf2-enzymes in yeast. In summary, 
transcriptional regulation often requires concerted function of several distinct 
complexes.  
In addition, some HATs interact with each other in vivo (for example Chen 
et al. 1997). In fact, PCAF was first identified as a protein associated with 
p300/CBP (Yang et al. 1996). However, whether this interaction occurs within 
the context of the STAGA/TFTC/PCAF complexes, is not clear. During 
terminal differentiation of myocytes, the transcription factor MyoD recruits both 
p300 and PCAF (Puri et al 1997a; Puri et al. 1997b). However, while the HAT 
activity of PCAF appears to be required for acetylation of MyoD, the HAT 
activity of p300 is essential for gene specific expression in the cell fusion 
process, even though the specificity of these regulatory events is currently a 
matter of debate (Vaute et al. 2002). These data show that individual 
chromatin-remodeling-enzymes may perform specific functions even as parts 
of multi-subunit protein complexes. Furthermore, they may play roles in 
transcription that go beyond simple histone and factor acetylation, such as 
assembly of RNA polymerase or other rate limiting steps.  
 
 
3. Cell Cycle Control in Mammalian Cells 
3.1. The Cell Cycle  
In order to reproduce, eukaryotic cells undergo the cell division cycle, or 
short, the cell cycle. This process can be divided into four phases (Figure 2): 
Two gap phases, G1 and G2, are interrupted by the synthesis phase (S), 
during which the DNA is replicated. Following G2 is mitosis (M), in which the 
nucleus and subsequently the cytoplasm divide to give rise to two daughter 
cells. G1 represents a regulatory switch, during which cells must decide 
whether to enter a new cell cycle, or whether to withdraw from the cycle and 
enter quiescence (G0), for example due to contact inhibition, serum 
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withdrawal, or TGF-β treatment (reviewed in Pardee 1989; Sherr 1994b; Sherr 
1994a). The decision must be made before cells pass the restriction point (R), 
after which they are dedicated to completing the cycle even in absence of 
mitogenic factors (Zetterberg et al. 1995; Planas-Silva and Weinberg 1997; 
Blagosklonny and Pardee 2002). However, cell cycle progression can be 
halted or delayed in G1 and G2 through so-called checkpoint signaling 
cascades, which are activated, for example, by DNA-damage (reviewed in 
O'Connor 1997; Molinari 2000). During cellular transformation, deregulation of 
the cell cycle occurs due to accumulation of mutations in genes governing 
restriction point and checkpoint decisions (reviewed in Bartkova et al. 1997; 
Kaelin 1997; Molinari 2000). Thus, tumor cells commonly fail to withdraw from 
the cell cycle. In summary, whereas most normal cells in metazoans are not 
actively dividing (i.e. are in G0), tumor cells are able to cycle without restraint.  
G1G2
G0
M
S
R!  
Figure 2: The Cell Cycle of Eukaryotes. 
The eukaryotic cell cycle is divided in four phases: Two gap phases (G1 and G2) that are 
separated by the synthesis phase (S), during which the DNA is replicated. After G2, cells 
divide in mitosis (M), and enter a new G1. Cells can withdraw from the cycle, and arrest in 
quiescence (G0). Once cells are past the so-called restriction point (R) in late G1, they are 
dedicated to finishing the initiated cell cycle.  
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The G1 Phase of the cell cycle is regulated at a variety of levels (Figure 
3). One critical player is the transcription factor E2F (reviewed in Nevins et al. 
1997b; Johnson and Schneider-Broussard 1998; Nevins 1998; DeGregori 
2002; Stevaux and Dyson 2002; Trimarchi and Lees 2002). E2F is an obligate 
heterodimer consisting of an E2F and a DP moiety. It regulates transcription 
of a variety of target genes (Ishida et al. 2001; Kel et al. 2001; Muller et al. 
2001; Weinmann et al. 2001; Polager et al. 2002; Ren et al. 2002; Stanelle et 
al. 2002; Weinmann et al. 2002). These encode proteins involved in 
regulatory events before and during S-Phase (ccna1, ccne1, ccne2, cdc2, and 
p107), and genes necessary for DNA metabolism (such as dhfr, ts, and tk) 
and replication (mcm2-7, polα2, cdc6, and orc1). In addition, various other 
genes have recently been found to be regulated by E2F, suggesting roles for 
E2F in processes such as mitosis (for instance bub1), DNA repair (for 
example polδ, msh2, and brca1), and apoptosis (several caspases, p73, 
apaf1, and cdkn2a). Interestingly, E2F may also participate directly in 
surveillance of replication, as it localizes to origins of replication in a ternary 
complex with Mre11 and Nbs1, proteins known to be crucial for genomic 
integrity (Maser et al. 2001). Such a complex may suppress replication after 
DNA-damage, thus preventing genomic instability.  
In quiescence and during G1/S transition, E2F activity is negatively 
regulated by the three Retinoblastoma (Rb) family proteins, p110Rb, p107, and 
p130 (Figure 3; reviewed in Nevins et al. 1997a; Harbour and Dean 2000b; 
Nevins 2001, Harbour and Dean 2000b; Classon and Harlow 2002, DeGregori 
2002; Trimarchi and Lees 2002). All three bind E2F and these complexes 
repress activation of E2F target genes (see chapter 3.2.4. pp. 41). Repression 
of E2F targets is necessary for Rb-family proteins to exert their growth 
inhibitory effect. 
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Figure 3: Regulation of the G1/S Transition in Mammalian Cells. 
Regulation of the mammalian cell cycle in G1 converges on the E2F/Rb transcriptional 
network. For further details, see text. Growth promoting proteins are shown in blue, while 
growth inhibitory proteins are in red.  
 
Rb-family proteins in turn are negatively regulated by several Cyclin-
Dependent-Kinases (CDKs). CDKs are serine/threonine kinases that govern 
the transitions between the distinct phases of the cell cycle (reviewed in 
Hengstschlager et al. 1999; Blagosklonny and Pardee 2002). Phosphorylation 
of Rb-family proteins by CDKs results in its dissociation from E2F, and from 
several corepressors (see chapter 3.2.4. pp. 41). In order to be active, CDKs 
must form heterodimers with a Cyclin subunit (reviewed in Hengstschlager et 
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al. 1999; Obaya and Sedivy 2002). mRNA and protein levels of distinct 
Cyclins are induced sequentially as cells exit from quiescence and progress 
through G1. At least some ccn and cdk genes (encoding the Cyclins and 
CDKs, respectively) are direct targets of E2F, creating a positive feedback 
regulation loop. During early G1, the principal kinases are CDK4 and CDK6, 
which bind D-type Cyclins (Cyclin D1, D2, and D3; reviewed in (Sherr 1993; 
Sherr 1994b; Hamel and Hanley-Hyde 1997; Planas-Silva and Weinberg 
1997; Hengstschlager et al. 1999; Obaya and Sedivy 2002). Later, the 
predominant kinase is CDK2, bound by either Cyclin E1 or E2 (in late G1), or 
by Cyclin A (in S). While D-type Cyclins appear to strictly regulate Rb-family 
phosphorylation, Cyclin E1 is required for S-Phase entry even in the absence 
of functional Rb, suggesting that other substrates are rate limiting for Cyclin 
E1 induced proliferation (Ohtsubo et al. 1995; Geng et al. 1996; Alevizopoulos 
et al. 1997; Lukas et al. 1997; Alevizopoulos et al. 1998). These may include 
NPAT (which is involved in histone gene transcription during S-Phase; Zhao 
et al. 1998a; Ma et al. 2000; Zhao et al. 2000), several subunits of the BAF 
complex (Shanahan et al. 1999), the HAT p300/CBP (Perkins et al. 1997; Ait-
Si-Ali et al. 1998; Ait-Si-Ali et al. 2000), and the CDK inhibitor p27Kip1 (Sheaff 
et al. 1997; Vlach et al. 1997), all of which can be phosphorylated by Cyclin 
E/CDK2. During S-Phase CDK4/6 activities are low, but CDK2 activity is 
sustained, as E-type Cyclins are replaced by Cyclin A (reviewed in Yam et al. 
2002). In mammalian cells, Cyclin A/CDK2 also regulates initiation of DNA 
replication, as it binds to, and colocalizes with, PCNA at the sites of DNA 
replication (Cardoso et al. 1993; Sobczak-Thepot et al. 1993; Fotedar et al. 
1996). Furthermore, Cyclin A/CDK2 can bind E2F1, and it also 
phosphorylates DP1 in S/G2, resulting in loss of DNA-binding of E2F/DP 
heterodimers (see chapter 3.2.1. pp. 35; Krek et al. 1994; Krek et al. 1995). 
These events are presumably important in shutting down E2F-dependent 
transcription after S-Phase entry, preventing untimely DNA synthesis.  
CDK inhibitors (CKIs) provide yet another level of regulation (Figure 3; 
reviewed in Ekholm and Reed 2000; Moller 2000; Blagosklonny and Pardee 
2002; Ortega et al. 2002). CKIs can be divided into two classes, the INK 
family proteins (p15INK4b, p16INK4a, 18INK4c, and p19INK4d), and the Cip/Kip 
family (p21Cip1, p27Kip1 and p57Kip2). While the INK proteins specifically inhibit 
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CDK4/6 by preventing their association with D-type Cyclins, Kip/Cip family 
proteins inhibit virtually all G1-specific Cyclin/CDK complexes. In contrast to 
INK family CKIs, Kip/Cip proteins do not prevent complex formation of active 
kinases, but directly bind to a Cyclin/CDK heterodimer to inhibit its catalytic 
activity. Interestingly, p21Cip1 and p27Kip1 can also act as assembly factors for 
D-type Cyclin/CDK complexes, and thus have somewhat antagonistic roles in 
cell cycle regulation (LaBaer et al. 1997). Nevertheless, overexpression of 
CKIs generally induces cell cycle arrest. Some CKIs appear to participate in 
regulation of specific functions, such as senescence (p16INK4a; Haber 1997; 
Huschtscha and Reddel 1999; Sharpless and DePinho 1999; Bringold and 
Serrano 2000; Lundberg et al. 2000), TGFβ response (p15 INK4b and p21Cip1; 
Hannon and Beach 1994; Reynisdottir et al. 1995; Sandhu et al. 1997; Feng 
et al. 2000; Feng et al. 2002), and DNA-damage induced growth arrest 
(induction of p21Cip1 through p53-dependent transactivation; for review see 
Boulaire et al. 2000; Bartek and Lukas 2001).  
Many components of the network regulating S-Phase entry are targets of 
tumorigenic mutations. In fact, Rb exhibits features of a classical tumor 
suppressor in mice and humans, and deregulation of Rb/E2F-network 
proteins is a common event in tumorigenesis (reviewed in Weinberg 1991; 
Weinberg 1992; Sherr 1996; Nevins 2001; Classon and Harlow 2002; Sherr 
and McCormick 2002). For example, the gene encoding Cyclin D1 is often 
amplified in breast tumors, as well as some types of neck and head 
carcinomas (Donnellan and Chetty 1998; Steeg and Zhou 1998, Donnellan 
and Chetty 1998). While it is not clear whether ccne1 itself is an oncogene, it 
is often overexpressed in breast cancer, and this correlates with poor 
prognosis (Donnellan and Chetty 1999). Low levels of p27Kip1 also correlate 
with poor prognosis, and in one mouse knockout model p27Kip1 behaves like a 
haplo-insufficient tumor suppressor (Fero et al. 1996; Fero et al. 1998; 
Donnellan and Chetty 1999; Moller 2000). p16INK4a is one of two tumor 
suppressors encoded by the cdkn2a locus (the other one being p14ARF), 
which is frequently mutated or silenced in tumors (Sharpless and DePinho 
1999; Serrano 2000; Sherr 2001; Ortega et al. 2002). In summary, 
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deregulation of the Rb/E2F pathway, and as a consequence, liberation of E2F 
activity, is probably an event necessary for tumorigenesis.  
 
3.2. The Transcription Factor E2F: A Critical Regulator of S-Phase Entry 
3.2.1. Biochemistry of E2F 
The transcription factor E2F was originally identified as a cellular activity 
that is required for transcriptional activation of the adenoviral E2 gene 
promoter (reviewed in Nevins 1992). Like many transcription factors, E2F is a 
heterodimer of two different polypeptides, an E2F and a DP moiety, and 
dimerization is essential for DNA-binding and transcriptional regulation 
(reviewed in DeGregori 2002, Stevaux and Dyson 2002; Trimarchi and Lees 
2002). In vitro binding assays revealed that all E2F/DP dimers preferentially 
bind the same DNA sequence, TTTSGCGCSAAA. However, while one CHIP 
study did not show any specific preference of distinct E2Fs for certain DNA 
sequences, other studies indicate, that individual E2Fs may indeed exhibit 
differential specificities for a given target gene (Takahashi et al. 2000; Wells et 
al. 2000). Thus, whether distinct E2F/DP heterodimers possess intrinsic ability 
to distinguish between target genes remains to be determined.  
Until now, six e2f and two dp genes have been identified, giving rise to at 
least seven E2F proteins (E2F1, E2F2, E2F3a, E2F3b, E2F4, E2F5, and 
E2F6; Figure 4) and three DP proteins (DP1, DP2, and DP3; reviewed in 
(Dyson 1998; Helin 1998). The E2F proteins are commonly subdivided into 
three groups: “Activating” E2Fs (E2F1, E2F2, and E2F3a), “repressing” E2Fs 
(E2F4, and E2F5), and the structurally distinct E2F6, which is also associated 
with repression (reviewed in DeGregori 2002, Stevaux and Dyson 2002; 
Trimarchi and Lees 2002). The division into "activating" and "repressing" E2Fs 
is based on biological observations and is not fixed, as the domain containing 
transactivating capability overlaps with the domain responsible for repression 
(Figure 4). Furthermore, E2F1-3a may be involved in repression in vivo, while 
E2F4 and E2F5 can induce proliferation in some settings, again arguing in 
favor of some functional overlap between these two classes. The role of 
E2F3b is unclear, with roles consistent with both activation and repression 
(Leone et al. 2000; Wu et al. 2001).  
 34
Structurally, the E2F gene products are related polypeptides (Figure 4; 
reviewed in Trimarchi and Lees 2002). All E2F proteins contain a core domain 
consisting of a DNA-binding-domain (DBD), a marked-box (MB), and a 
leucine-zipper (LZ). This core is responsible for interaction with the DP 
proteins, and for DNA-binding (Bandara et al. 1993; Helin et al. 1993; Krek et 
al. 1993; Wu et al. 1995). In addition, all E2Fs except E2F6 possess a C-
terminal transactivation domain (TAD)/Rb-family-binding domain. This domain 
mediates protein-protein interactions with both Rb-family proteins (Bagchi et 
al. 1991; Bandara et al. 1991; Chittenden et al. 1991; Ewen et al. 1991; 
Hannon et al. 1993; Li et al. 1993), and transcriptional coactivators, such as 
TRRAP (McMahon et al. 1998). Activating E2Fs (but not E2F3b) further 
possess an N-terminal domain crucial for the interaction with Cyclin A/CDK2 
(Krek et al. 1994; Krek et al. 1995), and a nuclear localization signal (NLS) 
that is also present in E2F3b (Muller et al. 1997; Verona et al. 1997). In 
contrast, repressing E2Fs apparently contain a nuclear export signal (NES), 
and are subject to CRM1-dependent nuclear export (Gaubatz et al. 2001; 
Apostolova et al. 2002). All activating E2Fs can be acetylated by PCAF and/or 
p300/CBP, and three lysines critical for acetylation of E2F1 are conserved in 
E2F2 and E2F3, but not in repressing E2Fs or E2F6 (Martinez-Balbas et al. 
2000; Marzio et al. 2000). Since it lacks the TAD/Rb-family-binding domain, 
E2F6 can not repress E2F targets via Rb-family proteins (Trimarchi et al. 
1998). Instead, it recruits PcG-proteins to induce Rb-independent repression 
of E2F target genes (Trimarchi et al. 2001).  
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Figure 4: The E2F-family of Transcription Factors: Structural Features. 
All E2F proteins possess a core domain that mediates DNA-binding and DP dimerization 
(encompassing the marked-box, MB, and the leucine-zipper, LZ sequence motifs). The 
TAD/Rb-family-binding domain (TAD) is only present in E2F1-5. The activating E2Fs (E2F1, -
2, and -3a) also share a canonical nuclear localization signal (NLS), while the repressing 
E2Fs (E2F4 and -5) contain a nuclear export signal (NES). E2F6 lacks the TAD/Rb-family 
binding domain, and instead contains a C-terminal repression domain responsible for 
interaction with Polycomb-group (PcG) proteins.  
 
3.2.2. Biological Activities of E2F 
Activating E2Fs are capable of driving quiescent cells into S-Phase (and 
sometimes induce apoptosis), when overexpressed in mouse embryonic 
fibroblasts (MEFs) and transformed cells (Johnson et al. 1993; Lukas et al. 
1996). Ectopic expression of E2F1 can also bypass G1 arrests imposed by 
expression of p16INK4a, TGF-β, and DNA-damage (DeGregori et al. 1995; 
Mann and Jones 1996; Alevizopoulos et al. 1997). Overexpression of E2F1 
can transform cell lines, or cooperate with oncogenic Ras to transform primary 
cells (Johnson et al. 1994; Singh et al. 1994; Xu et al. 1995). However, at 
least in some contexts, ectopic E2F1 can also induce senescence. Most 
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biological activities have been associated with the abilities of activating E2F to 
induce transcription of target genes required for entry and progression of S-
Phase (reviewed in Lavia and Jansen-Durr 1999). Consistent with this, 
activating E2Fs are downregulated in quiescent cells, but accumulate as cells 
enter a new cycle (Slansky et al. 1993; Slansky and Farnham 1996; Leone et 
al. 1998). When bound by Rb, however, activating E2Fs loose the ability to 
activate transcription; instead, these complexes with Rb repress transcription 
(Helin et al. 1992; Flemington et al. 1993; Helin et al. 1993).  
E2F4 also binds Rb, and seems to account for the majority of E2F activity 
in most cells (Beijersbergen et al. 1994). Furthermore, E2F4 and E2F5 
specifically interact with p130 and p107, respectively, and these complexes 
accumulate in the nuclei of quiescent cells to repress transcription (Ikeda et 
al. 1996; Moberg et al. 1996), with E2F4/p130 complexes being predominant 
(Beijersbergen et al. 1994; Hijmans et al. 1995; Takahashi et al. 2000). In 
contrast to activating E2Fs, repressing E2Fs are expressed throughout the 
cell cycle, but are exported from the nucleus as cells progress into S-Phase 
(Lindeman et al. 1997; Verona et al. 1997; Gaubatz et al. 2001). Accordingly, 
E2F4 and E2F5 only possess weak S-Phase induction ability, but can induce 
S-Phase entry, when co-expressed with DP1 (Alevizopoulos et al. 1998).  
Besides inducing proliferation, E2F1 can also promote apoptosis, 
probably through transactivation of genes such as cdkn2a-arf (Zhang et al. 
1998; Parisi et al. 2002), p73 (Lissy et al. 2000; Stiewe and Putzer 2000), 
apaf1 (Moroni et al. 2001), several caspase genes (Nahle et al. 2002), and 
others (reviewed in Phillips and Vousden 2001; Ginsberg 2002). Both p53-
dependent and p53-independent mechanisms contribute to E2F1-induced cell 
death (Qin et al. 1994; Shan and Lee 1994; Wu and Levine 1994; Hiebert et 
al. 1995; Hsieh et al. 1997; Pan et al. 1998). Consistent with this, protein 
levels of E2F1 are upregulated following DNA-damage, as is DNA-binding 
activity (Blattner et al. 1999; Hofferer et al. 1999; Lin et al. 2001). While these 
regulatory mechanisms are apparently unique to E2F1, both E2F1 and E2F3 
contribute to apoptosis in developing mice (Phillips et al. 1997; Pan et al. 
1998; Tsai et al. 1998; Phillips et al. 1999; Ziebold et al. 2001). Based on 
these data, a model has been suggested, whereby activating E2Fs contribute 
towards a pool of total activity, which induces proliferation when above a 
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certain threshold, and apoptosis, when total activity surpasses a second, 
higher threshold (Ziebold et al. 2001). Support for this model has been 
obtained from studies with mice harboring gene deletions for individual E2F 
genes (see next chapter).  
 
3.2.3. Lessons from Mouse Models 
All six individual E2F proteins have been inactivated in mice by targeted 
gene deletion. Unexpectedly, the observed phenotypes are often devoid of 
the general defects in proliferative processes that would be expected from 
mutations in major components of cell cycle regulation pathways. This has 
been attributed mostly to the redundancy of individual E2F proteins. 
Nevertheless, some important clues can be drawn from studies performed 
with mouse models and MEFs derived from these mice (reviewed in 
DeGregori 2002).  
Mice lacking E2F1 show defects in T-lymphocyte maturation due to 
reduced apoptosis (Field et al. 1996). Additionally, hyperproliferation and 
tumor development can be observed in older mice, suggesting that E2F1 has 
growth inhibiting and tumor suppressor activities in vivo (Yamasaki et al. 
1996). E2F2-/--mice also exhibit defects in T-cell maturation, but not due to 
diminished apoptosis (Murga et al. 2001). Instead, T-cells proliferate 
inappropriately, leading to an excess of self-reactive mature memory cells, 
and ultimately to autoimmune diseases. Thus, these two E2Fs cooperate to 
regulate the major components of immunological self-tolerance, at least in 
mice. E2F3 deletion results in partial lethality, as offspring arises only at a 
quarter of the expected frequency (Humbert et al. 2000b). MEFs from E2F3-/--
mice exhibit decreased proliferation rates, and are delayed in entering S-
Phase after exiting from quiescence. Induction of several E2F target genes is 
delayed, and weaker than in wild-type MEFs. While similar deregulation is 
absent from E2F1-/--MEFs, it is noteworthy that E2F1 overexpression can 
rescue the proliferation defects caused by deletion of E2F3. Another study 
showed that absence of all three activating E2Fs results in a total loss of 
proliferation, with MEFs arresting in all phases of the cell cycle (Wu et al. 
2001). Somewhat contradictory to this, it was recently published that, while 
functional activating E2F is critically required for cell cycle entry from 
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quiescence, it is dispensable for exponential growth of MEFs (Rowland et al. 
2002).  
While MEFs lacking E2F4 exhibit no defects in proliferation or cell cycle 
control, E2F4-/--mice are smaller, and show several differentiation defects 
(Humbert et al. 2000a; Rempel et al. 2000; Fajas et al. 2002). Similarly, 
deletion of E2F5 results in no detectable proliferation defect, but mice die due 
to hydrocephalus resulting from impaired development of neuronal tissue 
(Lindeman et al. 1998). Thus, repressive E2Fs apparently have non-
redundant functions in differentiation on mice. E2F4-/-/E2F5-/--mice die during 
embryogenesis, while MEFs from these mice are not impaired in induction of 
quiescence, presumably due to compensatory mechanisms by other E2F 
proteins (Gaubatz et al. 2000). However, they fail to arrest in response to 
p16INK4a overexpression, suggesting that repressive E2Fs are necessary for 
some, but not other growth inhibitory pathways. Finally, E2F6-/--mice are also 
viable, and MEFs from these mice show no defects in proliferation or 
induction of quiescence following serum withdrawal (Storre et al. 2002). 
However, mice lacking E2F6 exhibit homeotic transformation of the axial 
skeleton, similar to those found in mutations of Polycomb proteins, which fits 
well with the finding that E2F6 can associate with several PcG group proteins 
(Trimarchi et al. 2001).  
The three members of the Rb-family have also been mutated in mice. 
Mice lacking one copy of the rb1 gene are viable, but highly prone to tumor 
development. Deletion of both copies results in embryonic lethality due to 
excessive proliferation and apoptosis (Clarke et al. 1992; Jacks et al. 1992; 
Lee et al. 1992). Mice lacking p107 or p130 exhibit mouse-strain-dependent 
hyperplasia, cell cycle deregulation and apoptosis (p107-/-), or embryonic 
lethality (p130-/-), respectively (Cobrinik et al. 1996; Lee et al. 1996). 
Combined deletion of p107 and p130 results in death shortly after birth, again 
dependent on the mouse strain (LeCouter et al. 1998a; LeCouter et al. 
1998b). Mutation of Rb and either p107 or p130 aggravates the defects 
observed in Rb-/--mice (Robanus-Maandag et al. 1998; Dannenberg et al. 
2000). MEFs from mice lacking single Rb-family members display cell cycle 
defects, but still arrest in response to serum withdrawal. Composite p107-/-
/p130-/--MEFs fail to arrest in response to serum withdrawal and p16INK4a 
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overexpression (Hurford et al. 1997). Finally, triple-knockout (TKO) MEFs 
completely fail to respond to any growth arrest signals, including DNA-
damage and p27Kip1 overexpression, and do not undergo senescence 
(Dannenberg et al. 2000; Sage et al. 2000). These data indicate that Rb-
family members are critical for normal cell cycle regulation.  
Interesting clues to the functions of individual E2F and Rb-family 
members stem from crosses of KO-mice heterozygous or homozygous for 
distinct E2F- and Rb-family proteins. For example, loss of E2F1 rescues, at 
least in part, from excessive proliferation and apoptosis found in Rb-/--mice 
(Tsai et al. 1998). Moreover, tumorigenesis in Rb+/--mice is reduced, when 
E2F1 is lost simultaneously (Pan et al. 1998). These data suggest growth-
promoting roles for E2F1 in vivo, in addition to the growth inhibitory roles 
observed in E2F1-/--mice. Similarly, loss of E2F3 reduces excessive apoptosis 
and proliferation in Rb-/--mice, further proving the importance of E2F3 for 
proliferation (Ziebold et al. 2001). Interestingly, E2F4 loss also suppresses 
tumorigenesis, inappropriate gene expression, and proliferation in Rb-/--mice 
(Lee et al. 2002). Biochemical analyses suggest that this tumor suppression 
occurs via a novel mechanism: E2F4 loss allows p107 and p130 to regulate 
the normally Rb-regulated E2F1, -2, and -3. All these data argue in favor of a 
model, whereby Rb specifically regulates activating E2Fs, who contribute 
towards a pool of total E2F activity that must exceed a certain threshold to 
sustain proliferation. In contrast, E2F4 and -5 are regulated by p107 and 
p130, and are more critical for induction of quiescence. The fact that 
components of the Rb/E2F regulatory cascade are often mutated in tumors 
substantiates the relevance of this pathway in regulation of proliferation in 
vivo.  
 
3.2.4. E2Fs and Rb-Family Proteins Modify Chromatin Structure 
As described above, Rb and E2F proteins act to regulate transcription of 
E2F target genes. The molecular mechanisms underlying this regulation have 
only recently started to be understood. E2F-dependent transactivation may 
involve a variety of other transcription factors that have been shown to interact 
and/or cooperate with E2Fs, such as YY1 (Schlisio et al. 2002), and TBP 
(Hagemeier et al. 1993). Moreover, TRRAP and Gcn5/PCAF (Martinez-
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Balbas et al. 2000; Marzio et al. 2000) as well as p300/CBP (Trouche et al. 
1996; Trouche and Kouzarides 1996), also interact with E2F, making histone 
acetylation a likely participant in E2F-dependent transactivation.  
Downregulation of transcription by E2F has been studied in-depth in the 
past few years (reviewed in Harbour and Dean 2000a). Importantly, inhibition 
of activation and active repression are biochemically distinct (Ross et al. 
1999; Ross et al. 2001). The former appears to block interactions of E2F with 
activators, such as TBP (Hagemeier et al. 1993). The latter apparently 
involves several classes of chromatin-remodeling-enzymes. First, Rb, p107, 
and p130 all interact with Brg1/hBrm, the enzymatic subunits of the BAF 
complex (see above; Dunaief et al. 1994; Strober et al. 1996; Trouche et al. 
1997). Growth arrest induced by Brg1/hBrm depends on functional Rb, and 
conversely, Brg1 is required for Rb to arrest some cell lines (Strobeck et al. 
2000; Zhang et al. 2000). Thus, chromatin-remodeling by the BAF complex 
appears to be an important part of Rb-dependent repression of E2F targets in 
G0 and G1.  
Rb also interacts with HDAC1, 2, and 3, and p107 and p130 bind HDACs 
as well (Brehm et al. 1998; Kuo and Allis 1998; Magnaghi-Jaulin et al. 1998). 
Recruitment of HDAC can reverse histone acetylation at E2F targets, and this 
correlates with transcriptional repression (Zhang et al. 1999; Zhang et al. 
2000). Furthermore, the presence of repressive E2F4/p130/HDAC-complexes 
in quiescent cells correlates with hypoacetylated histone H3 and H4 on 
several E2F targets (Ferreira et al. 2001; Lai et al. 2001; Rayman et al. 2002). 
Thus, deacetylation of histones in E2F target gene promoters is an important 
role of Rb-family proteins.  
Cyclin/CDK-dependent phosphorylation of Rb-family proteins affects their 
interactions with corepressors (Harbour et al. 1999). Specifically, Cyclin 
D/CDK4 activity disrupts the Rb/HDAC interaction in early G1, while Cyclin 
E/CDK2 inactivates Brg1/Rb complexes (Zhang et al. 2000). The interaction 
of Rb with HDACs depends on the LxCxE motif found in many Rb interacting 
proteins (Dahiya et al. 2000; Zhang et al. 2000). Even though it is unclear 
whether the LxCxE motif in HDACs is sufficient for Rb interaction, the binding 
of HDAC is apparently essential for Rb to exert its growth inhibitory functions. 
In contrast, the Brg1/Rb interaction occurs independently of the LxCxE motif, 
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which allows formation of a ternary Brg1/Rb/HDAC complexes. Therefore, the 
question arises of whether, or how, these two different machineries interact to 
induce Rb-dependent repression of E2F targets. Recent data suggest that 
Brg1 is required for Rb/HDAC dependent repression of the ccne1 gene. In 
contrast, Rb/Brg1 is apparently sufficient to repress cdc2 and ccna1, even 
after loss of HDAC from the complex in early G1. From these results a model 
has been suggested, whereby Cyclin D/CDK4 disrupts HDAC/Rb interaction, 
leading to increased expression of Cyclin E1, which then causes 
phosphorylation and inactivation of the remaining Rb/Brg1 complexes, leading 
to transcription of other E2F target genes, such as cdc2. Another level of 
regulation is provided by a distinct Rb-containing repressor complex, which 
contains the PcG-proteins HPC2, Ring1, and CtBP (Dahiya et al. 2001). This 
complex specifically represses cdc2 and ccna1, but not ccne1, and apparently 
imposes cell cycle arrest in G2/M. In summary, individual target genes may 
exhibit different requirements for distinct corepressor and Cyclin/CDK 
complexes, and these requirements may ultimately lead to ordered, 
sequential gene expression of E2F targets (Harbour and Dean 2000a; 
Harbour and Dean 2000c).  
Rb has also been shown to recruit a complex of SUV39H1 and HP1α to 
the ccne1 promoter (Nielsen et al. 2001). Interestingly, these two proteins 
induce formation of transcriptionally silent heterochromatin (reviewed in 
Eissenberg and Elgin 2000; Dillon and Festenstein 2002; Peters et al. 2002). 
These data have led to a model, in which transcriptionally active targets are 
initially repressed by deacetylation, and then subjected to more permanent 
silencing by methylation of H3K9, which is followed by binding of HP1α and 
formation of heterochromatin. Another corepressor of the Rb/E2F is DNMT1, 
which co-purifies with Rb, E2F1, and HDAC1 (Robertson et al. 2000). These 
data suggest that DNA methylation is also important for silencing by Rb/E2F.  
E2F6 is present in cells as part of at least two distinct multi-protein 
complexes. One contains two different HMTs, the Mga/Max dimer, and 
HP1γ (see chapter 3.3. pp. 44; Ogawa et al. 2002). CHIP analysis showed 
that this complex is present on four E2F targets in quiescent cells. The other 
complex contains several Polycomb-group proteins, including RYBP, Bmi1, 
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and Ring1 (Trimarchi et al. 2001), all of which have been associated with 
transcriptional repression. Therefore, E2F6 may repress transcription through 
Rb-independent chromatin-remodeling events at E2F targets.  
 
3.2.5. DNA Tumor Viruses Target the Rb Pathway 
Many DNA tumor viruses encode proteins that inactivate Rb-family 
proteins. These include adenovirus E1A, papilloma-virus E7, and SV40 large 
T antigen. For example, E1A contains the LxCxE motif found in many Rb 
binding proteins, and thus can disrupt interactions between Rb and 
corepressors, enabling derepression of E2F genes, and cell cycle entry 
(reviewed in Ben-Israel and Kleinberger 2002). Interestingly, while targeting of 
the Rb/E2F-pathway is essential for E1A to transform cells, E1A requires 
additional functions to overcome growth arrest (Alevizopoulos et al. 1998). It 
is noteworthy that the domain required for these biological activities allows 
association of E1A with TRRAP (Deleu et al. 2001). Furthermore, TRRAP and 
the TRRAP-containing p400 complex are targets necessary for transformation 
by E1A (Fuchs et al. 2001). The p400 complex is highly similar to the Tip60 
complex and also contains TRRAP (but not Tip60). Finally, E1A also binds 
PCAF, and hence may target the other of the two TRRAP-containing HAT-
complexes (Chakravarti et al. 1999; Hamamori et al. 1999a). Thus, it appears 
that TRRAP, and presumably TRRAP-associated HAT-complexes described 
above, are important targets of E1A in cellular transformation. In summary, 
E1A may liberate E2F activity by both relieving Rb-mediated repression, and 
by targeting cofactors of E2F.  
 
3.3. The Myc/Max/Mad Network of Transcription Factors 
The Myc-family of transcription factors is composed of three different 
genes, L-myc, N-myc, and c-myc (reviewed in Luscher 2001). While the 
former two are expressed in tissue or development specific fashion in mice 
and humans, Myc, the product of the c-myc gene, is ubiquitously expressed in 
proliferating cells. Myc is extremely unstable, and is subject to 
ubiquitin/proteasome-dependent degradation (Gross-Mesilaty et al. 1998; 
Salghetti et al. 1999; Sears et al. 1999). mRNA and protein are induced 
rapidly following mitogenic stimulation, and Myc levels and activity peak in 
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early G1 (reviewed in Kelly and Siebenlist 1986; Luscher and Eisenman 
1990). Biological roles of Myc include induction of cell growth, proliferation, 
apoptosis, and suppression of terminal differentiation (reviewed in Cole and 
McMahon 1999; Dang et al. 1999; Lutterbach and Hann 1999; Eisenman 
2000; Grandori et al. 2000). Furthermore, all members of the Myc-family are 
oncogenes, and deregulation of the c-myc gene is common in a variety of 
cancers, for example lymphomas and leukemias. Similarly, N-myc is 
commonly deregulated tumors such as neuroblastoma (reviewed in Boxer and 
Dang 2001; Hoffman et al. 2002; Lutz et al. 2002).  
Myc is a member of the basic helix-loop-helix leucine-zipper (bHLH-LZ) 
family of transcription factors (reviewed in Grandori et al. 2000; Amati et al. 
2001; Eisenman 2001; Luscher 2001). In addition to an N-terminal 
transactivation domain (TAD), it contains the C-terminal bHLH-LZ, which is 
responsible for DNA-binding and dimerization with its obligatory partner Max. 
Myc/Max dimers bind the E-box (CACGTG), as well as non-canonical sites, 
and activate transcription of a variety of target genes. These include genes 
involved in cell cycle regulation (for example e2f1, ccnb1, ccnd2, ccne1, and 
cdk4), apoptosis (several caspases, apaf1, pig8), ribosomal metabolism 
(Nucleolin, Nucleophosmin, and several ribosomal proteins), protein synthesis 
and folding (eIF4F, eIF5A, several HSP chaperones), basic metabolic 
pathways (ldh, and several enzymes of the glycolytic pathway), and others 
(Grandori et al. 1996; Coller et al. 2000; O'Hagan et al. 2000; Boon et al. 
2001; Schuhmacher et al. 2001; Schuldiner and Benvenisty 2001; Menssen 
and Hermeking 2002; Schuldiner et al. 2002; Watson et al. 2002). Two 
conserved domains in the TAD of Myc, termed Myc-boxes 1 and 2 (Mb1 and 
Mb2) appear to be critical for transcriptional activation. They constitute 
interaction surfaces for a variety of proteins, including TRRAP (McMahon et 
al. 1998). It was speculated that Myc might induce histone acetylation of 
target genes, a hypothesis confirmed by our laboratory and others (Bouchard 
et al. 2001; Frank et al. 2001; Xu et al. 2001a). Another report demonstrated 
that Myc is capable of interacting with Snf5, a subunit of the BAF complex 
(Cheng et al. 1999). Furthermore, Myc associates with a variety of other 
known transcription factors and cofactors, such as p107, YY1, and Nmi1 
(reviewed in Sakamuro and Prendergast 1999). Finally, at least in vitro Myc 
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can also bind TBP (Hateboer et al. 1993; McEwan et al. 1996), and might 
therefore directly recruit the core transcriptional machinery (Roy et al. 1993). 
Interestingly, Myc can also repress transcription, through interaction with 
the Miz1 protein (Peukert et al. 1997; Schneider et al. 1997; Seoane et al. 
2001; Staller et al. 2001). Miz1 activates transcription of target gene 
promoters containing an initiator (Inr) element. Myc binding to Miz1 leads to 
repression of this transactivation, presumably by inhibiting recruitment of 
coactivators such as p300. One of the key targets of Miz1 is the cdkn2b gene 
(encoding p15INK4b), and suppression of cdkn2b transactivation is a key 
contribution of Myc-induced proliferation. Similarly, Myc represses Miz1-
dependent activation of the cip1/waf1 gene (encoding p21Cip1) following DNA-
damage (Seoane et al. 2002). In summary, Myc can activate and repress 
transcription, depending on the promoter context.  
Opposing the transactivating and proliferative effects of Myc are Mad 
family members (reviewed in Eisenman 2000; Grandori et al. 2000; Baudino 
and Cleveland 2001; Luscher 2001). These include the Mad1, Mxi1 (Mad2), 
Mad3, and Mad4 proteins. Mad protein levels are upregulated following 
induction of differentiation. When overexpressed, Mad proteins inhibit 
proliferation, apoptosis, and transformation induced by Myc, and other factors. 
Like Myc, Mad is a bHLH-LZ protein, but contains an N-terminal Sin3 
interaction domain (SID), instead of a TAD. As a consequence Mad/Max 
dimers repress target genes containing E-boxes by recruiting HDAC/Sin3 
complexes to deacetylate promoters (see above; Ayer et al. 1995; Schreiber-
Agus and DePinho 1998; Xu et al. 2001a). Another Myc related protein is Mnt, 
which is constitutively expressed, but whose role in regulation of transcription 
and proliferation is unclear (Hurlin et al. 1997; Meroni et al. 1997). Mga is yet 
another Myc-related transcription factor (Hurlin et al. 1999). It presumably acts 
in concert with E2F6 to repress transcription of target genes containing 
adjacent E2F-sites and E-boxes, and may induce cell cycle arrest (see above; 
Ogawa et al. 2002). In summary, switching from Mad/Max to Myc/Max is a 
key step in the induction of growth and proliferation in metazoans.  
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AIM OF THIS WORK 
 
In recent years, the mechanisms of transcriptional repression by both 
E2F/Rb and Max/Mad have become understood in detail, in particular with the 
demonstration that HDACs act as corepressors of both pathways. However, 
the molecular pathways involved in activation by E2F and Myc still remain 
very much obscure. Recent data showed that chromatin-remodeling-
complexes, in particular HATs, are involved in many transactivation pathways. 
Consistent with this, both E2F1 and Myc can associate with TRRAP, a subunit 
of two distinct HAT-complexes (the Tip60 complex, and STAGA/TFTC/PCAF 
complex). Nevertheless, at the onset of my thesis it was unclear whether this 
interaction had any functional consequences. Thus, I set out to analyze the 
biochemical and molecular roles of HATs, in particular TRRAP-associated 
complexes, in transactivation by E2F1 and Myc. Understanding how these 
two proteins regulate transcription will help to understand their biological 
functions, and ultimately their role in normal and transformed cells.  
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RESULTS 
 
4. E2F Recruits the Tip60 Complex to Chromatin  
4.1. Summary 
TRRAP has been shown to associate with both E2F1 and c-Myc 
(McMahon et al. 1998). Importantly, it is required for cellular transformation 
induced by both c-Myc and E1A, the latter acting by inducing E2F activity. 
Since TRRAP is also a subunit of at least two different HAT-complexes, it was 
plausible that some of these complexes are involved in transactivation by E2F 
of Myc proteins.  
In this chapter, I show that several subunits of the Tip60 complex, 
including TRRAP, are recruited to E2F targets following serum stimulation. 
E2F1 is sufficient to induce recruitment of these proteins, and acetylation of 
E2F target genes. Using a mutant E2F1, I demonstrate that functional 
activating E2F is required for association of the Tip60 complex with E2F 
targets, acetylation of histone H4, and entry of a new cell cycle. Moreover, H4 
acetylation and Tip60 recruitment are common features of E2F targets.  
 
4.2. Synchronization of T98G Cells  
Selection of an appropriate cell system is crucial for studies of E2F, which 
is an intrinsic component of the cell cycle machinery. The glioblastoma cell 
line T98G has been successfully used to investigate E2F biology (for example 
Takahashi et al. 2000). These cells have retained growth arrest mechanisms 
characteristic of primary cells: They enter quiescence upon serum withdrawal, 
and re-enter the cell cycle when stimulated with serum. To achieve 
synchronous passage through the G1 and S-Phases, cells were allowed to 
grow to confluence, and then starved in serum free medium. After 48 hours, 
cells were passaged into fresh, serum containing medium. Cell cycle analysis 
was subsequently performed at different time-points by means of two-
dimensional flow cytometry (Figure 5 A). Briefly, cells were labeled with 33µM 
BrdU for 30 minutes before harvesting at each time-point. Subsequently, 
nuclei were isolated, permeabilized, and stained with a monoclonal anti-BrdU 
antibody, as well as with propidium iodide (PI) dye, which stains DNA. Thus, 
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BrdU/PI double positive cells could be identified as S-Phase cells. T98G cells 
arrest in G0 when exposed to the serum deprivation/contact inhibition 
treatment (Figure 5 B). S-Phase commenced approximately 15 hours after 
release from quiescence, and peaked around 18 to 21 hours. Importantly, 
passage of the population through G1/S was highly synchronous, confirming 
the utility of T98G for E2F related cell cycle studies. A quantitation of the 
panels is shown in Figure 5 C. 
 
4.3. Quantitative Chromatin Immunoprecipitation of E2F1: Binding of E2F1 to 
Targets 
To study the function of different E2F proteins, I used chromatin 
immunoprecipitation (CHIP; Orlando et al. 1997). This technique allows 
analyzing the DNA-binding activities of different E2Fs in live cells at a given 
point in the cell cycle, and at multiple target genes. Here, I used a protocol for 
quantitative CHIP previously developed in our laboratory (Figure 6; Frank et 
al. 2001). Briefly, live cells were crosslinked with formaldehyde, and chromatin 
was subsequently sheared by sonication. Following SDS denaturation, 
protein-DNA complexes were immunoprecipitated with the antibody of choice 
(Figure 6 A). After extensive washes the crosslinks were reversed, the 
proteins digested, and the DNA purified by phenol/chloroform extraction and 
ethanol precipitation. Recovery of DNA was analyzed by real-time PCR. CHIP 
readout was expressed as the fraction of total input chromatin recovered in 
each immunoprecipitation (% total). Figure 6 B shows typical amplification 
curves obtained with primers specific for the E2F site in the p107 promoter of 
an E2F1 CHIP from serum-stimulated T98G cells. To ensure accuracy of the 
technique, each CHIP was performed in triplicate within each experiment. 
Thus, single data points represent average and standard deviation of three 
independent IPs.  
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Figure 5: Cell Cycle Synchronization of T98G Cells. 
T98G cells were rendered quiescent by serum starvation and contact inhibition, then 
stimulated with serum for the indicated lengths of time, and subsequently analyzed by two-
dimensional flow cytometry. (A) Cells in S-Phase were detected as PI/BrdU double positive 
cells. (B) Cells synchronously pass through a new cell cycle after release from quiescence. 
(C) Quantitation of the same experiment is shown in. One of two independent experiments is 
shown.  
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Figure 6: Quantitative Chromatin Immunoprecipitation (CHIP). 
(A) Schematic representation of CHIP. IPs were performed with antibody of choice, washed, 
the DNA purified and analyzed with primers against the known DNA sequences. (B) 
Representative PCR amplification curves as obtained from the Taqman 5700 real-time PCR 
amplifier. In this example, primers specific for the E2F binding site in the p107 promoter were 
used. Calculation of the amount of precipitated DNA relative to that present in total input 
chromatin is shown in the right panel. CT, cycle threshold, cycle number at which each 
reaction reaches a predetermined fluorescence threshold, set within the linear range of all 
reactions. 
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E2F proteins regulate a plethora of target genes, including many essential 
for S-Phase initiation and progression (see chapter 3.1. pp. 29). For a 
preliminary analysis, a subset of well-characterized target genes was chosen, 
consisting of mcm3, mcm4, pcna, and p107. I designed primers flanking 
known or putative consensus E2F binding sites in their promoters, as well as 
control primers for the achr promoter (that does not contain an E2F binding 
site). Binding of E2F1 to chromatin was analyzed in T98G cells that had been 
starved and released into a new cell cycle, as described above. E2F1 
associated with all four targets, but not with the achr promoter (Figure 7 A). In 
every case, binding was minimal in quiescent cells (0 hours), peaked at 15 
hours, and declined thereafter. This correlates well with the regulatory role of 
E2F1 in the G1/S transition. In order to further analyze the correlation of E2F1 
binding and S-Phase entry, additional time-points were investigated by CHIP. 
Figure 7 B shows that maximal binding of E2F1 to the mcm4 promoter 
immediately preceded S-Phase. To confirm the specificity of the CHIP assay, 
IPs were performed without antibodies. These nonimmune control CHIPs 
recovered very low levels of DNA, independently of the cell cycle stage 
(approximately 0.01% total for all investigated targets; Figure 7 C). 
Interestingly, E2F1 signals in quiescent cells were significantly higher than 
background (approximately 0.1% total), arguing that residual E2F1 is present 
on promoters in arrested cells. In conclusion, E2F1 is induced following serum 
stimulation of T98G cells and binds to E2F sites in the regulatory regions of 
four target genes. 
Binding of transcription factors should be spatially limited to their 
consensus target sites. Thus, E2F-specific CHIP should exclusively recover 
DNA fragments containing E2F binding sites. To address this hypothesis, 
primers amplifying sequences upstream and downstream of E2F binding sites 
in each gene were designed (subsequently called walking primers). For 
convenience, only DNA from the 0- and 15-hour E2F1 CHIP was analyzed. 
Figure 7 D shows that recovery of amplicons upstream and downstream of 
the E2F sites strongly decreased as a function of distance from the E2F 
binding site. Thus, E2F1 localized to the predicted sites.  
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Figure 7: E2F1 Recruitment to Chromatin in T98G Cells. 
(A) E2F1 binds to four target gene promoters in T98G cells stimulated with serum for the 
indicated time (in hours, on the x-axis). Binding is expressed as percentage of total input 
chromatin on the y-axis. No E2F1 is detected on the acetylcholine receptor. (B) Binding of 
E2F1 to the mcm4 promoter was monitored, and every sample was also analyzed by two-
dimensional flow cytometry. Binding of E2F1 (black line) peaks just prior to S-Phase entry 
(quantitated in grey bars). (C) Control CHIPs performed without antibody (only Protein A) fail 
to enrich for E2F specific targets at any time after serum stimulation. (D) Mapping of E2F1 
binding along the different loci in quiescent cells (white bars), and cells at G1/S transition (15 
hours; black bars). Numbers on the x-axis indicate the distance in bp from the E2F site. E2F = 
E2F binding site. 
 
 
4.4. Binding Patterns of Other E2F-Family Members 
Since several E2F proteins presumably have redundant functions (see 
chapter 3.2.1. and 3.2.2. pp. 35), it was important to address the binding 
patterns of other E2F-family members to chromatin during the serum 
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response of T98G cells. Thus, CHIP experiments were performed to 
investigate recruitment of E2F2, E2F3, and E2F4. Whereas E2F3 and E2F4 
CHIPs yielded strong signals, recovery of DNA from E2F2 CHIPs was less 
efficient, a result that is consistent with previously published reports 
(Takahashi et al. 2000; Wells et al. 2000). This is possibly due to antibody 
inefficiency. Alternatively, E2F2 levels could be lower than E2F1 and E2F3 
levels in T98G cells.  
Both E2F2 and E2F3 exhibited similar, though not identical binding 
characteristics as those observed for E2F1 (Figures 8 A-B, compare with 
Figure 7 A). As seen for E2F1, E2F2 was virtually absent from target 
promoters in quiescent cells. After recruitment in G1 promoter binding peaked 
prior to S-Phase, and then decreased. E2F3, in contrast, was present in 
significant amounts on all promoters in quiescent cell populations. Even more 
DNA was recovered in E2F3 CHIPs from late G1 populations, although the 
increase was not as dramatic as for E2F1 or E2F2. It should be noted, 
however, that two differently spliced E2F3 proteins have been described, 
which the antibody used in this study does not distinguish. Thus, the 
recruitment of each of these would have to be assessed by isoform specific 
antibodies. In summary, activating E2Fs are mostly absent from target gene 
promoters in quiescent cells, but binding increased following serum 
stimulation.  
CHIP with antibodies directed against E2F4 (a repressive E2F) showed 
occupancy at all four promoters in quiescent cells, but a weaker recovery from 
cells that were about to undergo S-Phase entry, as expected (Figure 8 C). 
Similarly p130, a Rb-family member was present on all targets in G0 cells but 
its signals are strongly reduced in G1/S-Phase cells (data not shown; see 
Figure 18 F). However, E2F4 was not completely absent from promoters in S-
Phase. The remaining signal could originate from E2F4/p107 complexes, 
which have been previously described in cells undergoing DNA replication.  
To verify localization patterns of E2F2, -3, and -4, the 0 and 15 hours 
samples were analyzed using the same walking primers as above. Again, 
binding of all the E2F proteins was limited to the E2F site as the signals 
amplified using up- or downstream amplicons were significantly weaker 
(Figures 8 D-F). In summary, the response of T98G cells to serum stimulation 
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exhibits a switch from repressive E2F4/p130 to activating E2F1, E2F2 and 
E2F3, which fits well with previously published reports (Takahashi et al. 2000; 
Wells et al. 2000).  
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Figure 8: Specific Association of E2F-Family Members with E2F Targets. 
CHIP was performed with antibodies for E2F2 (A, D), -3 (B, E), and -4 (C, F) in T98G cells. 
Temporal (A, B, C) and spatial (D, E, F) distributions of association with the indicated target 
loci are shown. Cell cycle populations and amplicons are identical to those used in Figure 7. 
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4.5. Acetylation of E2F Targets Temporally and Spatially Correlates with 
Recruitment of Activating E2F Proteins 
Histone acetylation is regulated by many transcription factors, and both 
HATs and HDACs have been shown to interact with E2Fs (reviewed in 
Trimarchi and Lees 2002). Thus, I decided to verify if E2F targets undergo 
regulated histone acetylation at G1/S transition, when they are being actively 
transcribed. CHIP was performed with antibodies specifically recognizing 
acetylated H3 and H4. Both histones were hypoacetylated in quiescent T98G 
cells (Figure 9 A-B; 0hrs). As cells progressed through the cell cycle 
hyperacetylation occurred, and both H3 and H4 acetylation peaked at 12 to 15 
hours. While this was a little earlier than maximal E2F1 binding, it should be 
noted that significant E2F1 (and E2F2 and E2F3) is bound at 12 hours, and 
this may be sufficient to induce acetylation. Furthermore, E2F3 binding 
peaked at 12 hours on all promoters and could contribute to acetylation. After 
15 hours, acetylation decreased on all loci. Thus, the timing of maximal 
histone acetylation at E2F target promoters correlated well with the binding 
kinetics of activating E2F proteins.  
If activating E2Fs were indeed responsible for histone acetylation, a 
spatial correlation should be expected as well. To verify this hypothesis, I 
used an extended set of walking primers. Interestingly, acetylation was more 
widespread, as most targets exhibited acetylation domains approximately 1.5 
to 3kb wide (Figure 9 C-F). Nevertheless, acetylation of both histone H3 and 
H4 was centered to the E2F sites, which the exception of the mcm4 gene, on 
which acetylation was strongest approximately 600bp upstream of the binding 
site. Another interesting case was the pcna promoter, which, while exhibiting 
most acetylation on the E2F site, also showed significant acetylation of 
upstream regions. This may be due to acetylation from other transcription 
factors. In summary, E2F1 binding appeared to induce hyperacetylation that 
reached the nucleosomes just adjacent to the E2F biding site. Since one 
nucleosome corresponds to approximately 146bp, acetylation probably 
covered not more than two or maximally three nucleosomes. Others have 
reported similar, narrow localization patterns of E2F-dependent responses 
(Morrison et al. 2002; Rayman et al. 2002). In conclusion, serum stimulation 
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of quiescent T98G cells induced acetylation of discrete domains of E2F target 
genes overlapping with and centered on the E2F binding site.  
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Figure 9: Induction of H3 and H4 Acetylation on E2F Targets in T98G Cells. 
Acetylation of H3 and H4 at E2F targets was monitored by CHIP. Time-courses show that 
both H3 (A) and H4 (B) acetylation on all E2F targets is maximal prior to S-Phase (15 hours), 
whereas no acetylation is detected on the achr. Mapping of acetylation along the different loci 
using proximal and distal primer pairs revealed that acetylation of both H3 (dark blue: 0 hours; 
light blue 15 hours) and H4 (red: 0 hours; orange 15 hours) was centered to the E2F sites on 
mcm4 (C), mcm3 (D), pcna (E), and p107 (F) promoters. Numbers on the x-axis indicate the 
distance in bp from the E2F site. E2F = E2F binding site.  
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4.6. The Tip60 Complex is Recruited to E2F Targets in T98G Cells 
The simplest explanation for the above results is that activating E2Fs 
recruit HATs, which in turn acetylate nucleosomes in E2F target promoters. 
Supporting this hypothesis is the fact that E2F1 has been reported to bind 
TRRAP, which is a subunit of at least two distinct HAT-complexes. 
Furthermore, E2F has also been shown to bind several HATs, including the 
TRRAP-associated Gcn5 and PCAF (Martinez-Balbas et al. 2000; Marzio et 
al. 2000). Thus, I decided to investigate if subunits of HAT-complexes were 
recruited to E2F targets.  
Antibodies to subunits of several HAT-complexes were purchased, or 
generated as described (see Materials and Methods, and Appendix A). 
TRRAP and Tip60 CHIP did enrich for E2F targets, so I analyzed recruitment 
of the Tip60 complex to E2F targets first.  
CHIP was performed in T98G cells after serum stimulation. Both TRRAP 
and Tip60 were recruited to all investigated E2F targets, but not to the achr 
promoter (Figure 10 A-B). Kinetics of recruitment resembled the binding 
pattern of activating E2Fs: Maximal CHIP signals were obtained from 
populations just about to enter S-Phase, decreasing afterwards. While signals 
were weaker than those obtained for most E2Fs, they were reproducibly well 
above Protein A background (e.g. 0.1% total TRRAP on mcm4 as opposed to 
0.01% Protein A). Thus, even though the recovery of DNA was one order of 
magnitude lower than that obtained for E2F1 CHIP, it was significant.  
To determine whether localization of the coactivators was identical to 
E2F1 localization, I ran the walking primers on TRRAP and Tip60 CHIPs 
(Figure 10 C-D). Both proteins exhibited a spatial distribution reminiscent of 
that detected for E2F1. Altogether, TRRAP and Tip60 were recruited to E2F 
targets in a spatial and temporal manner that resembled the binding pattern of 
activating activating E2Fs, suggesting that they are coactivators of E2F in a 
physiological setting.  
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Figure 10: TRRAP and Tip60 are Recruited to E2F Targets in T98G Cells. 
CHIP was performed with serum stimulated T98G cells using antibodies to TRRAP (A, C), 
and Tip60 (B, D). Recruitment of all proteins to E2F targets peaked just prior to S-Phase. 
Spatial distribution of binding was analyzed in (B) and (D) on chromatin from quiescent cells 
(white bars), and cells at G1/S transition (15 hours; black bars). Cell cycle populations and 
amplicons are identical to those used in Figure 7.  
 
Several other subunits of the Tip60 complex have been identified (see 
introduction, Table 3), and of those, Tip49 has been shown to interact with 
E2F1 (Dugan et al. 2002). Thus, CHIPs were performed with Tip48, Tip49, 
and p400 antibodies. Recovery of DNA in p400 CHIPs, however, was 
extremely low, and no conclusive data were obtained in T98G cells (data not 
shown; but see Figure 16 F). Tip48 and 49 CHIP in contrast yielded strong 
signals. Both proteins bound to E2F targets. Induction was not as strong as 
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for TRRAP or Tip60, increasing only 2 to 3-fold over signals in quiescent cells 
(Figure 11 A-B). This was due to significant promoter binding by Tip48 and 
Tip49 in quiescent cells. This was probably E2F-independent recruitment, 
possibly by PolII, with which both proteins were recently shown to associate 
(M. Gstaiger, and W. Krek, unpublished results). However, regulated binding 
of Tip48 and Tip49 was localized to E2F consensus sites (Figure 11 C-D), as 
found for the other coactivators. One notable exception was mcm4, which 
additionally exhibited significant binding of both Tip48 and Tip49 in upstream 
regions. In summary, four subunits of the Tip60 complex are recruited 
specifically to E2F targets in T98G cells upon serum stimulation.  
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Figure 11: Tip48 and Tip49 are Recruited to E2F Targets in T98G Cells. 
CHIP was performed with serum stimulated T98G cells using antibodies to Tip48 (A, C), and 
Tip49 (B, D). Recruitment of all proteins to E2F targets peaked before S-Phase. Spatial 
distribution of binding was analyzed in (B) and (D) on chromatin from quiescent cells (white 
bars), and cells at G1/S transition (15 hours; black bars). Cell cycle populations and 
amplicons are identical to those used in Figure 7.  
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Experiments performed with Gcn5/PCAF antibodies did not reproducibly 
yield significant enrichment (data not shown). Similarly, CHIP with antibodies 
recognizing p300 and CBP, proteins known to bind E2F1, did not reveal 
specific enrichment over background. Since negative CHIP data cannot be 
interpreted conclusively in the absence of a positive control, this does not 
exclude that these proteins function in transactivation of E2F targets. Further 
experiments will be required to address this question.  
 
4.7. Tip60 Recruitment and H4 Acetylation are Features of Many E2F Targets 
So far, I showed that the Tip60 complex is involved in E2F responses to 
serum stimulation of T98G cells. However, the subset of targets has been 
limited to four genes involved in G1/S-Phase transition. Recent studies have 
revealed that E2F proteins target hundreds of genes involved in several 
different cellular processes, including DNA replication, DNA repair, apoptosis, 
and others (see introduction). Therefore, I decided to conduct a survey of 
other E2F target genes. Primers against 30 known targets were designed and 
tested. Subsequently, 0 and 15 hours CHIP samples from T98G serum 
stimulation time-courses were analyzed. All promoters exhibited significant 
E2F1 binding, as was expected (Figure 12 A). H4 acetylation was also 
induced, but there appeared to be no direct correlation of signal strength of 
E2F1 binding and induction acetylation (Figure 12 B). Even though many 
genes exhibited significant Tip60 binding, some (such as b-myb, polα2, rrm1, 
and p73) showed weak recruitment that might not be sufficient to explain the 
strong induction of acetylation. 36B4 exhibited significant Tip60 recruitment 
and induced H4 acetylation, but probably independent of E2F1 binding, which 
was only weakly present on this promoter. In summary, while Tip60 was 
recruited to most E2F targets, other HATs probably also contribute towards 
total acetylation. A combination of CHIP experiments and molecular genetic 
approaches will be required to address this issue.  
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Figure 12: Tip60 Recruitment and H4 Acetylation is a Characteristic of Many 
E2F Targets. 
E2F1 (A), AcH4 (B), and Tip60 (C) CHIP was performed with quiescent (white bars) and G1/S 
transition (15 hours; black bars) T98G cells. Primers for a selection of E2F targets were used. 
Loci are indicated below each panel, and are ordered for highest value of E2F1 binding along 
the X-axis. 
 
4.8. ER-E2F1 is Sufficient to Induce Acetylation of E2F Targets 
Having shown a correlation between histone acetylation and recruitment 
of activating E2F proteins, it was important to prove the role of activating E2Fs 
in this process. First, I addressed whether E2F1 is sufficient for induction of 
acetylation. In order to address this question, a human osteosarcoma cell line 
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expressing a chimeric ER-E2F1 protein was used (U2OS/ER-E2F1 cells; Vigo 
et al. 1999). This fusion of human E2F1 to the ligand-binding-domain of the 
estrogen-receptor (ER) is constitutively expressed, but only translocates from 
the cytoplasm to the nucleus when cells are treated with the estrogen analog 
4-hydroxytamoxifen (4-OHT). Thus, it is possible to study rapid E2F1-
dependent events in an otherwise unchanged cellular context.  
Initially, I needed to verify if chimeric ER-E2F1 exhibited binding 
characteristics comparable to endogenous E2F1. Cells grown to confluence 
were starved for 96 hours in the absence of serum to eliminate endogenous 
E2F1. Then ER-E2F1 was activated by addition of 4-OHT for 0, 20, or 60 
minutes, and cells were analyzed by CHIP. Judging from the amounts of DNA 
recovered in the CHIP, ER-E2F1 binding was at least as efficient as that of 
endogenous E2F1 during a serum response. ER-E2F1 rapidly associated with 
all four targets but not with the achr promoter (Figure 13 A). Moreover, 
localization of ER-E2F1 binding was the same as in serum stimulated T98G 
cells (Figure 13 B). As an additional control, U2OS cells without the transgene 
did not induce recruitment of E2F1 on any target upon stimulation with 4-OHT 
(Figure 13 C). Thus, 4-OHT rapidly induced localized binding of ER-E2F1 to 
its specific target genes, effectively mimicking the serum induced E2F1 
response in T98G cells. A survey of four different clones of U2OS/ER-E2F1 
revealed no differences in their responses to 4-OHT, confirming the reliability 
of this system (data not shown). 
No H4 acetylation was induced in U2OS cells without the transgene 
(Figure 13 F), while binding of ER-E2F1 was accompanied by acetylation of 
both H3 and H4 on all targets, but not the achr (Figure 13 D-E). Initiation of 
acetylation in U2OS-ER-E2F1 cells was delayed, as it was barely detectable 
at 20 minutes. Possibly, assembly or activation of HAT-complexes is not as 
rapid as E2F1 binding. Interestingly, maximal acetylation of H4 was reduced 
when compared to levels reached in T98G cells (for example 3-4% total in 
U2OS/ER-E2F1 as opposed to 6-10% total in T98G). H3 acetylation was 
induced less dramatically than in the T98G system, due to higher initial 
acetylation levels in U2OS cells (compared to T98G cells). Spatial 
distributions of acetylation across the loci were very similar to those found in 
the T98G cells, with localization being centered to the E2F site at the mcm3 
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and the p107 locus, and more widespread for mcm4, as seen in T98G cells 
(Figure 14 A-D). The pcna promoter exhibited a strong H3 and H4 acetylation 
upstream of the E2F binding site, which preceded 4-OHT treatment, and thus 
is presumably E2F-independent, results similar to those found in T98G cells. 
In summary, ER-E2F1 was sufficient to directly induce localized acetylation of 
both histone H3 and H4.  
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Figure 13: ER-E2F1 is Sufficient to Induce H3 and H4 Acetylation. 
(A) Quiescent U2OS/ER-E2F1 cells were stimulated for 0, 20, and 60 minutes (on the x-axis) 
with 4-Hydroxytamoxifen (4-OHT), to induce nuclear localization of ectopic ER-E2F1. CHIP 
with antibodies specific for E2F1 showed rapid recruitment to E2F targets but not the control 
promoter (binding in % total on the y-axis). E2F1 recruitment was localized to E2F sites (B), 
and accompanied by acetylation of both H3 (D), and H4 (E). No E2F1 binding or H4 
acetylation was detected when U2OS cells void of the transgene were stimulated with 4-OHT 
(C, F). 
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Figure 14: Acetylation of E2F Targets in U2OS/ER-E2F1 Cells is Localized to 
E2F Sites. 
Spatial distribution of acetylation induced by ER-E2F1 was analyzed as above (Figure 9). 
Primers for mcm4 (A), mcm3 (B), pcna (C), and p107 (D) promoters were run on AcH3 and 
AcH4 CHIPs from uninduced (dark blue and red bars, respectively) and induced cells (60 
minutes stimulation, light blue and orange bars, respectively). In all cases acetylation is 
centered to the E2F sites. 
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Figure 15: ER-E2F1 is Sufficient to Induce Recruitment of the Tip60 Complex. 
U2OS/ER-E2F1 cells were stimulated as in Figure 13, and CHIP was performed with 
antibodies to TRRAP (A), Tip60 (B), Tip48 (C), Tip49 (D), and p400 (E). Control CHIP was 
performed without antibody (F). All five Tip60 complex subunits bound to E2F target 
promoters, while CHIP with Protein-A controls did not enrich for the same promoters. 
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Figure 16: Tip60 Complex Subunits Localize to the E2F Sites. 
Spatial distribution of Tip60 complex subunits was analyzed using the same primer pairs as 
described in Figure 7. TRRAP (A), Tip60 (B), Tip48 (C), Tip49 (D), and p400 (E) are all 
localized exclusively to the E2F binding sites. CHIP from unstimulated populations are 
represented in white bars, black bars represent populations from cells treated with 4-OHT for 
60 minutes. 
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4.9. ER-E2F1 is Sufficient to Recruit Five Different Subunits of the Tip60 
Complex  
Since ER-E2F1 is sufficient to induce acetylation, it should also suffice to 
drive HAT-complex recruitment. In order to test this for the Tip60 complex, 
CHIP was performed with TRRAP, Tip60, Tip48, and Tip49 antibodies on 
U2OS/ER-E2F1 cells stimulated as described above. These experiments 
revealed that all proteins were rapidly recruited to E2F targets, paralleling the 
kinetics of E2F1 binding (Figure 15 A-D). p400 CHIP was not very efficient, 
but a low signal was reproducibly obtained, and was above signals from 
Protein-A control CHIPs (Figure 15 E, F). Again, kinetics of association with 
E2F targets resembled those of E2F1. If E2F1 were responsible for the 
recruitment of these five cofactors, localization would be expected to be 
limited to the E2F site. Using the same walking primers as in previous 
experiments showed that all proteins were recruited to the E2F sites, but not 
adjacent domains in chromatin, establishing the spatial correlation (Figure 
16). In conclusion, E2F1 was sufficient to induce localized recruitment of five 
different subunits of the Tip60 HAT-complex, including Tip60, the catalytic 
subunit of the complex.  
 
4.10. ER-E2F1 Binds Targets only Weakly Bound in Serum Response  
Transcription of some E2F target genes is presumably not fully induced 
after serum stimulation. For example, genes involved in apoptosis (p73, 
apaf1), or DNA repair (msh2, polδ) may require additional stimuli to be 
strongly activated. Consistent with this, p73 was bound only weakly by E2F1 
and Tip60, and H4 acetylation was also lower (compared to, for example, 
mcm3). However, when p73 primers were run on CHIPs from an U2OS/ER-
E2F1 experiment, it became apparent that the p73 promoter is bound well by 
E2F1 and Tip60, even better than mcm3, therefore establishing it as bona fide 
E2F target (Figure 17 A). Acetylation of H4 and H3 was as strong as that 
observed on most targets in serum stimulated T98G cells (Figure 17 B-C). 
However, while also exhibiting increased E2F1 binding, no increase in histone 
acetylation was observed on other DNA-repair related E2F target genes 
(Figure 17 A-C). It may be that conditions, which induce transcription of these 
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genes, are necessary for increased recruitment of E2F1/Tip60 complexes, 
and enhanced histone acetylation.  
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Figure 17: The p73 promoter, but not other DNA-damage associated E2F-
targets, is acetylated by ER-E2F1. 
U2OS/ER-E2F1 cells were stimulated as in Figure 13, and CHIP was performed with 
antibodies to E2F1 (A), AcH3 (B), and AcH4 (c). All investigated promoters exhibit strong 
E2F1 binding, but only the p73 target gene shows increased acetylation after 4-OHT 
stimulation. 
 
4.11. Overexpression of a DNA-binding Deficient E2F1 Prevents Association 
of Endogenous E2F with Chromatin 
Having shown that ER-E2F1 is sufficient for recruitment of the Tip60 
complex, and for histone acetylation, I wished to investigate if activating E2F 
proteins are required for the recruitment of the Tip60 complex. In theory, this 
could be addressed by means of knockout mouse embryonic fibroblasts (KO-
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MEFs) that lack single, or combinations of the activating E2Fs. However, it is 
easy to conceive that (a) all three individual E2F activators could potentially 
recruit coactivator complexes, and that (b) in case of absence of one or two of 
the E2Fs, the other E2F(s) could compensate for the loss, hampering studies 
designed to address the necessity of individual E2Fs. Therefore, I made use 
of adenoviruses expressing a dominant negative (DN) E2F.  
Of the E2F mutants described in the literature, I decided to test the DNA-
binding-deficient mutant E2F1-Eco132 (Johnson et al. 1993). Due to a single 
point mutation in its DNA-binding-domain, this mutant is unable to bind to E2F 
targets, but retains all protein-protein interaction surfaces, including the 
domain responsible for binding to the obligate dimerization partner DP. 
Previously, this mutant has not functioned as a DN mutant. However, when 
strongly overexpressed, one would expect that E2F1-Eco132 blocks any 
recruitment of functional E2F to promoters by titrating all DP away from 
endogenous E2F proteins.  
To test this hypothesis, T98G cells were serum-stimulated to enter a new 
cell cycle and simultaneously infected with adenoviruses expressing GFP only 
(AdGFP, vector control), wild-type E2F1 (WT), and E2F1-Eco132 (Eco132). 
GFP expression (data not shown) and ectopic E2F1 expression (Figure 18 A) 
were comparable in all infected cells. E2F1 CHIP showed that infection with 
AdGFP did not affect the kinetics or localization of E2F1 recruitment to the 
mcm4 promoter, when compared to non-infected T98G (Figure 18 A, compare 
with Figure 7 B; and data not shown). Overexpression of wild-type E2F1 
caused premature binding to the mcm4 promoter, whereas overexpression of 
E2F1-Eco132 prevented binding of E2F1 (Figure 18 A). Similar results were 
obtained for the mcm3, pcna, and p107 promoters (Figure 18 B, and data not 
shown). Furthermore, CHIP with antibodies against E2F2 and E2F3 showed 
that both of them were also prevented from associating with target genes 
(Figures 18 C-D). E2F4 and p130 were present in quiescent cells, as 
expected (Figures 18 E-F). However, since both of these proteins are 
normally absent from G1/S transition cells, this was not influenced by 
expression of E2F1-Eco132. Thus, these experimental settings did not allow a 
formal assessment of whether the DN-E2F displaces repressive E2F. In 
summary, overexpressing E2F1-Eco132 efficiently prevented binding of 
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activating E2F complexes to target sites during the serum stimulation of T98G 
cells.  
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Figure 18: A DNA-Binding-Deficient Mutant E2F Inhibits Binding of E2F-family 
Members to E2F Targets when Expressed from Adenoviruses. 
(A) T98G cells were starved as described. Upon releasing into a new cell cycle, they were 
infected with adenoviruses expressing GFP only (vector control, orange), wt E2F1 (blue), or 
the DNA-binding-deficient mutant E2F1-Eco132 (yellow). E2F1 CHIP was performed on cell 
populations at different points in the cell cycle, and showed that the WT E2F1 induced 
premature binding to the mcm4 promoter, whereas E2F1-Eco132 prevented binding of any 
E2F1. Proteins were expressed at similar levels, as judged by Western blot (top left panel). 
Similarly, expression of E2F1-Eco132 (yellow bars), but not empty vector (orange bars), 
prevented induction of binding after quiescence (compare red bars to brown bars) of E2F1 
(B), E2F2 (C), and E2F3 (D) to four target genes, as judged by CHIP. E2F4 (E), and p130 (F) 
were absent from promoters in all cell populations, except in quiescent cells. Signals from 
noninfected and control vector infected cells were comparable in all cases (compare red and 
orange bars).  
 70
A
IP: TRRAP
C
IP: Tip48
LOCUS:
B
IP: Tip60
LOCUS: MCM4 MCM3 PCNA p107 AchR
E
IP: AcH3
LOCUS: MCM4 MCM3 PCNA p107 AchR
D
IP: Tip49
LOCUS: MCM4 MCM3 PCNA p107 AchR
F
IP: AcH4
LOCUS: MCM4 MCM3 PCNA p107 AchR
%
 to
ta
l
MCM4 MCM3 PCNA p107 AchR
0
0.02
0.04
0.06
0.08
0.1
0
0.02
0.04
0.06
0.08
0.1
0.12
0
0.1
0.2
0.3
0.4
0.5
0
0.2
0.4
0.6
0.7
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0
1
2
3
4
5
6
%
 to
ta
l
%
 to
ta
l
%
 to
ta
l
%
 to
ta
l
%
 to
ta
l
LOCUS: MCM4 MCM3 PCNA p107 AchR
0hrs
15hrs non. inf
15hrs GFP
15hrs Eco132
 
 
Figure 19: Activating E2F is Required for Recruitment of Tip60 Complex 
Subunits and Induction of H4 but not H3 Acetylation. 
Cells were infected as in Figure 18, and CHIP was performed with antibodies to TRRAP (A), 
Tip60 (B), Tip48 (C), Tip49 (D), AcH3 (E), and AcH4 (F). Serum induction of cofactor 
recruitment (compare brown and red bars) is blocked in cells expressing E2F1-Eco132, but 
not upon expression of GFP only (compare orange and yellow bars). Acetylation of AcH3 is 
only reduced, whereas acetylation of H4 is totally blocked (E and F, compare orange and 
yellow bars). 
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4.12. Recruitment of the Tip60 Complex Requires Functional Activating E2F 
The Tip60 complex was recruited to E2F target genes during serum 
stimulation of T98G cells (Figure 10), and ER-E2F1 is sufficient to drive this 
recruitment (Figure 14). In order to determine, whether activating E2F is 
required for this recruitment, I performed CHIP with antibodies against 
TRRAP, Tip60, Tip48, and Tip49 in cells infected with the DN-E2F as 
described above. Recruitment of all of these cofactors was blocked by 
expression of E2F1-Eco132, but not by infection with adenoviral vector, or in 
non-infected control cells (Figures 19 A-D). In summary, activating E2F is 
required for recruitment of the Tip60 complex to E2F target genes following 
serum stimulation of T98G cells. 
 
4.13. Acetylation of H4 Depends upon Functional Activating E2F 
Having shown that binding of activating E2F and coactivators is abolished 
in cells expressing E2F1-Eco132, I addressed, whether activating E2F is 
necessary for induction of acetylation. CHIP experiments showed that 
acetylation of H4 was reduced to levels similar to those found in quiescent 
cells, when E2F1-Eco132 was overexpressed, but not when cells only 
expressed GFP (Figure 19 F). Interestingly, some acetylation on the p107 
promoter remained detectable, which correlated with some residual E2F1 
binding. This confirmed the strict correlation of E2F1 binding and H4 
acetylation (Figure 18 B). In contrast to H4 acetylation, H3 reproducibly 
exhibited significant, but not full acetylation on all targets when E2F1-Eco132 
was expressed (Figure 19 E). Thus, induction of H4 acetylation absolutely 
required binding of activating E2F, whereas H3 acetylation was only partially 
dependent upon it. Taken together, these data suggest that removal of 
repressive E2F complexes alone is not sufficient to induce H4 acetylation, 
although derepression may account for the partial increase in H3 acetylation.  
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Figure 20: E2F Activity is Required for Cell Cycle Entry in T98G Cells. 
Cells were infected as in Figure 18. At different times they were treated with 33µm BrdU for 
30 minutes. (A) Analysis by two-dimensional flow cytometry showed that expression of mutant 
E2F1-Eco132 prevented S-Phase entry after cells were serum-stimulated whereas 
expressing of adenoviral vector only had no effect. Quantitation of the panels is shown in (B).  
 
4.14. Binding of Activating E2F Proteins is Necessary for Cell Cycle Entry in 
T98G Cells 
The results described show that activating E2F is required for Tip60 
complex recruitment and histone acetylation of E2F targets. As a 
consequence, transcription and, ultimately, S-Phase entry should also depend 
on the presence of functional E2F activators. Thus, a mutant like E2F1-
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Eco132 that removes all E2F protein from the cellular promoters should 
prevent cell cycle entry of T98G cells after serum stimulation. To test this 
hypothesis, two-dimensional flow cytometry was performed on T98G cells 
treated and infected as described. Expression of the E2F1-Eco132 mutant 
efficiently blocked S-Phase entry, whereas non-infected and AdGFP infected 
cells entered S-Phase efficiently (Figure 20). This implies that functional 
activating E2F is strictly required to drive quiescent T98G into S-Phase, 
whereas removal of repressive E2F4/p130 complexes alone is not sufficient. It 
has recently been published that activating, but not repressive E2Fs are 
dispensable in exponentially growing cells (Zhang et al. 1999; Rowland et al. 
2002). In contrast, functional activator complexes were found to be required 
for cells entering a new cycle from quiescence. These results fit well with 
results described here.  
 
4.15. Protein Levels of TRRAP and Tip60 do not vary throughout the Cell 
Cycle 
Many proteins involved in cell cycle regulation exhibit tight regulation of 
protein levels, including activating E2Fs. Tip60 itself is regulated by 
ubiquitin/proteasome-dependent degradation (Legube et al. 2002), raising the 
possibility that its protein levels vary throughout the cell cycle. Thus, I decided 
to test if TRRAP and Tip60 levels change in T98G cells after serum 
stimulation. Cells were starved and allowed to enter a new cycle as before, 
and cell lysates were prepared at different time points. Proteins were 
separated by SDS-PAGE and analyzed by immunoblot with TRRAP and 
Tip60 antibodies. Neither TRRAP nor Tip60 levels varied considerably over 
an extended time-course (Figure 21). Similar results were obtained for Gcn5, 
HBO1, p300 and CBP (data not shown). Thus, it appears that levels of all 
these HATs are stable during transition from G0 to G1 and S-Phase. 
Furthermore, these data proved that the binding of Tip60 and TRRAP to E2F 
targets following serum stimulation was due to specific recruitment by 
activating E2F, and not a mere consequence of chromatin binding by the 
Tip60 complex after de novo protein synthesis following cell cycle entry.  
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Figure 21: TRRAP and Tip60 Levels are Constant during G1/S-Phase 
Transition. 
T98G cells were arrested and released into a new cycle as described. Cell lysates from 
different time points were analyzed by immunoblot with antibodies to TRRAP, and Tip60. 
Tip60 runs as a doublet, consistent with previously published results that two differently 
spliced proteins are present in cells. Protein levels do not vary during the cell cycle.  
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5. Myc Binds the HATs Gcn5 and Tip60  
 
5.1. Summary 
Besides E2F, TRRAP has been shown to bind Myc (McMahon et al. 
1998). Thus, I decided to investigate if TRRAP/Tip60 complexes also play a 
role in Myc-dependent transactivation. Here, I show that Myc recruits HAT 
activity, and can bind the two TRRAP-associated HATs.  
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Figure 22: Transfected Myc Recruits HAT Activity. 
293T cells were transiently transfected with vectors expressing the Flag-tag only, Flag-PCAF, 
or Flag-Myc. After 48 hours, cells were lysed, and IP-HAT assays were performed as 
described in Materials and Methods. Flag-PCAF and Flag-Myc both precipitate significant 
HAT activity, whereas no activity is recovered from cells only expressing the Flag-tag. 
Proteins were expressed at comparable levels (data not shown). One of two independent 
experiments is shown. 
 
5.2. Myc Recruits HAT Activity when Overexpressed in 293T Cells 
Myc has previously been published to bind TRRAP when expressed as a 
Flag-tagged protein in 293T cells. TRRAP is a subunit of at least two HAT-
complexes in mammalian cells, suggesting that Flag-Myc can recruit HAT 
activity. To test this, 293T cells were transfected with vectors expressing Flag- 
Myc or Flag-PCAF (positive control). Flag-IPs were assayed for HAT activity 
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as described in Materials and Methods (chapter 8.2.9. p.111). These assays 
showed that Myc recruited a significant amount of HAT activity, nearly half as 
much as the potent HAT PCAF (Figure 22). Thus, Myc is capable of recruiting 
HAT activity in transient transfection assays.  
 
5.3. Myc Binds to the SAGA Complex Components Gcn5 and Spt3 
Since Gcn5 is a TRRAP-associated HAT, it could contribute to Myc-
associated HAT activity. Therefore, transfection experiments were designed 
to find out whether Gcn5 associates with Myc. 293T cells were transiently 
transfected with vectors expressing Flag-tagged Myc, and un-tagged Gcn5. 
Lysates were immunoprecipitated with antibodies against the Flag-tag, and 
immunoblotted. Gcn5 was present in Flag IPs when cotransfected with Myc, 
but not in cells that expressed only Myc, or Gcn5 (Figure 23 A). Proteins were 
expressed at equal levels in all transfections.  
In yeast, Gcn5p is part two distinct HAT-complexes composed of common 
and unique subunits (Grant et al. 1998). The SAGA complex is different from 
the other complex in that it contains the Spt class of proteins. The human 
complex STAGA is the orthologue of SAGA, and it contains the human 
counterpart of yeast Spt3p, hSpt3.  
In order to find out whether Myc interacts with Gcn5 in the context of the 
STAGA complex, HA-tagged Myc was cotransfected with Flag-HA-tagged 
hSpt3, and lysates were immunoprecipitated with antibodies against Max, to 
test if the Myc/Max dimers can associate with hSpt3. When Myc was 
cotransfected, these IPs efficiently recovered transfected hSpt3 (Figure 23 B). 
In conclusion, Myc is capable of interacting with two different STAGA complex 
components in transient transfection experiments, suggesting that Myc 
recruits the STAGA complex to transactivate target genes. Similar results 
have been found by others (McMahon et al. 2000).  
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Figure 23: Myc Associates with STAGA Complex Components. 
(A) Flag-Myc and un-tagged Gcn5 were transfected into 293T cells, alone, or in combination, 
as indicated. Cells were lysed after 48hrs, and lysates immunoprecipitated with Flag M2 
monoclonal antibodies. IPs were immunoblotted for Gcn5, which was coprecipitated only 
when Myc and Gcn5 were cotransfected. Proteins were expressed at similar levels in all 
transfections. (B) HA-Myc and Flag-HA-Spt3 were transfected into 293T cells, alone or in 
combination. Cells were lysed after 48hrs, and lysates immunoprecipitated with Max2.1 
antibodies. IPs were immunoblotted for Spt3, which was coprecipitated only when Myc and 
Spt3 were cotransfected. Proteins were expressed at similar levels in all transfections. 
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5.4. Myc and Tip60 Interact when Overexpressed in 293T Cells 
The Tip60 complex also contains TRRAP, which raises the possibility that 
Myc can associate with Tip60 (Ikura et al. 2000). To verify, whether there is 
such an interaction, 293T cells were transfected with vectors expressing un-
tagged Myc and Flag-HA-tagged Tip60, alone or in combination. Lysates were 
immunoprecipitated with antibodies against Tip60 or the Flag-tag, and IPs 
immunoblotted for coprecipitated Myc. Indeed, both Tip60 IPs contained 
significant amounts of Myc, whereas none was detected in control non-
immune IPs (Figure 24 A). The interaction of Tip60 and Myc could also be 
detected when the lysates were immunoprecipitated with Myc antibodies, and 
immunoblotted for Tip60 (Figure 24 B).  
As an additional control, I substituted the vector encoding Tip60 with an 
expression vector for HBO1 (Iizuka and Stillman 1999; Sharma et al. 2000; 
Burke et al. 2001). HBO1 is a Tip60 related protein, which has not been 
described to have a role in transcription. Consistent with this, no interaction 
with Myc was detected by immunoprecipitation-immunoblot experiments, 
arguing that the interaction is specific to Tip60 (Figure 24 C). In summary, 
Tip60 and Myc specifically interact in transfected cells, suggesting that a 
Tip60 containing HAT-complex plays a role in Myc function. Consistent with 
this, recent work in our lab demonstrated that TRRAP and Tip60 are recruited 
to chromatin by Myc (S. Frank, and B. Amati, unpublished results).  
 
 79
BA
W C L
W C L
IP : α  T ip 6 0 IP : p re - im m
IP : α  F la g IP : α  V S V
α -  c -M y c  (9 E 1 0 )
α -  H A
α -  c -M y c  (N -2 6 2 )
α -  T ip 6 0  (C T )
M y c
F la g H A -T ip 6 0
+
+
+
+
+
+
+
+
+
+
+
+
W C L
IP : α  M y c  (C 3 3 )
α -  H A
IP : α  4 1 9
IP s
M y c
F la g H A -T ip 6 0
+
+
+
+
+
+
+
+
W C L IP : M y c  (C 3 3 )
α -  M y c  (N -2 6 2 )
α -  F la g
W C L IP : α -  H A
M y c
F la g H A -H B O 1
+
+
+
+
+
+
+
+
C
 
Figure 24: Myc Binds to Tip60, but not HBO1 in Transient Transfections. 
(A) Flag-HA-Tip60 and un-tagged Myc were transiently transfected into 293T cells, alone or in 
combination. Cells were lysed after 48hrs and lysates immunoprecipitated with Flag M2 
monoclonal antibodies (lower panel), or Tip60 polyclonal antibodies (upper panel). IPs were 
immunoblotted for Myc, which was coprecipitated only when Myc and Tip60 were 
cotransfected. No Myc was coprecipitated with VSV monoclonal isotype control antibody 
(lower panel), or preimmune Tip60 antisera (upper panel). Proteins were expressed at similar 
levels in all transfections. (B) Myc and Flag-HA-Tip60 were transfected into 293T cells, alone, 
or in combination. Cells were lysed after 48hrs, and lysates immunoprecipitated with Myc 
monoclonal antibodies, or 419 monoclonal isotype control antibodies. IPs were 
immunoblotted for Tip60, which was coprecipitated only when Myc and Tip60 were 
cotransfected (lower panel). Proteins were expressed at similar levels in all transfections 
(upper panel). (C) Myc and Flag-HA-HBO1 were transfected into 293T cells, alone, or in 
combination. Cells were lysed after 48hrs and lysates immunoprecipitated with Myc 
monoclonal antibodies (upper panel) or HA antibodies (lower panel). IPs were immunoblotted 
for HBO1 (Flag M2) or Myc. No interaction was detected. Proteins were expressed at similar 
levels in all transfections. 
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6. A Role for the STAGA Complex in the G1 Phase of the Cell Cycle 
 
6.1. Summary 
When mammalian cells are infected with adenovirus, the key function of 
the adenoviral oncoprotein E1A is to induce cell cycle progression (reviewed 
in Ben-Israel and Kleinberger 2002). It does so by bypassing the requirement 
for G1-specific Cyclin/CDK complexes, thus liberating E2F activity, and 
ultimately inducing E2F target genes. Interestingly, the E2F-binding HATs 
PCAF and p300 are targets of E1A (Reid et al. 1998; Chakravarti et al. 1999; 
Hamamori et al. 1999b). Furthermore, E1A associates with TRRAP, and the 
domain of E1A responsible for this interaction is required to overcome a 
p27Kip1 imposed cell cycle arrest (Alevizopoulos et al. 1998; Deleu et al. 
2001). The targeting of HATs by E1A suggests that in normal cells the 
activities of these HATs may be regulated by the cell cycle machinery, in 
particular by G1-specific Cyclin/CDK complexes.  
Here, I show that Cyclin E and D are capable of interacting with the HATs 
Gcn5 and PCAF. Cyclin E also binds the STAGA complex subunit hSpt3. 
Finally, HAT activity of Flag-tagged PCAF is reduced in cells arrested with the 
CDK-inhibitors (CKI) p16INK4a or p27Kip1.  
 
6.2. Cyclins E and D Bind Gcn5 in Transient Transfections 
If Cyclin/CDK complexes target the same set of substrates as E1A, an 
interaction between these cyclins and the HATs PCAF/Gcn5 would be 
expected. Thus, I tried to verify if Cyclins could interact with Gcn5 in transient 
transfections. 293T cells were cotransfected with vectors expressing HA-
tagged Cyclin D, E1, or E2. Cells were lysed, and analyzed for protein 
expression by immunoblot. Cyclin E2 was expressed at lower levels, probably 
due to rapid degradation (Figure 25 A). Otherwise, protein levels were similar 
in all transfections (Figure 25 A). Lysates were then subjected to 
immunoprecipitation with Gcn5 antibodies (Figure 25 B) and HA or Cyclin E 
antibodies (Figure 25 C). An interaction of Gcn5 with Cyclin E was detected in 
cells coexpressing the two proteins. Furthermore, Gcn5 also associated with 
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Cyclin D1. Thus, it appears that Gcn5 is capable of interacting with two 
discrete, G1-specific Cyclins.  
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Figure 25: Cyclin E Interacts with Gcn5 when Overexpressed in Transient 
Transfections. 
HA-tagged Cyclins were cotransfected with un-tagged Gcn5 in 293T cells. (A) Immunoblot of 
cell lysates with Gcn5 and HA antibodies revealed that all transfected proteins were 
expressed at equal levels in all transfections. (B) To detect interactions, lysates were 
immunoprecipitated with Gcn5 antibodies, and IPs immunoblotted for the presence of Cyclins 
using HA antibodies. Both Cyclin D1 and E were detected in Gcn5 immunoprecipitates. (C) 
Lysates were immunoprecipitated with Cyclin E antibody (HE172) or HA antibody (HA.11). 
Immunoblotting revealed presence of Gcn5 in Cyclin E precipitates. WCL = Whole cell lysate.  
 82
IP α-CycE1
Spt3
crude
α-Spt3
CycE1
FlagHA-Spt3 +
+
+
+
+
C
A
IgG
CycE1/ E 2
IP α-FlagWCL
α-HA
Flag-PCAF
+ + +CycE1-HA
CycE2-HA + + +
+ ++
α-HA
α-Flag PCAF
CycE1/ E 2
Flag-PCAF +
+CycE1-HA
CycE2-HA
+
++
++
+
B
 
 
Figure 26: PCAF and hSpt3 are Capable of Interacting with Cyclin E when 
Cotransfected. 
(A) HA-tagged Cyclins were cotransfected with Flag-PCAF into 293T cells. Lysates were 
immunoblotted for equal protein expression with Flag M2 and HA.11 monoclonal antibodies 
(upper panels). Flag-IPs were immunoblotted with HA-antibodies and revealed presence of 
coprecipitated Cyclin E (lower panel). (B) Flag-HA-tagged hSpt3 was coexpressed in 293T 
cells with un-tagged Cyclin E, and cell lysates were immunoprecipitated with Cyclin E 
monoclonal antibody HE172. Lysates were immunoblotted with Flag monoclonal antibody M2, 
which revealed presence of hSpt3 in the Cyclin E IPs. 
 
6.3. Cyclin E Associates with PCAF and hSpt3 in Transient Transfections 
Having shown that Gcn5 can bind to Cyclin E, I wanted to investigate, 
whether PCAF, a HAT closely related to Gcn5, can also bind Cyclin E. 293T 
cells were transiently transfected with expression vectors for HA-tagged 
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Cyclins E1 and E2, and Flag-tagged PCAF, alone or in combination. Lysates 
were analyzed for protein expression by immunoblot, showing equal 
expression in all cotransfections (Figure 26 A). Flag-IPs contained Cyclin E, 
indicating that PCAF is capable of binding it just as well as Gcn5 does (Figure 
26 B).  
The interaction data presented above indicate that Cyclin E binds to a 
Gcn5/PCAF containing HAT-complex. If this were the STAGA complex, an 
interaction with hSpt3 would also be expected. Thus, 293T cells were 
transfected with plasmids encoding a Flag-HA-tagged hSpt3 and un-tagged 
Cyclin E. Lysates were immunoprecipitated with the Cyclin E monoclonal 
antibody HE172, and immunoblotted for the presence of hSpt3. Only when 
both proteins were coexpressed, such an interaction was detected (Figure 26 
C). In conclusion, Cyclin E is capable of interacting with at least two 
components of the STAGA complex in transient transfection assays.  
 
6.4. Cell Cycle Arrest by p16INK4a and p27Kip1 Reduces the HAT Activity of 
Transduced PCAF 
The fact that Cyclins bind to a Gcn5/PCAF suggests that they may 
regulate the activity of a Gcn5/PCAF HAT-complex, for example by CDK-
dependent phosphorylation. To address this possibility, I used a Rat1 cell line 
stably transduced with a retrovirus expressing Flag-tagged PCAF 
(Rat1/FlagPCAF). Exponentially growing cells were superinfected with 
retroviruses expressing either the p16INK4a or p27Kip1 CKI, or empty vector 
(BP). After infection, cells were grown to confluence, and then passaged into 
media containing Puromycin for selection purpose. After two days, all cells of 
an uninfected control population not expressing the resistance gene had died. 
Cells expressing the CKIs were growth arrested, as determined by colony 
formation assay (data not shown). Cells were harvested, and lysates analyzed 
by immunoblot and HAT assay. Whereas PCAF protein levels were not 
reduced in cells expressing either of the CKIs, HAT activity dropped to 
background levels (Figure 27). This suggests that HAT activity be regulated in 
response to growth inhibitory stimuli. However, whether modulation of HAT 
activity is a cause, or a consequence of growth arrest, remains to be 
determined.  
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Figure 27: Cell Cycle Arrest by CKIs Reduces PCAF Associated HAT Activity. 
Rat1 cells were transduced with a retrovirus expressing FlagPCAF. For HAT assays, 
exponentially growing populations were transduced with either BP retrovirus (empty vector 
control), or vectors expressing either p16INK4a or p27Kip1. After two days of selection with 
Puromycin, the stably transduced cells were harvested, and IP-HAT assays were performed 
as described in Materials and Methods (upper panel). For expression analysis, cell lysates 
were immunoblotted with M2 Flag monoclonal antibody (lower panel). HAT activity in arrested 
cells was significantly reduced, compared to control infected cells. One of three independent 
experiments is shown. 
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DISCUSSION 
 
7. TRRAP-Associated HAT-Complexes are Involved in E2F and Myc 
Transactivation and in Cell Cycle Control 
 
7.1. Analysis of Binding Patterns of E2F Proteins 
During my thesis, I analyzed the role of TRRAP-associated HAT-
complexes in E2F function. To this aim, I initially investigated a number of 
genomic loci for their association with different E2F proteins during the cell 
cycle using quantitative CHIP. I found that in quiescent T98G cells E2F4/p130 
complexes are predominant on the promoters of E2F targets. As cells 
progressed through G1, activating E2Fs (E2F1, -2, and -3a) replaced E2F4. 
Their binding peaked just before to S-Phase, then dropped. Presumably 
Cyclin A/CDK2, which is activated in S-Phase, phosphorylates all activating 
E2Fs to release them from their targets, as was shown for E2F1. These 
results fit well with previously published reports (Takahashi et al. 2000; Wells 
et al. 2000; Rayman et al. 2002), and establish T98G cells as a system useful 
for analysis of cofactor recruitment and histone acetylation by E2F.  
Others and we detected robust signals for both E2F1 and E2F3, while 
E2F2 CHIP resulted in only weak specific enrichment, suggesting that E2F2 
may not be highly expressed in these cells (Takahashi et al. 2000; Wells et al. 
2000). Alternatively, the antibody used in these studies might not be very 
efficient. However, in exponentially growing, but not in synchronized MEFs, 
significant E2F2 and E2F3 signals have been obtained by CHIP (Wells et al 
2000). Thus, E2F2 may be more important in cycling cells than in the first 
cycle after quiescence, as has been previously proposed for E2F3. 
Alternatively, individual E2Fs may play distinct roles in different cell types, as 
has been suggested from results obtained with mouse models (see chapter 
3.2.3; pp. 39). Another interesting result was that, while promoter occupancy 
by E2F1 and -2 in quiescence was low, E2F3 was present in significant 
amounts. As noted above, the antibody used in this study does not distinguish 
between the E2F3a and E2F3b isoforms. Nevertheless, the data suggest that 
E2F3 can play a role in transcriptional repression in G0.  
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Using an artificial system expressing hormone inducible E2F1 (U2OS-ER-
E2F; Vigo et al. 1999), it was possible to analyze E2F1 binding to target 
genes that were not strongly bound after mitogenic stimulation. Indeed, some 
of those were efficiently bound by ER-E2F1, for example p73. Presumably, 
additional signals are required to achieve enhanced binding of endogenous 
E2F1 to these promoters. In this context it is noteworthy, that E2F1, but not 
E2F2 or E2F3, exhibits protein stabilization and enhanced DNA-binding after 
DNA-damage (Lin et al. 2001). Such conditions may favor binding of E2F1 to 
the promoters of p73 and other DNA-damage related genes like msh2, polδ, 
and apaf1, but this hypothesis remains to be tested.  
Ectopic ER-E2F1 bound to targets at least well as endogenous E2F1. 
Furthermore, when nuclear localization of ER-E2F1 was induced, or when 
E2F1 was overexpressed from an adenoviral vector, association with E2F 
binding sites was immediate. Thus, E2F1 is fully capable of binding to its 
targets as soon as it is expressed, or imported into the nucleus, without the 
need of additional signals (for example serum) that modulate DNA-binding. 
This suggests that E2F1 is able to displace E2F4/p130 complexes, which 
presumably are occupying E2F targets in quiescent U2OS/ER-E2F1 cells. 
The reason for this might be a higher specific affinity of E2F1 (compared to 
E2F4) for its binding sites.  
E2F sites are commonly located within promoters, close to the 
transcriptional start site. Many promoters also possess binding sites for other 
transcription factors, and these may contribute to transcriptional regulation. 
For instance, a complex of p107, a repressive E2F, and Smad2/3 has recently 
been found to specifically repress transcription of the c-myc gene after TGF-β 
treatment (Chen et al. 2002). While not recruited via E2F sites, the entity of an 
E2F and a Rb-family protein may recruit corepressors to the Smad-sites in the 
c-myc gene, just as for "regular" E2F target genes. Another possible co-
regulator is YY1, which has recently been shown to interact with E2F2 and 
E2F3, and cause synergistic activation of the cdc6 promoter, even though the 
nature of this synergy has not been determined (Schlisio et al. 2002). 
Similarly, binding sites for Sp1 occur in many E2F target genes (cdkn2a, 
cdc6, and tk), and combinatorial coactivation has been suggested (for 
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example Chang et al. 2001; Huang et al. 2001; Blais et al. 2002; Parisi et al. 
2002; Nichols et al. 2003). Moreover, at least some E2F target genes (for 
instance nuc, mcm4, ccne2) also contain Myc binding sites, and Myc binding 
can induce acetylation of promoters in early G1, at least on nuc (Greasley et 
al. 2000; Fernandez et al. 2002). Transcriptional activation upon mitogenic 
stimulation might thus be a complex response achieved by simultaneous, or 
sequential, action of several transcription factors. Interestingly, a chromatin-
modifying-complex containing E2F6/DP1 and Mga/Max, antagonists of the 
E2F and Myc activators, has been shown to bind several E2F targets in 
quiescent primary fibroblasts (Ogawa et al. 2002). Thus, promoters containing 
both E-boxes and E2F sites might be subject to coregulation by repressive 
and activating branches of two independent transcription factor families. 
Lastly, it is important to note that at least some of the E2F targets involved in 
DNA-damage are also transactivated by p53 (for example p73, apaf1; 
reviewed in Xu and Raafat el-Gewely 2001). Therefore, transcriptional 
regulation of these genes in response to DNA-damage might also depend on 
combined actions of at least two distinct transcription factors.  
 
7.2. Activating E2F is Required for Cell Cycle Entry in T98G Cells 
The role of activating versus repressing E2F in the cell cycle has been a 
focus of debate (see introduction). Depending on the cellular context, 
overexpression of activating E2F proteins can cause S-Phase induction, 
overcome artificially imposed G1 arrest, or induce apoptosis. E2F4 and E2F5 
are also capable of inducing S-Phase when overexpressed, raising the 
possibility that these studies do not necessarily reflect the role of endogenous 
E2Fs. Nevertheless, it is clear that at least E2F3 plays an important role in G1 
progression as E2F3-/--MEFs are delayed in S-Phase entry following 
mitogenic stimulation, and gene expression of specific targets is reduced. 
Consistent with this E2F1 and E2F3 loss also reduce excess proliferation in 
Rb-/--mice. Furthermore, the combined mutation of E2F3 with E2F1, or E2F2, 
or both leads to progressive reduction in cell cycle entry, such that TKO-MEFs 
do not detectably enter the cell cycle, and fail to proliferate. However, in these 
MEFs repressive E2F may become dominant, so that lack of proliferation may 
not be due to absent activators, but enhanced inhibitory E2F. Therefore, the 
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necessity of activating E2F for proliferation and cell cycle entry remains 
formally unproven.  
In this study, I used a mutant E2F1 that is deficient in DNA-binding, but 
retains the capacity to interact with DP1 (E2F1-Eco132). Expression from an 
adenoviral vector resulted in levels far above endogenous E2F1 protein. The 
ectopic E2F1-Eco132 presumably titrates all DP protein away from 
endogenously expressed E2F, effectively acting as a dominant negative E2F. 
Indeed, as analyzed by CHIP, no E2F (including E2F4) was detected on 
promoters after infecting T98G cells with Ad-E2F1-Eco132. In these cells, 
BrdU incorporation was strongly delayed. Thus, even though repressive E2F 
complexes were absent from promoters, cells expressing Ad-E2F1-Eco132 
are unable to efficiently enter S-Phase. These experiments suggest that 
activating E2F is strictly required for cell cycle entry in T98G cells. Consistent 
with my results, it has recently been published that activating E2F is 
dispensable for continuous proliferation, but required for mitogen stimulated 
induction of S-Phase (Rowland et al. 2002; Zhang et al. 1999). Possibly, 
activating E2F is specifically required to induced transcription of proteins that 
are downregulated in quiescence, but are expressed in cycling cells, due to 
the action of alternative transcription factors. Alternatively, in quiescent cells, 
E2F target genes may exist in a chromatin conformation that requires 
recruitment of cofactors for remodeling and transcription. Accordingly, in 
cycling cells the role of activating E2F may be different, maybe effecting 
timing, or levels of target gene transcription. Altogether, studies with a DN-
E2F1 confirm the importance of activating E2F for S-Phase induction from 
quiescence following mitogenic stimulation. 
 
7.3. E2F Induces Histone Acetylation in a Temporally and Spatially Restricted 
Fashion 
In many eukaryotes histone acetylation is a hallmark of transcriptional 
activation. Indeed, several E2F targets have previously been found to be 
acetylated in T98G cells (Takahashi et al. 2000). Here, I significantly 
expanded these studies. The data show that acetylation is not limited to a 
subset of E2F target genes involved in G1/S transition. Instead, all 25 
investigated target genes exhibited induction of H4 acetylation in serum 
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stimulated T98G cells, including DNA-damage/apoptosis related target genes 
like p73, polδ, and msh2. Thus, it appears that histone acetylation is a general 
feature of E2F target gene activation. Interestingly, there are strong 
differences in total acetylation on individual targets. Possibly, acetylation on 
each locus depends on events other than just the simple recruitment of one 
transcription factor to a target promoter at a given time.  
Furthermore, I analyzed in-depth the histone acetylation patterns on four 
well-characterized E2F targets (mcm3, mcm4, pcna, and p107). Interestingly, 
acetylation of both H3 and H4 was transient, increasing through G1, peaking 
at G1/S transition, and then decreasing. Thus, acetylation paralleled the 
binding of activating E2Fs. The fact that acetylation was transient suggests 
that a deacetylase activity must be recruited once cells are in S-Phase. 
Consistent with this, complexes of E2F4 and p107 have been described in S-
Phase cells, and these may recruit HDACs to E2F target genes during DNA 
replication. Alternatively, global and non-targeted deacetylation may restore 
histone acetylation to basal levels following induction, as has recently been 
suggested (Vogelauer et al. 2000; Katan-Khaykovich and Struhl 2002).  
In addition to the temporal pattern of acetylation, its spatial distribution 
was also analyzed. Using amplicons that reach over several kb of these target 
promoters, I found that, unlike E2F binding, acetylation was more widespread. 
In fact, while being centered to the E2F sites, it extended over the whole 
promoter. However, acetylation did not spread far into the coding region, as 
little regulated acetylation was observed beyond two kb downstream of the 
transcriptional start site. This suggests that activating E2F remodels 
chromatin locally. Rather than increasing access to a large chromatin domain, 
the observed acetylation may represent a signal-like modification. This fits 
with the “histone code” model, where distinct modifications in the tails of 
histones can act sequentially or in combination, to create a code that is read 
by other proteins to bring about downstream events. Therefore, while histone 
acetylation of E2F target promoters may be important in transcriptional 
activation, it may not constitute the ultimate or total signal generated by E2F 
activators. Furthermore, it is important to note that the acetyl-histone 
antibodies used in this study recognize acetylation on any of the lysines in H3 
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or H4 tails. While total acetylation increased from G0 to G1 to S, acetylation of 
individual lysines may not follow the same temporal or spatial acetylation 
pattern. Recently, lysine specific CHIP grade antibodies against both H3 and 
H4 have been described (Suka et al. 2001). Making use of these reagents 
would allow determining the exact acetylation patterns on individual E2F 
target genes. Possibly, different HATs and/or HDACs contribute 
acetylation/deacetylation of different lysines on E2F targets. In summary, 
while induction of histone acetylation is likely to be an important part of E2F 
function, the exact “histone code” remains to be determined.  
 
7.4. E2F is Sufficient for Induction of Histone Acetylation 
Using the ER-E2F1 chimera, I showed that induced binding of ectopic 
E2F1 is followed by histone acetylation. Compared to the acetylation induced 
by serum, however, maximal levels of acetylation were lower, suggesting that 
additional signaling is required to achieve full acetylation, for example serum. 
Remarkably, acetylation induced by ER-E2F1 was delayed: E2F1 and 
cofactor recruitment significantly increased after only 20 minutes of treatment, 
whereas acetylation was not yet strongly induced above initial levels. 
Presumably assembly of HAT-complexes is followed by another step 
necessary for histone acetylation. Interestingly p73, a target promoter that 
was only weakly bound by E2F1 in serum stimulation, but well in the ER-E2F1 
experiments, exhibited strong H3 and H4 acetylation. Possibly, a serum 
response is not sufficient to induce full activation of the p73 gene, whose 
transcription is induced in responses to apoptotic stimuli. Other target genes 
(for example msh2, or polδ) were not acetylated in ER-E2F1 experiments, 
even though E2F1 binding was induced, suggesting a requirement for 
additional signaling events. Nevertheless, these experiments show that E2F1 
is sufficient to induce significant changes in acetylation on most E2F targets.  
 
7.5. Activating E2F is Required for Full H4 but not H3 Acetylation 
Time-course analysis in T98G cells showed that H4 acetylation closely 
correlated with binding of activating E2Fs, suggesting that they are 
responsible for this modification. Interestingly, for H3 the correlation was less 
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strict, as acetylation appeared to peak a little before maximal binding of E2F 
activators. Using the DN-E2F proved that inhibition of activator recruitment 
correlates with block of H4 acetylation. In contrast, only a partial block of H3 
acetylation was observed. Thus H4, but not H3 acetylation appears to strictly 
depend on recruitment of activating E2F. Nevertheless, in the context of the 
DN-E2F, H3 did not become fully acetylated, indicating that E2F-dependent 
HAT recruitment contributes to full H3 acetylation. In cells infected with DN-
E2F, removal of G0-specific E2F4/p130/HDAC complexes may be followed by 
binding of H3 HATs, which cause the observed partial H3 acetylation. For 
instance, Gcn5 may bind promoters in E2F-independent fashion, as has been 
suggested in yeast (Vogelauer et al. 2000). Alternatively, distinct HATs may 
contribute to full H3 acetylation by E2F-dependent and independent 
recruitment.  
The differences between H3 and H4 acetylation are compelling, and 
suggest that H3 and H4 exhibit different susceptibility to HDAC removal. 
Interestingly, in quiescent p107-/-/p130-/--KO MEFs, H3 acetylation of the e2f1 
gene was strongly increased (in comparison to WT MEFs), whereas only a 
modest increase in H4 acetylation was detected (Rayman et al. 2002). This 
fits with my findings that repressive E2F is predominantly required to maintain 
hypoacetylated H3. However, in these MEFs the absence of p107 and p130 
also induced a moderate change in H4 acetylation on the E2F1 locus, a result 
not reproduced by expression of the dominant negative E2F mutant. This 
could result from untimely recruitment of activating E2F to the promoter in 
quiescent cells, recruiting an H4 HAT. In summary, it appears that H4 
acetylation is strictly dependent on functional activating E2F, whereas 
removal of repressive complexes is sufficient to result in partial, but not full H3 
acetylation.  
 
7.6. Activating E2F Recruits the Tip60 Complex 
The centerpiece of this study is the result that the Tip60 complex is 
involved in the transcriptional response of activating E2F. Four lines of 
evidence indicate that this is the case: First, four subunits of the Tip60 
complex were recruited to E2F target promoters after serum stimulation of 
T98G cells. Importantly, the kinetics of TRRAP and Tip60 recruitment 
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paralleled association of activating E2F with target promoters. Second, 
whereas histone acetylation was more widespread, localization of all four 
subunits was strictly limited to the E2F sites in all tested promoters. Third, an 
ER-E2F1 chimera was sufficient to induce rapid binding of five different Tip60 
complex components to E2F targets. Again, both timing and spatial 
distribution mimicked the E2F1 binding pattern. Fourth, when DN-E2F was 
overexpressed, no Tip60 complex components were recruited to promoters, 
proving a necessity of activating E2F in the process. How individual 
components of the Tip60 complex, and its HAT activity, contribute towards 
E2F-dependent transactivation, remains to be elucidated. Nevertheless, these 
results strongly imply an important role for the Tip60 complex in chromatin-
remodeling at E2F target genes.  
Recently, it has been published that, when overexpressed, not only E2F1, 
but also E2F4 interacts with TRRAP (Lang et al. 2001). Therefore, one would 
assume that TRRAP would be recruited to chromatin in quiescent cells, when 
E2F4 is predominant on all investigated E2F targets. However, my CHIP 
experiments failed to detect TRRAP and Tip60 on E2F targets in quiescent 
cells. Thus, no temporal correlation between E2F4 and TRRAP/Tip60 binding 
could be established, suggesting that the observed interaction may be an 
artifact of overexpression. Alternatively, TRRAP may be recruited by E2F4 in 
conditions not investigated in this study, (for instance differentiation specific 
events), or such a complex may be target gene specific.  
While it is clear that Tip60 and E2F associate with each other on 
chromatin, I failed to show a physical association between Tip60 and E2F1 in 
lysates (data not shown). It is possible that this interaction can only occur on 
native chromatin. However, three subunits of the Tip60 complex (TRRAP, 
p400, and Tip49) have been published to bind E2F1 (McMahon et al. 1998; 
Fuchs et al. 2001; Dugan et al. 2002). It is also noteworthy that a complex 
highly similar to the Tip60 complex has recently been purified from 
mammalian cells (the p400 complex; Fuchs et al. 2001). The only difference 
between the two is the absence of Tip60 in the p400 complex, raising the 
possibility that Tip60 is a substoichiometric component of this complex. 
Interestingly, the p400 complex was identified as a critical target of the 
adenoviral oncoprotein E1A, whose main function is induction of cell cycle 
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entry by liberating E2F activity. Thus, based on my studies, targeting of the 
Tip60 complex by E1A may provide an additional avenue by which this 
oncoprotein regulates E2F-dependent transcription (Figure 28).  
CHIP with antibodies to other HATs did not yield any reproducible and 
significant result. Previously, others have also failed to CHIP p300/CBP and 
Gcn5/PCAF on E2F targets (Rayman et al. 2002). Nevertheless, both classes 
of HATs have been shown to interact with activating E2Fs in biochemical 
assays (Marzio et al 2000; Martinez-Balbas 2000). Possibly, antibodies are 
not able to interact with these HATs on E2F targets in the context of 
chromatin, even though all these proteins have been successfully detected by 
CHIP at other loci. It will be important to determine their role in E2F-
dependent transactivation. p300, CBP, Gcn5, and PCAF possess intrinsic, 
H3-specific HAT activity, but CBP and PCAF have also been published to 
acetylate E2F itself. Thus, distinct HATs might be responsible for histone and 
E2F acetylation. Furthermore, p300/CBP possess dual activity towards H3 
and H4, and hence might contribute to H4, as well as H3 acetylation on E2F 
targets.  
The fact that E2F itself can be acetylated is interesting. Both p300/CBP, 
and PCAF (but not Gcn5) were found to acetylate E2F1, E2F2, and E2F3 (but 
not E2F4, E2F5, or E2F6). Target lysines lie just adjacent to the DNA-binding-
domain, and acetylation leads to prolonged protein half-life, enhanced DNA-
binding, and increased transactivation potential (Martinez-Balbas et al. 2000; 
Marzio et al. 2000). A mutant E2F1 having the three acetylation-targeted 
lysines substituted by alanines has been described. It would be interesting to 
see how such a protein effects cofactor recruitment, and/or histone 
acetylation. Such questions could be addressed using the adenoviral system 
described in this study, or using retroviruses. Similarly, it would be useful to 
analyze other E2F mutants in these systems, such as the mutant lacking the 
Cyclin A/CDK2 interaction domain, which should prevent downregulation of 
E2F's DNA-binding in S-Phase (Krek et al. 1995).  
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Figure 28: A Model for a Role of TRRAP and its HAT-Complexes in the 
Regulation of Growth and Proliferation. 
The E2F/Rb and Myc/Max/Mad networks of transcription factors regulate growth and 
proliferation. Both recruit TRRAP and its associated HATs. These proteins are also targets of 
E1A, and/or components of the cell cycle regulatory network. Thus, TRRAP or its associated 
proteins may play an important role in tumor development.  
 
Consistent with a role of E2F acetylation, Rb-associated HDACs are 
capable of deacetylating E2F1. Interestingly, Rb itself can also be acetylated 
by p300 (Chan et al. 2001). In this case, acetylation inhibits phosphorylation 
by Cyclin/CDK complexes, thus stabilizing Rb-repression. Taken together, 
these results suggest that p300 can contribute to both S-Phase progression 
(by acetylation of activating E2Fs, and possibly by coactivating E2F 
transcription), and S-Phase inhibition (by maintaining repressive Rb/E2F 
complexes). In summary, whether the differential effects of p300 in G1/S 
transition result in signals promoting or inhibiting the cell cycle, remains to be 
determined.  
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7.7. Do E2F Targets Require Additional Chromatin-Remodeling Before 
Transactivation? 
HAT-complexes represent only one type of chromatin modifying enzymes 
involved in transcriptional responses. E2F proteins have been found to 
interact with a variety of other chromatin-remodeling-complexes, for example 
the Swi2/Snf2-family proteins Brg1/hBrm, and also with DNA 
methyltransferases (DNMT1), histone deacetylases (HDACs1 and 2), histone 
methyltransferases (SuVAR39H1), and Polycomb-group proteins (PcGs, such 
as Bmi1, Ring1, HPC2). However, HDACs, HMTs, and PcG proteins are all 
primarily involved in repression and/or silencing. In contrast, Swi/Snf-
chromatin-remodeling-complexes can coactivate transcription by several 
transcription factors. Thus, it would be interesting to test whether chromatin-
remodeling participates in E2F coactivation, prior or subsequent to G1 specific 
histone acetylation events. Cell lines lacking, or harboring mutations in, some 
of the subunits of these complexes have been described, and present a 
potential tool to study such events (Zhang et al. 2000; Dahiya et al. 2001).  
 
7.8. The Tip60 Complex is Involved in the Transcriptional Activity of Myc 
Myc recruits TRRAP, and induces H4 acetylation in early G1 following 
mitogenic stimulation, suggesting that TRRAP-associated HAT-complexes are 
involved in Myc-dependent chromatin-modifying events (McMahon et al 1998; 
McMahon et al. 2000; Bouchard et al. 2001; Frank et al. 2001). Consistent 
with this, I showed that Myc interacts with Tip60 in transient transfections. 
Tip60 was also recruited to several Myc targets, as judged by CHIP (S. Frank 
and B. Amati, unpublished data). Additionally, like E2F, Myc recruited at least 
four other subunits of the Tip60 complex to chromatin, TRRAP, p400, Tip48, 
and Tip49 (S. Frank, T. Parisi, and B. Amati, unpublished data). Previously, it 
has been proposed that Myc interacts with Tip48/49 and TRRAP within 
different complexes (Nikiforov et al. 2002). However, this contrasts with the 
observation that Myc can interact with these proteins in the context of the 
purified p400 complex, suggesting that Myc recruits a TRRAP/Tip60/p400 
complex to chromatin (Fuchs et al. 2001). In any case, this does not rule out 
the possibility that other, TRRAP or Tip48/49 containing HAT-complexes are 
also recruited by Myc. In fact, I showed that Myc bound two STAGA complex 
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components in transient transfections. Myc can also induce H3 acetylation on 
several promoters in a variety of cell lines (P. Fernandez, S. Frank, and B. 
Amati, unpublished data). In summary, Myc probably recruits two classes of 
TRRAP-associated HATs, Tip60 and GCN5/PCAF, to mediate acetylation of 
H4 and H3, respectively. Alternatively, unidentified HATs may also contribute 
to total histone acetylation in a Myc-response.  
 
7.9. Are TRRAP Containing HAT-Complexes Involved in G1/S Transition? 
The finding that E2F and Myc both recruit a TRRAP/Tip60/p400 complex 
is striking, and establishes this complex as a part of the machinery that 
controls the cell cycle. Interestingly, adenoviral E1A protein can bind the p400 
complex through a short domain in its N-terminus. Chimeric proteins in which 
this domain was fused to the Myc DNA-binding-domain mimic Myc activity by 
binding TRRAP, inducing histone acetylation, activating hTERT expression, 
and promoting cellular transformation (S. Frank and B. Amati, unpublished 
results; Deleu et al. 2001; Nikiforov et al. 2002). Thus, the TRRAP/p400-
binding motif of E1A functionally substitutes for the Myc N-terminus, 
strengthening the notion that recruitment of these co-factors is crucial for Myc 
activity. In the context of full-length E1A, the TRRAP/p400-binding domain is 
required for maximal transforming activity, and for bypassing cell cycle arrest 
imposed by the CDK2 inhibitor p27Kip1 (Alevizopoulos et al 1998; Deleu et al. 
2001). These data indicate that regulation of TRRAP/p400 complexes is an 
important role of E1A. In addition, several groups also reported a modulation 
of PCAF's HAT activity by E1A, thus implying the other major TRRAP-
containing HAT-complex as an E1A-target (Chakravarti et al. 1999; Hamamori 
et al. 1999a; Reid et al. 1998). However, if HAT activity is actually enhanced 
or inhibited by E1A remains controversial. In fact, it might depend on the 
cellular context, since PCAF is involved in a broad variety of coactivation 
events. Nevertheless, all these observations suggest that, like other cellular 
targets of E1A, TRRAP complexes are key regulators of cellular growth and 
proliferation.  
E1A substitutes for Cyclin/CDKs function after adenoviral infection. For 
example, E1A binds and inactivates Rb-family proteins, usually a critical 
function of Cyclin/CDK complexes. Similarly, E1A stimulates the HAT activity 
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of p300, also a target of Cyclin E (Ait-Si-Ali et al. 1998). Interestingly, the 
timing of this stimulation (G1/S transition) fits with a possible role in E2F-
dependent transcription. Here, I show that Cyclin E is capable of binding two 
STAGA complex components, again suggesting that a TRRAP-associated 
HAT-complex is regulated during G1/S transition. Consistent with this, the 
HAT activity of PCAF was downregulated upon cell cycle arrest by CKIs. 
Overall, it appears likely that different HAT-complexes are playing important 
roles in regulation of G1-specific transcriptional events, and are in turn 
controlled by G1-specific Cyclin/CDKs. This regulation highlights a second 
potential pathway essential for cell cycle control that runs in parallel to the 
Cyclin/CDK/Rb pathway in mammalian cells (Figure 28).  
 
7.10. A Possible Role for TRRAP-Associated HATs in DNA Repair and 
Apoptosis 
In yeast, Esa1p-dependent H4 acetylation is required for double strand 
break repair (Bird et al. 2002), and in human cells the Tip60 complex is 
involved in apoptosis following γ-irradiation (Ikura et al. 2000). Tip60 levels 
increase after DNA-damage by UV irradiation, presumably because 
ubiquitin/proteasome-dependent degradation of Tip60 is downregulated 
(Legube et al. 2002). In contrast, Tip60 levels remained constant during the 
G0/G1 and G1/S-Phase transitions in T98G cells. However, it is possible that 
the protein is differentially regulated in response to serum and to DNA-
damage. Interestingly, DNA-damage also induces stabilization of E2F1. This 
may represent a distinct upregulation of E2F1/Tip60, which is not normally 
activated in cells responding to mitogenic stimuli, but specifically after DNA-
damage.  
Similar to the Tip60 complex, Gcn5-containing HAT-complexes may also 
play a role in DNA-damage responses, as the human STAGA complex 
contains the UV-damaged-DNA-binding-protein 1 (DDB1), which is involved in 
nucleotide excision repair (Brand et al. 2001; Martinez et al. 2001). The 
STAGA related TFTC-Complex preferentially binds UV-irradiated DNA, and 
UV-damaged DNA inhibits TFTC-mediated PolII-transcription. Moreover, 
TFTC is recruited in parallel with the nucleotide-excision-repair-protein XP-A 
 98
to UV-damaged DNA. Finally, the DNA-binding subunit of DNA-dependent 
protein kinase, which is involved in DNA-damage signaling, interacts with and 
phosphorylates Gcn5, downregulating its HAT activity (Barlev et al. 1998). In 
all those cases, the role of the HAT-complexes may be both transcription-
related and unrelated. For example, they might remodel chromatin structure to 
allow easier access for the repair machinery to sites of damaged DNA.  
Another place where HATs may be involved in DNA repair is via p53, a 
regulator of transcription in response to DNA-damage. p53 induces 
transcription of various target genes, inducing either cell cycle arrest, or 
apoptosis (for review, see Vousden 2002). Several coactivators of p53 have 
been identified, including TRRAP and Gcn5 (Barlev et al. 2001). In yeast, p53 
is capable of interacting with the NuA4 complex, predicting an interaction with 
the Tip60 complex in mammalian cells (Nourani et al. 2001). Consistent with 
this, preliminary analysis indicates that Tip60 is indeed recruited to p53 
targets following DNA-damage (D. Donjerkovic and B. Amati, unpublished 
results). Therefore, the Tip60 and STAGA complexes may be involved in 
several distinct functions after DNA-damage has been inflicted.  
 
7.11. TRRAP-Associated HATs and Tumorigenesis 
Results from this study and from other recent publications indicate that 
TRRAP and its associated HATs are involved in a variety of cellular 
processes. Interestingly, E2F, Myc, and p53 are transcription factors 
commonly deregulated in human tumors. Thus, TRRAP, and/or Gcn5/PCAF 
and Tip60 may be targets of pathways deregulated in tumorigenesis. In fact, 
PCAF has previously been suggested to be a tumor suppressor (Schiltz and 
Nakatani 2000), and cell lines with mutations in the PCAF gene have recently 
been reported (Ozdag et al. 2002). The oncoprotein E1A apparently targets 
both PCAF/Gcn5 containing complexes and the TRRAP/p400 complex, 
results that strengthen the notion that TRRAP containing complexes are 
involved in tumorigenesis (Figure 28). Furthermore, the HATs p300/CBP 
behave as haplo-insufficient tumor suppressors in mice (Petrij et al. 1995; Yao 
et al. 1998; Oike et al. 1999b), and mutations of p300 have been found in 
human tumors (Muraoka et al. 1996; Gayther et al. 2000; Bryan et al. 2002). 
Heterozygosity for CBP, occurring in human Rubinstein-Taybi-Syndrome, also 
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predisposes for tumor development (Petrij et al. 1995; Giles et al. 1998; Oike 
et al. 1999a; Murata et al. 2001). Similarly, the gene encoding MOZ, another 
HAT, is a target of translocations that can lead to leukemogenesis (Giles et al. 
1997; Borrow et al. 1996). Finally, the BAF complex components Ini1/Snf5 
and Brg1 are tumor suppressors of the Rb/E2F-pathway, proving that 
mutations of other chromatin-remodeling-complexes can occur in cancer 
development (reviewed in Phillips and Vousden 2000; Klochendler-Yeivin and 
Yaniv 2001).  
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CONCLUSIONS AND PERSPECTIVES 
 
E2F-family proteins are critical regulators of S-Phase entry, and 
quiescence. Hence, they govern cellular proliferation in metazoans by 
regulating transcription of hundreds of target genes, whose individual 
functions and contributions towards proliferation are just emerging in recent 
years. Importantly, while the mechanisms of transcriptional repression by E2F 
also have begun to be understood, how E2F transactivates its targets still 
remains an unresolved mystery.  
Tip60 is involved chromatin-remodeling by E2F. An important clue 
towards elucidating these molecular mechanisms came from the identification 
of TRRAP, a subunit of chromatin-modifying HAT-complexes, as a protein 
interacting with E2F. Later, it was shown that E2F targets are deacetylated 
(by a complex of HDAC1/mSin3B) in G0, but acetylated at G1/S transition. 
Here, I expanded these studies by showing that E2F is required and sufficient 
for induction of histone acetylation on E2F targets. It does so by recruiting at 
least one of the two TRRAP containing HAT-complexes, the Tip60 complex. 
To my knowledge, this is the first time that a chromatin-modifying-enzyme has 
been experimentally implicated in E2F-dependent acetylation. However, while 
these results shed light on events governed by E2F, they raise even more 
questions.  
How about additional enzymatic activities? First, it will be critical to 
determine whether the Tip60 complex is indeed required for E2F-dependent 
induction of transcription. Experiments to address these issues are currently 
underway. Furthermore, while explaining H4 acetylation, the Tip60 complex is 
unable to acetylate H3. Thus, other HAT-complexes must also be present at 
E2F targets. Moreover, other chromatin modifying and/or remodeling 
enzymes may combine with HATs to create a chromatin environment that 
allows for efficient transcription of E2F target genes. It will be important to 
determine the identity of such cofactors in future experiments.  
What is the role of Tip60 in vivo? HAT-complexes are probably involved 
in regulatory processes other than just transcriptional regulation. Thus, while it 
will be important to find out what other transcription factors depend on Tip60 
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to induce transcription, other chromatin based processes should also be 
investigated. In this context, it is noteworthy that the Tip60 participates in 
DNA-damage response, and apoptosis. The human STAGA/TFTC/PCAF 
complexes may also participate in various processes, as suggested by the 
presence of splicing-associated and DNA-damage-associated proteins within 
these complexes. Similarly, TRRAP may have functions other than just being 
a subunit of HAT-complexes. The identification of the remaining subunits of 
the Tip60 complex, alternate complexes, and mechanisms regulating these 
complexes will help us understand such functions.  
TRRAP and Tip60 – potential tumor suppressors? The work presented 
here shows that Tip60 and TRRAP participate in the E2F/Rb, as well as the 
Myc/Max/Mad transcriptional regulatory pathways. Both of these are key 
elements of a network that governs growth and proliferation, and 
tumorigenesis. Thus, it is tempting to speculate that Tip60 and/or TRRAP may 
themselves play important roles in the processes that lead to tumor formation 
in mammalian organisms. Other chromatin-remodeling subunits, such as 
Ini1/Snf5 and Brg1, cofactors of E2F/Rb-dependent repression, are indeed 
known tumor suppressors. Moreover, PCAF, another TRRAP-associated 
HAT, has been suggested to be a tumor suppressor, and p300/CBP, a 
possible coactivator of E2F, does exhibit tumor suppressor characteristics. In 
addition, TRRAP and Gcn5 interact with the tumor suppressor p53. Finally, 
the adenoviral oncoprotein E1A targets several of these HATs, and other 
chromatin-remodeling-complexes. Taken together, these data suggest that 
regulation of chromatin structure is critical for normal cellular behavior, and 
that mis-regulation of this process can ultimately contribute to cellular 
transformation. Thus, understanding how chromatin-remodeling and 
modification cooperate to control transcription, may help us elucidate 
mechanisms causing transformation, and ultimately provide clues how to fight 
cancer. Consistent with these ideas, it has been suggested that the enzymes 
affecting the acetylation status of chromatin should be targets in cancer 
therapies (reviewed in Marks et al. 2001; Johnstone 2002; Kelly et al. 2002). 
Indeed, small inhibitory molecules targeting HDACs are active in vitro and in 
vivo, causing cancer cell growth arrest, differentiation and/or apoptosis. 
Several HDAC inhibitors are currently in clinical trials as anticancer agents, 
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and some have shown activity against cancers. In the light of these results, it 
may well be worth expanding these searches for molecules inhibiting HATs, 
as well as other chromatin modifying enzymes.  
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MATERIALS AND METHODS 
 
8.1. Cell Culture Techniques 
8.1.1. Mammalian Cell Culture  
Adherent mammalian cells (T98G, U2OS/ER-E2F1, U2OS, WS1, 293T, 
Bosc23, and Rat1 cells) were cultured in DMEM (Biowhittaker 12-064F) 
supplied with 10% Fetal Bovine Serum (FBS; Gemini Bioproducts 00-106) 
and antibiotics (Penicillin 10000 u/ml, and Streptomycin10mg/ml). Cells were 
incubated at 37oC in a 10% CO2 atmosphere saturated with water. Cells were 
rendered quiescent by growing to confluence followed by incubation for two 
days in serum-free medium. To induce cell cycle entry, cells were harvested 
by trypsinization, and reseeded onto plates containing DMEM/10%FCS.  
 
8.1.2. Transient Transfection of Bosc23 or 293T Cells 
Cells at 60 to 80% confluence were transiently transfected with 2 to 20 µg 
of total plasmid according to standard calcium phosphate transfection 
protocols, or using Fugene 6 Lipofect transfection reagent (Roche) according 
to the manufacturer’s protocol.  
 
8.1.3 Generation of High Titer Retroviral Supernatants and Infection Protocol 
Generation of high titer retroviruses was performed as described in 
previous protocols (Morgenstern and Land 1990; Vlach et al. 1996). Briefly, 
the gene of interest was cloned into the polylinker of pBabe retroviral vectors. 
Plasmids were transfected into Bosc23 or Phoenix cells (60% confluent 10cm 
dishes) in the presence of 25µM Chloroquine using transient transfection 
methods. After 12 hours the medium was aspirated, and replaced by 5ml of 
fresh medium. The retroviral supernatant was harvested after 48hrs, filtered to 
remove cell debris, and aliquots stored at -70oC. For infection, an aliquot was 
thawed at 37oC, added to 5ml of growth medium containing 4-8 µg/ml 
polybrene. This infection cocktail was vortexed and added to subconfluent, 
growing cells. The next day, the cells were passaged and selected for at least 
two days with the appropriate drug (Puromycin 2.5µg/ml, G418 1mg/ml, 
Phleomycin 50µg/ml, and Hygromycin B 150µg/ml).  
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8.1.4. Generation of Adenoviruses 
The cDNAs expressing human WT E2F1 or E2F1-Eco132 were cloned 
into the polylinker of pAdTrackCMV, followed by recombination in E. coli, viral 
production and amplification in 293T cells, and purification of recombinant 
adenovirus as described previously (He et al. 1998).  
 
8.1.5. High Efficiency Infection of T98G Cells with Adenovirus 
In order to achieve highly efficient adenoviral infection, I used a 
modification of a previously described protocol (Fasbender et al. 1997; Frank 
et al. 2001). Briefly, an infection cocktail of adenovirus (0.5x109 
particles/confluent plate of T98G cells), 5 to 10ml of serum free DMEM, and 5 
to 10µl of Superfect transfection reagent (QIAGEN) was mixed by vortexing 
and incubated at RT for 10min. Trypsinized cells were resuspended directly in 
the mixture, and plated into fresh, serum containing DMEM. Infection 
efficiency was verified by scoring for GFP positive cells by direct fluorescence 
in a Zeiss Axiovert S100 AttoArc 2 HBO 100W fluorescent microscope 
(adenoviral vectors contain a separate mRNA encoding GFP). Typically, after 
12 hours of infection 100% of the cells exhibited GFP expression.  
 
8.1.6. BrdU/PI FACS Analysis  
Cells were treated with 10µg/ml (approx. 33µM) BrdU for the desired time 
(pulse labeling 30min) by directly adding 33.3µl of 10mM BrdU aqueous stock 
solution per 10mls of DMEM. Cells were harvested by trypsinization, washed 
once in PBS, and resuspended in 200µl PBS. The suspension was added 
slowly to 5ml ice cold 70% v/v ethanol while vortexing (fixation step). Cells 
were then stored on ice for at least 30min. For FACS, fixed cells were pelleted 
at 1200rpm for 10min at 4oC. The supernatant was aspirated; the cells were 
resuspended in 0.5ml PBS, and transferred to Eppendorf tubes. Cells were 
spun in a tabletop centrifuge at 2000rpm at RT for 5min, and the supernatant 
was aspirated. Pellets were resuspended in 0.5ml 3M HCl, and incubated for 
20min at RT. 0.5ml of PBS was added and cells pelleted by centrifugation. 
Then cells were resuspended in 100mM sodium borate (Na2B4O7) pH 8.5, and 
incubated at RT for 3min. 0.5ml PBS containing 2.5% v/v FBS (block) was 
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added, and cells pelleted were by centrifugation. Cells were resuspended in 
0.5ml block, and incubated at RT for 15min. After pelleting cells by 
centrifugation, they were directly resuspended in 20 to 50µl of FITC-
conjugated anti-BrdU antibody (Becton Dickinson #7583), and incubated on 
ice in the dark for 45min. 0.5ml of block was added and after centrifugation 
pellets were resuspended in 0.5ml of block, containing 20µl of PI (stock 
solution of 250µg/ml is 25x) and 20µl of RNase A (stock solution of 10mg/ml is 
400x), and transferred to FACS tubes. After incubating at 37oC for 5 to 30min 
cells were stored on ice and analyzed in a FACScalibur (Becton Dickinson).  
 
8.2. Biochemical Techniques 
8.2.1. List of Antibodies 
E2F1 sc-193 (C-20) and KH20&KH95 (Upstate Biotech 05-379); E2F2 sc-
633 (C-20); E2F3 sc-878 (C-18); E2F4 sc-1082 (A-20); E2F5 sc-999 (E-19); 
p130 sc-317 (C-20); c-Myc sc-764 (N-262); c-Myc sc-42 (C-33), sc-40 (9E10), 
sc-788 (C-19), or sc-41 (C-8); Max sc-765 (C-124), or Max2.1; PolII sc-899 (N-
20); Acetyl-Histone H3 Upstate Biotech 06-599; Acetyl-Histone H4 Upstate 
Biotech 06-866; Tip60 affinity purified CLHF, CLGT, and RLPV (see 8.2.2; p. 
111); TRRAP CT affinity purified (K. Alevizopoulos); Gcn5 N-terminal (S. 
Roth); Spt3 #623 (E. Martinez); Flag M2 (Sigma); HA HA.11 (Babco Ascites); 
Tip48 and Tip49 affinity purified (T. Parisi); p400 affinity purified F20/21 (M. 
Fuchs, H.M. Chan, D.M. Livingston, unpublished); Cyclin E HE12, HE172 (E. 
Lees); Cyclin E2 8E6 (E. Lees); NRS and 419 controls (D. Parry).  
 
8.2.2. Peptides for Tip60, Gcn5, PCAF, and HBO1 Antibodies  
Peptides for antibodies were chosen according to some criteria from 
published human protein sequences. The following peptides were synthesized 
by Research Genetics:  
Tip60 RLPV peptide: CRLPVLRRNQDNEDEWPLAE (aa 11-29) 
Tip60 CIEL peptide: CIELGRHRLKPW (aa 234-245) 
Tip60 CLGT peptide: CLGTDEDSQDSSDGIPSAPRM (aa 192-212) 
Tip60 CLHF peptide: CLHFTPKDWSKRGKW (aa 499-512) 
Gcn5 CT peptide: CASALEKFFYFKLKEGGLIDK (aa 817-837) 
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PCAF CT peptide: CANILEKFFFSKIKEAGLIDK (aa 783-813) 
HBO1 CT peptide: KRSNSNKTMDPSCLKWTPPKGT (aa 589-611) 
 
8.2.3. PIERCE KLH Kit Coupling Protocol 
For conjugation, peptides were dissolved in 0.2 to 0.5ml of conjugation 
buffer (83mM sodium phosphate buffer pH 7.2, 100mM EDTA, 900mM NaCl, 
0.02% sodium azide). The peptide must be in molar excess of the KLH 
carrier, thus up to 2mg peptide per 2mg KLH carrier protein was used. 2mg of 
KLH carrier protein were suspended in 0.2ml H2O without vortexing or 
heating. The peptide and the carrier solutions were mixed immediately, and 
incubated for two hours at RT. If a precipitate formed, the reaction mix was 
briefly centrifuged (the precipitate was later added to the pooled, desalted 
fractions). The conjugate was purified by Gel-Filtration to remove EDTA. The 
conjugate containing fractions were filter sterilized, and frozen to -20oC before 
being sent for rabbit immunization. Pocono Rabbit Farm generated immune 
sera according to standard protocols.  
 
8.2.4. PIERCE Sulfolink Kit Protocol: Coupling of Peptides to Sulfolink Resin 
For coupling, a column was packed with 4ml 50% v/v Sulfolink beads, and 
equilibrated with 6 volumes of coupling buffer (50mM Tris/HCl, 5mM sodium 
EDTA pH 8.5), then drained. The peptide was dissolved in sample preparation 
buffer (100mM sodium phosphate buffer, 1mM sodium EDTA pH 6.0), and 
added to the beads. The column was filled up with coupling buffer, and the 
mix was incubated on a shaker at RT for 15min. After settling the beads for 
30min, the buffer was drained and the column washed with 3 volumes of 
coupling buffer. The OD280 of the wash was monitored to determine the 
efficiency of peptide binding. Then, nonspecific binding sites of the resin were 
blocked for 15 minutes at RT by incubating on a shaker in 1ml of blocking 
solution (80mg L-cysteine to 10ml coupling buffer, which creates a 50mM 
cysteine solution) per column. After settling the beads for 30min, the buffer 
was drained and the column washed with 2 to 4 volumes of washing buffer 
(1M NaCl) and 2 times with 4 volumes of PBS. Columns were stored in PBS 
containing 0.05% sodium azide at 4oC.  
 
 107
8.2.5. Affinity Purification of Crude Antisera 
10ml of crude rabbit serum were diluted in 40ml PBS containing 10% 
glycerol. The peptide affinity column to was brought to RT, and washed with 5 
volumes of PBS containing 10% glycerol to equilibrate. Then the serum mix 
was added to the beads, and incubated overnight on a shaker at 4oC. The 
column was subsequently washed with PBS to eliminate nonspecific proteins 
(efficiency of wash checked by monitoring OD280), then washed once with 
10mM sodium phosphate buffer pH 6.8. Bound antibody was eluted with 4 
volumes of elution buffer (100mM L-glycine pH 2.5-3) by collecting 1ml 
fractions (100µl of 1M sodium phosphate pH8.0 was added to each tube 
before elution to neutralize the factions). The OD280 of the elution was 
monitored, and the elution repeated if necessary. Then, the column was 
eluted again with 4ml of 100mM triethylamine pH11.5 (100µl of 1M sodium 
phosphate pH8.0 was added to each tube before elution to neutralize the 
factions). Fractions containing protein were pooled, and dialyzed against PBS 
overnight at 4oC. Dialyzed antibody was concentrated in a Centricon 30. To 
determine purity of the antibody, samples were separated by SDS-PAGE and 
stained with Coomassie Brilliant Blue. To restore the purification column for 
further use, it was washed with 8 volumes of PBS to remove any protein. 
Columns were stored in 2ml degassed PBS containing 0.05% sodium azide.  
 
8.2.6. Coupling Antibodies to Protein-A Beads 
2mg purified antibody were bound to 1ml Protein-A beads (50% w/v) by 
incubating overnight at 4oC on a shaker. The beads were collected by 
spinning at 3000g for 10min (the supernatant was also retained, as it may 
contain residual antibody), and washed twice with 10 volumes sodium borate 
(50-200mM, pH > 8.3). For coupling, the beads were resuspended in 10ml 
sodium borate buffer containing 20mM DMP. The solution was incubated at 
RT for 30min while rocking. The reaction was stopped by washing in 10 
volumes of 200mM ethanolamine pH 8.0. To completely block the reaction, 
the beads were incubated in 10 volumes of 200mM ethanolamine pH 8.0 for 
2hrs. The beads were then washed in PBS, and resuspended in PBS/0.1% 
sodium azide.  
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8.2.7. Generation of Protein Extracts and Immunoprecipitation (IP) 
Cultured cells were washed once in PBS and harvested by scrapping with 
a rubber policeman. Suspensions were briefly centrifuged in a tabletop 
centrifuge and the supernatant aspirated. Pellets were lysed on ice in IPH 
buffer (50mM Tris/HCl pH8.0, 150mM NaCl, 5mM EDTA, 0.5%v/v NP40) 
containing protease inhibitors (Roche Complete protease inhibitor cocktail), 
phosphatase inhibitors (20mM sodium fluoride and 40µM sodium 
orthovanadate), and deacetylase inhibitors (5mM sodium butyrate). After 
incubation for 20 to 60min cells were centrifuged for 10min at 4oC at 14000 
RPM. Protein concentration was determined by PIERCE BCA protein assay 
kit. For immunoblotting, small amounts were boiled in sample buffer, and 
separated by SDS PAGE. For IPs, antibodies against the desired proteins and 
30µl of a 50% protein-A (or protein-G) slurry were added to the extract, and 
the mix was incubated at 4oC on a shaker for 2 to 6 hrs. Cells were pelleted 
by centrifugation and washed 3 to 4 times with IPH buffer. The pellets were 
boiled in SDS-PAGE sample buffer, and precipitated proteins separated by 
SDS-PAGE.  
 
8.2.8. Immunoblotting  
SDS PAGE was carried out according to standard procedures. Proteins 
were transferred to PVDF membranes at 25V for at least 2 hours. Membranes 
were incubated in blocking solution (PBS, 0.1% Tween-20, 5% w/v milk 
powder) for at least 1 hour, followed by incubation in blocking solution 
containing the appropriate antibody (see above) for at least 1 hour at RT. 
After washing 4 times for 5min at RT with PBS containing 0.1% Tween-20, 
membranes were incubated in blocking solution containing the appropriate, 
HRP-conjugated secondary antibody for at least 30min. After washing 4 times 
for 15min at RT with PBS containing 0.1% Tween-20, and rinsing twice 
quickly with PBS, reactive proteins were detected by enhanced 
chemoluminescence (ECL; Amersham) according to the manufacturer’s 
protocol.  
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8.2.9. Immunoprecipitation-Histone-Acetyltransferase (IP-HAT) Assay 
IP-HAT assays were performed similarly to previously published protocols 
(Brownell and Allis 1995; Brownell et al. 1996). Cell culture and 
Immunoprecipitation was performed as described above, except that the IPs 
were incubated overnight. After the last wash of the IP, the supernatant was 
totally aspirated and the pelleted beads were resuspended in 30µl of reaction 
buffer (50mM Tris/HCl pH 8.0, 10% glycerol, 1mM DTT, 1mM PMSF, 0.1mM 
EDTA) containing 25µg histones (Boehringer Mannheim histone mix; stock 
solution: 5mg/ml histones in 1mM HEPES pH 7.5, 100mM PMSF), 1mM 
sodium butyrate, and 50nCi 3H or 14C labeled Acteyl-CoA (Amersham; e.g. 
0.2 to 0.4µl of 2-10Ci/mmol). The reaction mix was incubated at 30oC for 10 to 
60min. Then the mix was spotted onto Whatman P81 phospho-cellulose 
squares (2x2 cm) and allowed to air dry. Dry filters were washed 3 times for 
10min at RT with 200mM sodium bicarbonate pH 9.2 to remove 
unincorporated radioactive Acetyl-CoA. The filters were then placed in 
scintillation vials, and 2mls of scintillation fluid was added. After incubating the 
vials at RT for 10min, the amount of incorporated radioactivity was determined 
using a liquid scintillation counter. Alternatively the reaction mixtures were 
added to 30µl of 2x SDS-PAGE loading buffer and proteins separated by 
SDS-PAGE. Gels were dried on a Stacked Gel Dryer SGD300 (SAVANT) for 
1 hour at 80oC, and exposed to Kodak Biomax Films at -70oC for at least one 
day.  
 
8.2.10. CHIP Assay 
CHIP was performed according to previous protocols (Orlando et al. 1997; 
Frank et al. 2001). Formaldehyde was added directly to cultured cells (approx. 
5x106–1x107 cells per CHIP, i.e. six to eight confluent plates of T98G cells per 
time-out for four CHIP triplicates) to a final concentration of 1% to fix at RT for 
10min. Fixation was stopped by addition of glycine to final concentration of 
0.125M, and cells incubated for 5 min. Then plates were rinsed twice with 
TBS at RT. TBS was aspirated completely, and cells harvested in SDS buffer 
(100mM NaCl, 50mM Tris/HCL, pH8.1, 5mM EDTA ph 8.0, 0.2% sodium 
azide, 0.5% SDS) containing protease inhibitors. Cells were pelleted by 
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spinning in tabletop centrifuge for 10min at 2000RPM, and resuspended in 
4ml of ice-cold IP Buffer for sonication (IP buffer: 1 volume SDS Buffer + 0.5 
volume Triton Dilution Buffer. Triton Dilution Buffer: 100mM Tris/HCl pH 8.6, 
100mM NaCl, 5mM EDTA, 0.2% sodium azide, 5.0% Triton X-100). Samples 
were sonicated to an average length of 500-1000bp (e.g. pulse for 20 
seconds at power setting 3 and 100% duty cycle of Branson Sonifier 450, big 
probe), and the volume adjusted with IP buffer to 1ml/IP. Lysates were 
precleared with 30µl of Protein-A beads (50% v/v in TE containing 0.2mg/ml 
sonicated salmon sperm DNA and 0.5mg/ml lipid-free BSA) for 30min at 
14000RPM. Then, 20µl lysate were removed to be used as total. The primary 
antibody was added, and the mix incubated overnight at 4oC on a rotating 
wheel. After centrifugation for 20min at 14000RPM at 4oC, the supernatant 
was added to 30µl of 50% Protein-A beads, and incubated on a rotating wheel 
for two hours at 4oC. Pellets were washed 3 times in 1ml Mixed Micelle Wash 
Buffer (15ml 5M NaCl, 10ml 1M Tris/HCl, pH 8.1, 5ml 0.5M EDTA, pH 8.0, 
40ml 65% w/v sucrose, 1ml 10% sodium azide, 25ml 20% Triton X-100, 10ml 
10% SDS, H20 to 500ml) 2 times in 1ml Buffer 500 (0.1% (w/v) deoxycholic 
acid, 1mM EDTA, 50mM HEPES, pH 7.5, 500mM NaCl, 1% (v/v) Triton X-
100, 0.2% sodium azide), 2 times in 1ml LiCl/detergent buffer (0.5% (w/v) 
deoxycholic acid (sodium salt), 1mM EDTA, 250mM LiCl, 0.5% (v/v) NP-40, 
10mM Tris/HCl, pH 8.0, 0.2% sodium azide) and once in 1ml Tris/EDTA pH 
7.4. 250µl of a 1% SDS, 0.1M NaHCO3 solution was added to both the pellets 
and the totals, and samples incubated overnight at 650C to elute immune 
complexes, and to reverse the crosslinks. After a brief centrifugation, the elute 
was removed and added to 250 µl of proteinase K solution (1.5µl 20mg/ml 
glycogen in sterile H20, 5µl 20mg/ml proteinase K stock, 244.5µl TE buffer, pH 
7.6), and incubated at 37oC for 2 hours. 50 µl of 4 M LiCl was added, then 
500µl phenol/chloroform/iso-amyl-alcohohl. Tubes were shaken vigorously for 
90 seconds and phases separated for 10min at 14000RPM at RT. The upper 
phase was added to 1ml of 100% ethanol, mixed, and incubated at -20oC for 
15 min. The DNA was precipitated by microcentrifuging for 30min at 4oC at 
14000RPM, and the pellets washed with 1ml 70% ethanol at 4oC for 5min at 
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14000RPM. The supernatant was aspirated, the sample air-dried for 10min, 
and resuspended in 300µl H20.  
 
8.3. Molecular Biology Techniques 
8.3.1. Subcloning  
Subcloning of cDNAs into mammalian expression, retroviral, and 
adenoviral vectors was as described (Sambrook et al. 1989), using QIAGEN 
plasmid miniprep (#12161), maxiprep (#12163), and QIAquick gel extraction 
(#28704) kits according to the manufacturer’s protocols.  
 
8.3.2. Taqman Real Time PCR Analysis 
For analysis of DNA samples by real time PCR, a reaction mix of 6µl 
DNA, 4µl primer mix (H2O containing 0.33µl of 45µM primer stock per primer) 
and 10µl of SYBR Green PCR Master mix (Applied Biosystems #4309155) 
was analyzed in a Perkin Elmer Gene Amp 5700 Sequence Detector for 40 
cycles (15sec 94oC, 15sec, 55oC, 1min 72oC).  
 
8.3.3. Primer Design and List of Primers 
Primers against DNA of E2F targets for both CHIP and mRNA analysis 
was performed by using computer assisted primer design (PrimerExpress 
2.1).  
Gene Position Acc. Num. AP 
number 
Sequence 5'-3' (upper primer 1st line, lower 
primer second line) 
Comment Reference 
       
e2f1 E2F site    OK 
cdc2  E2F site    good 
cdc6  E2F site    no good 
cdc25a  E2F site    no good 
b-myb  E2F site    no good 
p107 E2F site    great 
ccna1  E2F site    good 
actin      no good 
Primers from Takahashi et 
al. 2000 
 
mcm4 E2F site NT023806 2755/56 GCGGTTTGGGAGCGCTA good Leone et al. 1998; Kel et al. 
2001 
    GACGACGCTCGCGGACT   
 E2F site  2757/58 GCCTACTTCTGGTTTACGCACG   
    CGCCACTGCGCATCG   
 E2F site  2759/60 CCGAGCGAGGCCTACTTCT great  
    GGACAGTGCCGCTTCTTTCA   
 E2F site  2771/72 ccaccacctcccgtccttaa   
    aatcacagcggcgctcgtac   
mcm5 E2F site AB003469 2761/62 GAAGGAGGCGAGGTCATGC OK Leone et al. 1998; Kel et al. 
2001 
    AGCGATTGGACCGTTCTGAG   
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 E2F site  2763/64 GCCAAATTGTTCCGCACAC great  
    TGATTGGCTGCAAAGTGCAT   
 E2F site  2773/74 tccttcccagccagaagttt no good  
    tcccactagcctcacctctg   
dhfr E2F site K01612  2787/88 GTCCTCCCGCTGCTGTCAT  Kel et al. 2001; Fry et al. 
1999; reviewed in Slansky 
and Farnham 1996 
    GGACACAGCGACGATGCA   
 E2F site  2789/90 GCCTCGCCTGCACAAATAG great  
    CAGAACGCGCGGTCAAGT   
e2f1 E2F site U47675 2791/92 GGCGGCTCGTGGCTCT  Takahashi et al. 2000; Kel 
et al. 2001 
    GCCGCTGCCTGCAAAG   
 E2F site  2793/94 GGCGGCTCGTGGCTCT   
    GAGGGCTCGATCCCGCT   
b-myb E2F site X82032 2795/96 CGCTTGGCGGGAGATAGA great Lam and Watson 1993; Kel 
et al. 2001 
    TCCTCGCTCGCAGGAACT   
 E2F site  2797/98 AGTTCCTGCGAGCGAGG good  
    TCGAAGGCGTCAGCGTG   
cdc2 E2F site X66172 2799/00 GGACGACACTCTCCCGACTG great Dalton 1992; Tommasi and 
Pfeifer 1995 
    GCGCCAACTGAGTGCGA   
 E2F site  2801/02 CTGGAGGAGAGCGCTTGCT   
    GGGTGGCTAGAGCGCGA   
cdc6 E2F site AJ009560 2803/04 GTGACTACAGCCAATCAGAATCGA great Hateboer et al. 1998; Yan 
et al. 1998 
    AATCCGAATGGCCACAGC   
 E2F site  2805/06 CGCTGTGCAGTTTGTTCAGG great  
    CACGCAGCCTCTCGGACT   
mcm6 E2F site D89335 2871/72 GCGCCGTTCATTGGTCAG good Leone et al. 1998 
    AATCGTGACACAGGAGCTGGA   
 E2F site  2873/74 CGAAATCTCCAGCTCCTGTGT OK  
    TTCCGACCTGCACGGC   
mcm3 E2F site AL034343 2921/22 TCTTTGGCAGCGGGCAT OK Leone et al. 1998 
    CGCAGCTCCACATCGTCC   
 E2F site  2923/24 GCGGGAAGAGTTCGGAAGTT   
    GTGGAGGTTCCCAGGATGACT   
orc1 E2F site U40152 2939/40 GCGATTGGCGCGAAGTT great Ohtani et al. 1996; Kel et al. 
2001 
    CAGGACCAAAGCGTGTGTCTC   
 E2F site  2941/42 CGCGATTGGCGCGA   
    GCCAGGACCAAAGCGTGT   
nuc E2F site M60858  2943/44 GCTGCCCAAGCCTACGG good Kel et al. 2001 
    TGGAATCGGGCGGTCTC   
 E2F site  2945/46 CGGAGACCGCCCGATT good  
    TCGTGGGACTGGCGTTTT   
polα E2F site M64481 2947/48 GCCCGACCGCTTCTTTCT great Pearson et al. 1991; Kel et 
al. 2001 
    TTGGCGCCCTGTGATGA   
 E2F site  2949/50 GGCACGTCAGTGGCCTTC   
    GAAAGCCAATCAGCGGCTC   
pcna E2F site J04718 2951/52 CTGGCTGCTGCGCGA good DeGregori et al. 1995; Kel 
et al. 2001 
    CACCACCCGCTTTGTGACT   
 E2F site  2953/54 TTTCGCGCCAAAGTCACA   
    GAACAGTGTTCCTGGCACTGC   
tk E2F site X15509 2955/56 ACGTCCATCGCCCTGATTT good Dou et al. 1994; Kel et al. 
2001 
    GAATCCGGGACGTGCG   
 E2F site  2957/58 GCACGTCCCGGATTCCTC good  
    GCTGACCTGGCGGGAGAT   
mcm7 E2F site AB004270 1179/80 CCGCCTTGTCCGATTGG good Leone et al. 1998 
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    AAATTGGCGCGAAACGTC   
 E2F site  1181/82 GGCTAGCGGGAGGTGAAGA good  
    CCGGCCAACCGAAATTG   
dut E2F site AF018429 3089/0 CTGCGGCGACGCTCAT good Ren et al. 2002 
    AGAAGGCGAGCGAGGAGAC   
 E2F site  3091/92 GCTCGCCTTCTGGCTCTG   
    AAATGGCGGGTGTCTCTTCA   
rrm1 E2F site AF107045 3093/94 AGCAGGAGAGCAGCATTTCC good DeGregori et al 1995 
    CATGGGCCCCATTGGAT   
 E2F site  3095/96 TGGGAGAGGCGTAGTCTTCTG   
    TGTAGCCGCCATGTTGAGTCT   
top2a E2F site AF071738 3097/98 CAAGCTTTCCGCACGAGAA good Polager et al. 2002; Ren et 
al. 2002 
    GGAATCTGGCCAATGAGAAGG   
 E2F site  3099/100 TCCCTGTCAATCTCTCCGCTAT   
    GACTAGAGAGGCTTCAAAAGGCAC   
polα2 E2F site XM006519 3101/02 CACTGCACAAACCATTTGGC good Polager et al. 2002; Ren et 
al. 2002 
    CGGTGGCAGAACTGAGTGG   
 E2F site  3103/04 GCAGGACGTTCTCACCAGGA   
    TGGAGGGAGCAGAAATCTCG   
ung E2F site X89398 3105/06 CAATTGCTGACCGCCACA  Polager et al. 2002; Ren et 
al. 2002 
    TCATCCTGGAGCTGAGGAGG   
 E2F site  3107/08 GGCGCGATCAAAGCTCAC   
    GAGGATCGCTTGAGGCCAG   
msh2 E2F site  3109/10 AGCTCTACTAAGGATGCGCGTC  Polager et al. 2002; Ren et 
al. 2002 
    CTTTAGCTACTGCGCATGCCT   
 E2F site  3111/12 GACTCCCACCCACCGAAAC OK  
    CACGGCGACCACACCC   
polδ E2F site L38719 3113/14 GCGGGAAACGCTGTTTGA  Ren et al. 2002 
    TCCCTACCAGGCCCACTG   
 E2F site  3115/16 GGCCACTTCGGAAGCTGAG OK  
    CAAGTGCGGGCAAGGC   
gar22 E2F site 3164077 3117/18 CGGTCCGTCCTCTGCAGTT OK Weinmann et al. 2002 
    GGACGCGGGAGGGTTAAG   
 E2F site  3119/20 TTATTGGAGCTCTGAGCCTGG   
    GGCGGCAGCCATGCTA   
rcql2 E2F site L36140 3121/22 GACCGCAGGAAAACGTGG  Weinmann et al. 2002 
    TCGACCGCGCCTTCTC   
 E2F site  3123/24 TTCCCGGGTTTCCTAAGACTC   
    GGTGTGGCACAGAACGGAG   
ts E2F site D00596 3125/26 CCGGGTTTCCTAAGACTCTCAG  DeGregori et al. 1995 
    GGTGTGGCACAGAACGGAG   
 E2F site  3127/28 CTGTGCTGCTGGCTTAGAGAAG   
    GGCTGGGAAGGACTGCG   
mcm4  -600 NT023806 3129/30 ACGCATTCCTGCCCCA   
    AGGAGACCTTGTCCGCTGC   
 -600  3131/32 CTGCTGCTCAGGACGCATT OK  
    CCTGGCCGGTCATCAACT   
 -400  3133/34 GGCTACTTGGTGTTGGACTTGG   
    TCGCTTGTTTTATCTGCCTCTG   
 -400  3135/36 GGCCTAGGTCAAGAGTTCCAAGT   
    GACTGCAGGCGGGCATC   
 -200  3137/38 AAGTGAGAAATGCATCTGTAATGTCCT   
    CTAGGGAGCGTGTGCTTCTTTATC   
 -300  3139/40 AGTCCCAACACTTTAGGAAGCTGA   
    GTCTCGAACTCCTGCGATCC   
 +200  3141/42 TCTGGGTCTCGCGGTTTG   
    GCTTGCCGACGACGCT   
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 +200  3143/44 TCTGGGTCTCGCGGTTTG   
    GCCGACGACGCTCGC   
 +500  3145/46 ACGTAGAGGCGAGGATTCCAC good  
    CAGGTCCACTCCAGGCGA   
 +500  3147/48 TCAGCTATCCCTCTTGACTTTGATG   
    GGTTCCCTCTACCCGAGAGC   
 +1000  3149/50 ACAACTCATCTCTTACCCACAGGAA   
    ACAGCCATGTCAAAAGTTGGAA   
 +1500  3151/52 GCATCTATCGAGCTGTGCCTATT bad  
    TAGACAGACTTCACATTACTCACTCTTGG   
 +2000  3153/54 GGCCTCACTGCGTACGTAATG good  
    CAGGACCAGCTGCCTTGTCT   
 +2000  3155/56 GGATCATCTGTCAGCTCAATGC   
    TTCCACTGAGACTCAATGGGATT   
 +3000  3157/58 GGGAAGACCGTGCGCTT good  
    ACCCATGTGGCGTGCAG   
 +3000  3159/60 ACTCGGGAGGTTGAGGCAG   
    AGTGCAGTGGCGCGATCT   
ubi TATA X04803 3161/62 CTTTCAGCGGCGCACG   
    GTTGCGTCACTTATCACCCCTC   
 TATA  3163/64 GAGACGGCGTCTACGTGAGG good  
    AGCTCACCCAACAAAGCCAA   
36B4  prom 17475111 3165/66 TGAGCTCCCTGTCTCTCCTCA good  
    CGTCAGGGATTGCCACG   
 prom  3167/68 GCGATTGCGCGTGTCC   
    AGGAGAGACAGGGAGCTCAGG   
achr  prom Y00508 3169/70 CAACCAAAGCCCATGTCCTC   
    AGGCACGCTACAGGGCTTC   
 prom  3171/72 CCTTCATTGGGATCACCACG good  
    AGGAGATGAGTACCAGCAGGTTG   
cited1 E2F site NM004143 3203/04 TTCCCGCCAATTTATCCAACT good Muller et al. 2001 
    ACGTTGTTGGCATTTCAGAGC   
 E2F site  3205/06 GATGTCAAGGGTGGCACCTC   
    CATCTCTTGGTTGGCATCCTC   
ccne2 E2F site NM057735 3207/08 ATATATTGGGTTGGCGCCG good A. Beck, N. Lauper, and B. 
Amati, unpublished 
    CCAGACCAGCTACCGCTCG   
 E2F site  3209/10 CAGCTGAGCCGAGCGGTA   
    TCTTTCAGGTGTATAAAACCTCGC   
p107  E2F site AL136172 3237/38 TGGATGACAACACGTCCCG   
    AACATCCCTTCAGGCCCC   
 E2F site  3239/40 TGGATGACAACACGTCCCG good  
    CACGGCCCCCGACTTC   
 -500  3241/42 CCACTCACTGGGCACTAGGAC good  
    AAAGTAGCCCCTGGACGAAGA   
 -300  3243/44 GAGGCCACCTCGCAGTAGG   
    CTGGTTAGGCTCTTGGGTTTTG   
 500  3245/46 AAGCTCAGGAAAGGAGCGG good  
    GGTAGAGGGAAGTGTGGTCAGG   
 500  3247/48 CTAGGTCCCGCGCCG   
    GTAGAGGGAAGTGTGGTCAGGAAG   
 1000  3249/50 TCAGCCCTACGTTTCCTCCTC   
    TGATGCAAAGCATCAGGACG   
 1000  3251/52 AATGAGTATTAGACTGCTTTCCAGGTG   
    AAGACAACCTTCTGAGCCTTGC   
mcm3 -700 AL034343 3295/96 TTTCCAAAATTTGTATAACACACGATG good  
    GTTTACCCTGCCCCCTAGAGA   
 -400  3297/98 GAATTTGGTCGTTGCATCGG   
    TTTTTGCAGGGTTTTTCAAGC   
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 -450  3299/00 CAGCTTGAAAAACCCTGCAAA   
    GCGTTCTGGGAGTTGTAGTGTTCT   
 -200  3301/02 TCAGTGAGTGAGGCGGAGG   
    ACGTACCATCCGGGATTCTCT   
 +350  3303/04 TCCAGCCCCAATCTTGTAACTT   
    ATGGGAACCTGTCGCCTTTT   
 +500  3305/06 GCGTTGCAGAGTGCTCAGATT   
    TTTTCCTCCAGGTAAAACGTCAGT   
 +1000  3307/08 GGATTTTATGTGCAACCCAAGAC good  
    GATGGTTTTTTCAACATTCTATGGC   
pcna -800 J04718 3309/10 CTCCACATATGCCCGGACTT good  
    CCTCTTTGACTCCTGAACCCG   
 -900  3311/12 TGCAGCAGCTGTACTCTCTTCAG   
    GCCTACCGGGAGGAAAAGC   
 -400  3313/14 AGGCCTGCTGGGATATTAGCTC good  
    GAGTCCATGCTCTGCAGGTTTAC   
 -500  3315/16 GCTCCTGAAGCCGAAACTAGC   
    GCTCCTGAAGCCGAAACTAGC   
 +400  3317/18 AATGGCATCCTCCAGCAGTC   
    AGGCCGTCTCAGAACTGGTG   
 +450  3319/20 CCTTCTAACCGCGTTCGAAATAC good  
    TTAAAATCAACGCCGTCTGCT   
 +900  3321/22 GTCTTGGCTCTGTTGCCCAG   
    AGAGAGCTATATGGCACTACTGCACT   
 +1000  3323/24 CTCAAGCAGTCCTCTTGCCTTAGT good  
    GGCCCGTAGTCCTTCCTAGC   
dut -1000 AF018429 3333/34 CAGAGCAAACAAGAAGAGCGAA   
    GCCGCCTCTGGCTGC   
 -650  3335/36 CTCTGCTACCATTTCCTTACGTCTCT   
    CGCGTTTTGCATCGCTG   
 -600  3337/38 TGCTACCATTTCCTTACGTCTCTG   
    CTCGCGCGTTTTGCATC   
 +650  3339/40 GCAGACTGCCTGTATCTACCACA   
    ACAGTAAAACGTGCTGTAGAGATGAAA   
 +650  3341/42 ATTTGAGAAGCATCTGAAAACGAA   
    AAAGTGTGGTAGATACAGGCAGTCTG   
p73 -3500 AF235000 3343/44 GATTTAAGCACCCTTCTGCCAC good Stiewe and Putzer 2001 
    TGGCTGGGATTTGAGGTCTT   
 -1750  3345/46 TGTGCCGCAGGGCTTTA   
    AAATCCCTGGTCGGAAGAAAC   
 #2  3347/48 TCAAGGAGAGAACGAATTTGCC good  
    TCAAGGAGAGAACGAATTTGCC   
 #2  3349/50 ATCACCCGCGCGCAT   
    CCAGACCCGCACGATTCTT   
 #2/#3  3351/52 CGTGCGCCCAGCAAAC   
    CCGGCTGACTCGCACATC   
 #2/#3  3353/54 GCGGTGCCGGCCTT   
    AGACGAATCCCATGCAGAGG   
 #3  3355/56 AGAGGCTCTCCGCGGG   
    AAGCAGGGCTTGCCACC   
 #3  3357/58 GATCCTCTGCCGGGCG   
    CAGGGCTTGCCACCCAC   
 #7/#8  3359/60 ATCGGCCCCTGGGACTT   
    CTCCTCGCAGGCTAGACTCTG   
 #7/#8  3361/62 GAGTTGGATCGGCCCCTG   
    GCTAGACTCTGGCCGCTCC   
 #9  3363/64 GTGCAGGTGGAAATCGCC   
    TCCTCAGGGAAGCTGAGGC   
 #7  3369/70 GGGACGAGCTAGTGGACAAGG good  
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    CCGATCCAACTCCGAGGG   
  #9 
+600 
 3371/72 CCTTTGCTCAGCTTGTATTTTGG good  
    TACATGGGCTTATCTCCTAGCGT   
  #9 
+600 
 3373/74 CAGCTTGTATTTTGGCCTGGA   
    TGTGCATACTACATGGGCTTATCTC   
  #9 
+1kb 
 3375/76 AGCTACTCGGGAGGCTGAGG   
    CCTCTCCATCCCAGGTTCAAG   
  #9 
+1kb 
 3377/78 ATGGTGAAACCCAGTCTCTACTTGA   
    TGCCACCATGCCCAGC   
cdkn2a-
arf 
site #2 AF082338 3417/18 GGGTGGGAAGATGGTGGTG  Kel et al. 2001 
    CCACTTTCCCGCCCTGT   
 site #2  3419/20 GGTGGGAAGATGGTGGTGG   
    CCTCTCCCTCCCGCCTAC   
 site #1  3421/22 CCTCCTGATTGGCGGATAGA   
    GGAAGAAAGGAAAGCGAGGTC   
 site #1  3423/24 ATAGAGCAATGAGATGACCTCGCT   
    TTTAAAAATGAAAAAGGAAGAAAGGAA   
 site #1  3425/26 GTTCAAAACTGACATTCAGCCTCC   
    AGGTCATCTCATTGCTCTATCCG   
 -1500  3427/28 CGTGGCATAGGTGCAGAGG   
    GCTCTATGGGAACCAGATCCTTT   
 -1000  3429/30 CGGCTCACGCTGTGGTTC   
    GCGCTTGGGCCTAGTGG   
 -3000  3431/32 AATTCCCCTGCATACTGCAACT   
    ACTGCCGCTGCCCAATAC   
apaf1 E2F site AB070829 3433/34 GACTGCTCCGCTGTCCAGA  Moroni et al. 2001 
    TCACGTCCACTCGCTACCTCT   
 E2F site  3435/36 TCCGGCGGGATTTGACT   
    GCTACCTCTTCTTCTCCGCCTC   
 p53 site  3437/38 TCTGGAGACCCTAGGACGACA   
    CACGTCCTGCTCCCCCT   
 p53 site  3439/40 CGACTTCTTCCGGCTCTTCA   
    TGCCCTGGGCTTGTCGT   
p107 -1200 AL136172 3491/92 ACTGGGATTACAGGCAAAGCA good  
    CTGTCTTCGTTCTTTTGTTGTTCC   
 -1100  3492/93 GGGCCCAGACACAGAATCTTC   
    TGGGAAACTTCTAGAGGGTATTTGG   
 -2000  3495/96 CATGCTTTGGGAGAACTCTGAA   
    TCTATGATTAGCCTCCCTGTTGTG   
 -1950  3497/98 CACACAATGGGATCAAAATAGAAACA good  
    TTTTGAGCCAGATACACATGAAGG   
 -1600  3499/00 CTGCCTCAGCCTCCCAAAG   
    GGTTGCAGTGGCTCACACCT   
 -1550  3501/02 TACAGGTGTGAGCCACTGCAAC good  
    CTGAATAGAAAATGAAGTATGGAAGGC   
 -2650  3503/04 GGTGGCGTGTGCCTGTAGT   
    AATTCTCCTTCCTCAGCCCC   
 -2500  3505/06 AGATCTTGCCACTGCACTCCA   
    TGAGACAGAGTCTCACTCTGTCACC   
 -3300  3507/08 GGAGCTTGGCTTAACCCTGA good  
    TTTGAAAATGTTCTAGTGACTCCCC   
 -3100  3509/10 CCGGGCACAGTGGTTCAC   
    GCCTCGGCCTCCCAAA   
 +1450  3511/12 AGCATAAGCCCAGTGTAGACAGAA good  
    TGCTACATGAAATACACTCCATCACA   
 +1650  3513/14 ATGTGTGCCTATATATGAAGGAGTAGTAC
CT 
good  
 117
    CCATTGTCCTTTACCCAGTCTATCC   
 +2200  3515/16 CGGTGGCTCACACCTGTAATC bad  
    TCTGCCCACCTCAGCCTC   
 +2250  3517/18 ACATCTTCAATGTTTGCTCTACTTATTTAT
TT 
  
    GGCCAAGACCCTGTTTCTAAGG   
 +2500  3519/20 GGCCTGGAATGCAGTGGT   
    CAGGAACATCACTTGAGCACAGA   
 +2600  3521/22 GATGTTCCTGCTTCAGCCTCC OK  
    TGGGCAACATAGTCAGATACTATCTCC   
pcna -2000 J04718 3571/72 GGCCTGTAATCCCAGCACTTT bad  
    TCTATTTATATGTCTGACTCCACAGCAG   
 -2000  3573/74 ATTGAAAATTTCTGGCTGGGC   
    CAAAGTGCTGGGATTACAGGC   
 -1500  3575/76 TGTGATGCTATGTTTTAAAGAGGTACTGA OK  
    AATTTTATGCCACGTACATCTTTTTATC   
 -1500  3577/78 TGACTCAGCTGTATTACTTCAAGGAGTT OK  
    ACCTTTGAGCACTTAGGCAATTTT   
 +1500  3579/80 TCATGATTTCTGTGCCATACTCTAATG OK  
    TCCTCCAGGGATAAAGTAAGAGAACA   
 +1500  3581/82 TTTGAGTGGAGTTTGTTAAGAAATTACG   
    TTCTGATTACTTTAAAATATGACTTGCGT   
 +2200  3583/84 ATCAAGTCCACACCGGCTCT OK  
    TTATACGCCTAACTTCCCAATCCT   
 +2400  3585/86 TTTAAAGGTGGAGAAGCAGGCT OK  
    TTTGGCTAAATTGTCACTTAAGGTTG   
mcm3 -1500 AL034343 3587/88 TTGGCTAAGGATCGATTTATCTGC OK  
    ACTGTATGTTTTGTGCCATCCTAGTG   
 -2000  358990 GCAACAACCTGATTGATTTTGG OK  
    CATGAAATCTTTAAGCAGAGGAAATG   
 -2200  3591/92 TGGAAAGAAAATTGAAATGGAGG OK  
    CAGTTTCCATACTTGGGTCACATTC   
 +1500  3593/94 GGCTGTTTTGCAGGAAGACC OK  
    GATCAGCTCCCGAACTTTGC   
 +1400  3595/96 TACCGGCTGATTGTCAATGTG OK  
    GTTAGCCCTCTTCTCGTTTTTCC   
 +2000  3597/98 GGACTCTTACCTCCTGCTTCCTC   
    GACAATGCCCTCCACACAGA   
 +2200  3599/00 TACGTGGTAAAACTTGGAGGGC OK  
    TTCATCATTCTACTAATACATGTGATTACTCAA  
mcm4 -1350 NT023806 3601/02 TTCTCAAAGTAGGAACGGCAAAT   
    GCCCGGCCAAGAGAAAGTAT   
 -1300  3603/04 CTGGTGGGATTAGGCGAGATT OK  
    GCCCGGCCAAGAGAAAGT   
 -2200  3605/06 ACTTCCCCTGGAATCTCTCAAGT   
    ACCTTCCATTTATGCCATATCTCC   
 -2100  3607/08 TTGAAACCCTGAGAAGAGAAAGTAATC OK  
    TCAAACAAAAAACTAACATTGCGTG   
 +1400  3609/10 AGTATGCAGTCTCCTGAAACCATCT   
    GAGTTACCCACATGATACCCGC   
 +1500  3611/12 TGTGTAGGCAGCAGCAGAAGA OK  
    TCTGTTCCCCAGATCACAAGTTT   
Table 4: List of Primers Used in this Study. 
All primers tested in this study are listed. Distances are in bp, from the E2F site. Primers that 
work in CHIP are indicated. For all E2F targets, references are listed.  
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APPENDIX A: Generation and Characterization of Gcn5, HBO1, PCAF, 
Tip60, and TRRAP Antibodies 
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Figure 29: Characterization of Polyclonal Antibodies. 
Rabbit polyclonal antibodies to Gcn5, HBO1, PCAF, Tip60, and TRRAP were affinity purified 
as described in Materials and Methods. Then, they were used to immunoblot lysates from 
293T cells transiently transfected with expression vectors for the immunogenic protein, Gcn5 
(A), HBO1 (B), PCAF (C), and Tip60 (D); for analysis of TRRAP antisera, untransfected cells 
were used. All antibodies recognized a single band corresponding to the transfected protein. 
Gcn5 and PCAF antisera also crossreacted weakly with the related PCAF, and Gcn5 proteins 
(A, C). Tip60 (a pool of all three peptide antibodies) and TRRAP antisera specifically 
immunoprecipitated proteins under SDS lysis conditions used in CHIP assay (D, E). For 
further information, see text.  
 
In order to investigate the recruitment of HAT-complex subunits by CHIP, 
rabbit polyclonal peptide antisera were raised against TRRAP, Gcn5, HBO1, 
Tip60, and PCAF (see Materials and Methods). Crude bleeds were affinity 
purified against the immunogenic peptides. For rapid characterization the 
purified antibodies were used to immunoblot lysates from 293T cells 
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transfected with expression vectors encoding the respective HAT (for TRRAP 
untransfected 293T cells were used). Both Gcn5 (Figure 29 A, lane 2) and 
PCAF (Figure 29 C, lane 3) antisera recognized single bands corresponding 
to the transfected HATs. However, antisera also crossreacted weakly with the 
other HAT, respectively, probably due to their high homology (Figures 29 A, 
lane 3, and C, lane 2). Nevertheless, crossreactions with unrelated HATs 
were not observed, even when the proteins were strongly overexpressed (for 
example, adenovirally expressed Tip60 was not revealed by Gcn5 blot; data 
not shown). HBO1 antisera detected a doublet in nontransfected cells, and a 
doublet of higher molecular weight in transfected cells, consistent with the 
higher increased weight of tagged, transfected Flag-HA-HBO1 (Figure 29 B, 
compare lanes 1 and 2). Tip60 antisera detected a single band in cells 
transfected with Flag-HA-Tip60 (Figure 29 D, lane 2). Finally, TRRAP antisera 
detected a single band of high molecular weight, correlating with the large 
size of TRRAP (434kDa; Figure 29 E, lanes 1 and 4).  
In addition, the TRRAP and Tip60 antisera were characterized for their 
ability to IP transfected (Tip60) or endogenous (TRRAP) proteins. Tip60 was 
immunoprecipitated under denaturing conditions (0.5% SDS) by a pool of all 
three individual peptide antisera, but not by the pre-immune control sera 
(Figure 29 D, compare lanes 4 and 5). The IP was as efficient as an IP 
performed with monoclonal antibodies against the Flag-tag of the transfected 
Tip60 (Figure 29 D, compare lanes 5 and 3). Similarly, endogenous TRRAP 
was efficiently immunoprecipitated under denaturing conditions by immune, 
but not pre-immune sera (Figure 28 E, compare lanes 6 and 5). In contrast, 
IPs were less efficient under native conditions (Figure 29 D, compare lanes 6 
and 3), even though both lysates contained a similar amount of TRRAP 
(Figure 29 D, compare lanes 1 and 4).  
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APPENDIX B: Analysis of E2F-Target Binding by Distinct E2F Proteins, and 
by p130.  
 
E2F proteins bind to promoter DNA with the consensus sequence 
TTTsGCGCsAAA. When analyzed by in vitro electro-mobility-shift assays 
(EMSA), E2F proteins do not exhibit target sequence specificity, i.e. E2F 
target sequences are bound equally well by all species of E2F proteins 
(reviewed in Trimarchi and Lees 2002). However, a recent study has 
suggested that different target genes exhibit distinct binding by various E2F 
proteins (Wells et al. 2000). Similarly, it is believed that individual E2F 
polypeptides may perform unique functions (reviewed in DeGregori 2002). For 
example, E2F1 may have a specific role in DNA repair and/or induction of 
apoptosis after DNA damage (Blattner et al. 1999; Hofferer et al. 1999; Lin et 
al. 2001). Consistent with this, some E2F target genes, such as APAF-1, are 
apparently induced specifically by E2F1, but not other E2F species (Moroni et 
al. 2001).  
During my investigations of the role of the Tip60 complex in E2F function I 
generated a collection of primers specific for approximately 25 bona fide E2F 
target genes. This allowed to analyze binding of individual E2Fs to these 
targets, by using CHIP experiments described before (see chapter 4.3. and 
4.4., pp. 50. Figure 30 A-C shows that all "activating" E2Fs exhibit similar 
binding patterns, i.e. targets with a lot of bound E2F1 also bound a lot of E2F2 
and E2F3. In contrast, there was no correlation between the binding of 
activating E2Fs and E2F4 (compare Figure 30 A-C with Figure 30 D). 
Similarly, there was no correlation between binding of E2F1 and p130 (Figure 
30 E-G), which is as expected, as E2F1 presumably acts mostly as an 
activator in T98G cells. However, there also was only a weak correlation of 
p130 binding and E2F4 binding (Figure 30 H-I). Possibly, p107 is predominant 
on targets with less bound p130.  
It is particularly noteworthy that DNA damage associated genes, such as 
p73, polδ, and Top2a, are bound by all activating E2Fs, rather than just E2F1, 
suggesting that they may be targeted by all of them in the serum response of 
T98G cells. Nevertheless, this does not exclude a specific role for E2F1 in 
 121
induction of these targets after DNA damage. In summary, these results 
suggest that the activating E2F proteins exhibit similar target gene 
specificities, at least in T98G cells. 
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Figure 30: Analysis of Binding Patterns of Individual E2F Proteins, and p130 
in T98G Cells.  
CHIP with antibodies specific for individual E2F proteins and p130 was performed as 
described in Figures 7 and 8. Cell populations were identical those used in Figure 7. Primers 
for E2F target genes are described in Materials and Methods, chapter 8.3.3.  
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Figure 30: Analysis of Binding Patterns of Individual E2F Proteins, and p130, 
in T98G Cells (continued).  
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